Product:   Pembrolizumab (MK -3475)  1 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
  
 
 
UNIVERSITY OF VIRGINIA  
HUMAN IMMUNE THERAPY CENTER  
 
 
MEL 64  
 
 
A TRIAL TO EVALUATE THE SAFETY, IMMUNOGENICITY, AND CLINICAL ACTIVITY 
OF A HELPER PEPTIDE VACCINE PLUS PD -1 BLOCKADE  
 
Abbreviated title:  PATHVACS ( PD-1 Antibody and T-Helper Vaccine And Correlative 
Studies)  
 
 
 
 
 
 
 
 
 
 
 
 Confidentiality Statement  
The information contained in this document is the prop erty of the University of Virginia Human 
Immune Therapy Center.  Distributing, copying, or disclosing information contained in this 
document requires  prior authorization  from the Human Immune Therapy Center, except that 
this document may be disclosed to th e appropriate institutional review boards and 
representatives of the U.S. Food and Drug Administration.   
Product:   Pembrolizumab (MK -3475)  2 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 TITLE:   A trial to evaluate the safety, immunogenicity, and clinical activity of a helper peptide vaccine 
plus PD -1 blockade  
Sponsor  University of Virginia Human Immune Therapy Center  
Principal Investigator  
Director, Human Im mune 
Therapy Center  Craig L. Slingluff, Jr.  
University of Virginia  
434-924-1730  
cls8h@virginia.edu  
Co-Investigators  William Grosh, MD  
434-924-1904  
wwg9u@virginia.edu  
 
Elizabeth Gaughan, MD  
434-924-7678  
emg5x@virginia.edu  
 
Lynn Dengel, MD  
434-284-1978  
ltd5b@hscmail.mcc.virginia.edu  
 
Varinder Kaur, MD  
434-394-5226  
vk4q@hscmail.mcc.virginia.edu   Carmel Nail, FNP -C 
434-982-4042  
cjn2r@virginia.edu  
 
Kathleen Haden, ANP -C 
434-924-1730  
km3s@virginia.edu  
 
Jennifer Eccles, MPAS, PA -C  
434-243-0066  
jme5j@virginia.edu   
 
Kimberly Bullock, PhD  
434-924-0180  
kb9d@virginia.edu  
 
Biostatisticians:  Gina R. Petroni, PhD  
434-924-8363  
grp4c@virginia.edu  
 Mark Smolkin, MS  
434-982-1032  
mes6r@virginia.edu  
 
Clinical Research 
Coordinators and Data 
Management  
 Emily Allred, PhD  
434-982-1902  
eh4m@virginia.edu  
 
Sarah Lewis, BA  
434-924-8709  
set5v @virginia. edu 
 
Meagan Darling  
434-982-6584  
mtd6wa@virginia.edu  Jessica Zareno, MS  
434-982-1901  
jhz4f@virginia.edu  
 
Adela Mahmutovic  
434-982-6714  
am6bd@hscmail.mcc.virginia.edu  
 
Authors:  
 Craig L. Slingluff, Jr., MD  
Kimberly Bullock, PhD  
Gina R. Petroni, Ph D 
 
 
 
 
 
  
Product:   Pembrolizumab (MK -3475)  3 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
  
SIGNATURE PAGE  
 
 
 
INVESTIGATOR’S AGREEMENT  
I confirm that I have read this protocol and I agree to conduct the study as outlined herein .  I agree to 
conduct the study in accordance with the ethical principles that have their origin in the Decla ration of 
Helsinki and that are consistent with Good Clinical Practices , as outlined in ICH E6 , and the 
applicable laws and regulations.   
  Sponsor -Investigator  
 
______________________   _________________________               ___________  
Name      Signature     Date  
 
Product:   Pembrolizumab (MK -3475)  4 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
  
IND NUMBER:  10825  
 
 
TABLE OF CONTENTS  
1.0 TRIAL SUMMARY  ................................ ................................ ................................ .......................  6 
2.0 TRIAL DESIGN  ................................ ................................ ................................ ...........................  6 
2.1 Trial Design  ................................ ................................ ................................ ................................  6 
2.2 Trial Diagram  ................................ ................................ ................................ ..............................  7 
3.0 OBJECTIVES  ................................ ................................ ................................ ..............................  7 
3.1 Primary Objectives  ................................ ................................ ................................ ....................  7 
3.2 Secondary Objectives  ................................ ................................ ................................ ...............  7 
3.3 Exploratory Objectives  ................................ ................................ ................................ ..............  7 
4.0 BACKGROUND & RATIONA LE ................................ ................................ ................................ . 8 
4.1 Background  ................................ ................................ ................................ ................................  8 
4.2 Study Rationale  ................................ ................................ ................................ ..........................  8 
4.2.1  Pharmaceutical and Therapeutic Background  ................................ ................................ ..... 9 
4.2.2  Preclinical and Clinical Trial Data  ................................ ................................ .......................  10 
4.3 Rationale  ................................ ................................ ................................ ................................ ... 10 
4.3.1  Rationale for the Trial and Selected Subject Population  ................................ ....................  10 
4.3.2  Rationale for Dose Selection/Regimen/Modification  ................................ ..........................  12 
4.3.3  Rationale for Endpoints  ................................ ................................ ................................ ...... 13 
5.0 METHODOLOGY  ................................ ................................ ................................ ......................  16 
5.1 Entry Criteria  ................................ ................................ ................................ ............................  16 
5.1.1  Diagnosis/Condition for Entry into the Trial  ................................ ................................ ........  16 
5.1.2  Subject Inclusion Criteria  ................................ ................................ ................................ .... 16 
5.1.3  Subject Exclusion Criteria  ................................ ................................ ................................ .. 18 
5.2 Trial Treatments  ................................ ................................ ................................ .......................  20 
5.2.1  Dose Selection/Modification  ................................ ................................ ...............................  20 
5.2.2  Timing of Dose Administration  ................................ ................................ ...........................  25 
5.2.3  Trial Blinding/Masking  ................................ ................................ ................................ ........  26 
5.3 Randomization or Treatment Allocation  ................................ ................................ ...............  26 
5.4 Stratification  ................................ ................................ ................................ .............................  26 
5.5 Concomitant Medications/Vaccinations (allowed & prohibited)  ................................ .........  26 
5.5.1  Acceptable Concomitant Medications  ................................ ................................ ................  26 
5.5.2  Prohibited Concomitant Medications  ................................ ................................ ..................  27 
5.6 Rescue Medications & Supportive Care  ................................ ................................ ................  27 
5.7 Diet/Activity/Other Considerations  ................................ ................................ ........................  30 
5.7.1  Diet ................................ ................................ ................................ ................................ ..... 30 
5.7.2  Contraception  ................................ ................................ ................................ .....................  30 
5.7.3  Use in Pregnancy  ................................ ................................ ................................ ...............  32 
5.7.4  Use in Nursing Women ................................ ................................ ................................ ....... 32 
5.8 Subject Withdrawal/Discontinuation Criteria ................................ ................................ ........  32 
5.9 Subject Replacement Strategy  ................................ ................................ ...............................  34 
5.10 Clinical Criteria for Early Trial Termination  ................................ ................................ ..........  34 
6.0 TRIAL FLOW CHART  ................................ ................................ ................................ ...............  35 
6.1 Study Flow Chart  ................................ ................................ ................................ .....................  35 
7.0 TRIAL PROCEDURES  ................................ ................................ ................................ ..............  40 
7.1 Trial Procedures  ................................ ................................ ................................ ......................  40 
7.1.1  Administrative Procedures  ................................ ................................ ................................ . 40 
7.1.2  Clinical Procedures/Assessments  ................................ ................................ ......................  42 
7.1.3  Laboratory Procedures/Assessments  ................................ ................................ ................  46 
7.1.4  Other Procedures  ................................ ................................ ................................ ...............  47 
Product:   Pembrolizumab (MK -3475)  5 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 7.1.5  Visit Requirements  ................................ ................................ ................................ .............  48 
7.2 Assessing, Recording, and Reporting Adverse Events  ................................ ......................  49 
7.2.1  Definitions  ................................ ................................ ................................ ...........................  49 
7.2.2  Attribution Assessment  ................................ ................................ ................................ ....... 51 
7.2.3  Evaluating Adverse Events  ................................ ................................ ................................  52 
7.2.4  Adverse Event Classificati ons ................................ ................................ ............................  55 
7.2.5  Agent -Specific Expected Adverse Events List  ................................ ................................ ... 56 
7.2.6  Dose -Limiting Toxicities ................................ ................................ ................................ ...... 56 
7.2.7  Recording and Reporting Adverse Events  ................................ ................................ .........  57 
7.2.8  Sponsor Responsibility for Reporting Adverse Events  ................................ .......................  63 
8.0 STATISTICAL CONSIDER ATIONS  ................................ ................................ ..........................  63 
8.1 Design  ................................ ................................ ................................ ................................ ....... 63 
8.2 Evaluation of Sample Populations and Criteria ................................ ................................ .... 63 
8.2.1  Safety ................................ ................................ ................................ ................................ .. 63 
8.2.2  Immunogenicity  ................................ ................................ ................................ ..................  63 
8.2.3  Clinical efficacy  ................................ ................................ ................................ ...................  64 
8.3 Sample Size and Accrual  ................................ ................................ ................................ ........  64 
8.4 Stratification  ................................ ................................ ................................ .............................  65 
8.5 Safety Monitoring  ................................ ................................ ................................ ....................  65 
8.6 Analyses  ................................ ................................ ................................ ................................ ... 65 
9.0 LABELING, PACKAGING,  STORAGE AND RETURN O F CLINICAL SUPPLIES  .................  66 
9.1 Investigational Product  ................................ ................................ ................................ ...........  66 
9.2 Packaging and Labeling Information  ................................ ................................ .....................  67 
9.3 Clinical Supplies Disclosure ................................ ................................ ................................ ... 67 
9.4 Storage and Handling Requirements  ................................ ................................ ....................  67 
9.5 Returns and Reconciliation  ................................ ................................ ................................ .... 67 
10.0 ADM INISTRATIVE AND REGU LATORY DETAILS ................................ ................................ . 67 
10.1 Study Conduct and Ethical Considerations  ................................ ................................ ..........  67 
10.2 UVA Institutional Review Board for Hea lth Sciences Research  ................................ .........  68 
10.3 Consent Forms and the Consenting Process ................................ ................................ ....... 68 
10.4 Compliance with Trial Registration and Results Post ing Requirements  ..........................  68 
10.5 Maintenance of Study Documents  ................................ ................................ .........................  68 
10.6 Data Collection  ................................ ................................ ................................ .........................  68 
10.6.1  Endpoint Data  ................................ ................................ ................................ .....................  68 
10.7 Monitoring Plan  ................................ ................................ ................................ ........................  69 
10.7.1  Monitoring Schedule  ................................ ................................ ................................ ...........  69 
11.0 LIST OF REFERENCES  ................................ ................................ ................................ ...........  70 
12.0 APPENDICES  ................................ ................................ ................................ ...........................  75 
12.1 ECOG Performance Status  ................................ ................................ ................................ ..... 75 
12.2 Common Terminology Criteria for Adverse Events V4.0 (CTCAE) ................................ ..... 76 
12.3 Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria for Evaluating 
Response in Solid Tumors  ................................ ................................ ................................ ................  77 
12.4 AJCC Staging System  ................................ ................................ ................................ .............  78 
12.5 New York Heart Association Disease Classification  ................................ ...........................  80 
12.6 Vaccine Lot Release and Stability Testing  ................................ ................................ ............  81 
12.7 Summary of Changes  ................................ ................................ ................................ ..............  83 
 
  
Product:   Pembrolizumab (MK -3475)  6 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 1.0 TRIAL SUMMARY  
Abbreviated Title  6MHP Vaccine Plus Pembrolizumab  
Trial Phase  Phase I/II  
Clinical Indication  advanced melanoma (stage IIIB -IV at initial presentation or on 
recurrence),  
Trial Type  Open -label  
Type of control  N/A 
Route of administration  IV (pembrolizumab ); SQ  and ID (6MHP)  
Trial Blinding  N/A 
Treatment Groups  Single Group:  6MHP + pembrolizumab  
Number of trial subjects  A maximum of 25 to obtain 22 evaluable subjects  
Estimated duration of trial  Approximately 47 months.  
Duration of Participation  Approximately 71 months  
Estimated average length of 
treatment per patient  Approximately 2 years   
 
 
 
 
2.0 TRIAL DESIGN  
2.1 Trial Design  
This study is  an open -label, phase I/II study of a vaccine comprised of a mixture of 6 synthetic 
melanoma helper peptides (6MHP) administered in Montani de ISA -51 (incomplete Freund’s 
adjuvant) combined with pembrolizumab  (Figure 1).  The study will accrue up to 25 subjects to 
obtain evaluable data on 22 subjects.  
All subjects will rece ive the same treatment regimen consisting of 6MHP  administered 
intradermally (ID) and subcutaneously  (SQ) on days 1, 8, 15, 43, 64, and 85. Pembrolizumab 
will be administered intravenously (IV) every 3 weeks , beginning on day 1.  Duration of 
pembrolizumab wil l be up to 2 years.  
Biopsy specimens will be collected from the tumor (days 1 and 22) and a sentinel immunized 
node (SIN; day 22).  The SIN biopsy will no longer be required  after protocol modification 
approval to remove the SIN biopsy component . Biopsy and peripheral blood specimens will be  
used in the immunologic analyses . 
Follow -up after last dose of pembrolizumab  will occur  30 days post last infusion .  Subjects will 
be followed annually  for disease status and survival . Tumor assessments will be completed  at 
screening and again at days 57, 127, and as indicated per standard care .  The expectation is 
that there will be additional follow -up as part of standard of care, either by the study physician 
or by a local referring physician. Every effort will be made  to obtain data on disease status and 
survival at all such visits, in addition to the mandated study visits.  
 
Product:   Pembrolizumab (MK -3475)  7 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 2.2 Trial Diagram  
Figure 1. Clinical Trial Schema  
 
3.0 OBJECTIVES  
3.1 Primary Objective s 
(1) Safety:   To determine whether the administr ation of pembrolizumab  plus a vaccine consisting of 6 
melanoma -derived class II MHC -restricted helper peptides (6MHP) is safe.  
(2) Immunogenicity:   To estimate the immunogenicity of 6MHP  in the blood when  co-administ ered 
with pembrolizumab , with or without rem oval of a sentinel immunized node.  
3.2 Secondary Objective s 
To determine whether  combined treatment with 6MHP vaccine plus pembrolizumab:  
(1) Modifies the tumor  microenvironment , including estimation of whether combined treatment:  
(a) Increases infiltration of CD4+ and CD8+ T cells into tumor metastases , especially CD4+ T 
cells reactive to the vaccine peptides.  
(b) Increases Th1 -dominant immune signatures in the tumor microenvironment .  
(2) Induces CD8+ responses to defined melanoma defined antigens (epitope -spreading)  and IgG  
antibody responses to 6MHP  in the b lood and SIN , when SIN biopsy specimen available .  
3.3 Exploratory Objective s 
(1) To obtain preliminary data on whether 6MHP vaccine plus pembrolizumab induces CD4+ or 
CD8+ T cell responses to mutated neoantigens  
 

Product:   Pembrolizumab (MK -3475)  8 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 (2) To obtain pre liminary data on whether 6MHP vaccine plus pembrolizumab induces clinical 
response s (as measured by RECIST 1.1 ) in patients with or without prior PD -1/PD -L1 blockade 
therapy.  
 
4.0 BACKGROUND & RATIONA LE 
4.1 Background  
Cancer immunotherapy for solid tumors is comin g of age, with FDA -approved immuno -
therapeutics in prostate cancer, melanoma, and renal cell cancer.  Interleukin -2 (IL-2) and the 
anti-CTLA -4 antibody ipilimumab are approved for melanoma; both induce durable clinical 
regressions. Recent data also show th at blockade of PD -1/PD -L1 induces durable clinical 
regressions of melanoma, renal cell cancer and non -small cell lung cancer (NSCLC) (1), and 
the PD -1 antibody pembrolizumab has been approved for treatment of a dvanced melanoma in 
patients who have progressed after ipilimumab therapy . Furthermore, antigen -specific adoptive 
T cell therapy induces clinical regressions that are durable in about 20% of treated patients  (2). 
There is excitement about this growing armamentarium of systemic immunotherapeutics, 
whose effects are mediated predominantly by T lymphocytes.  However, d espite the 
effectiveness of available immunotherapeutic approaches , current  therapies still fail in about 
70-80% of patients. Thus, t here is a need for new combination approaches that build on the 
demonstrated clinical value of immune therapy.  
Cancer vaccines inducing antigen -specific T cell responses are emerging as a component of 
combination immunoth erapy.  In the past few years, a cancer vaccine has been approved for 
prostate cancer, based on  improved survival outcomes from two randomized trials (3), and a 
randomized prospective trial in melanoma  patients showed that adding a peptide vaccine to 
high-dose IL -2 significantly prolonged progression -free survival (PFS) when compared to IL -2 
alone  (4).  Thus, after several decades of development and optimiza tion, there is now evidence 
that some cancer vaccines may improve clinical outcomes, in particular in combination with 
other active therapy.  
We have developed a vaccine incorporating 6 intermediate -length peptides that induce s CD4+ 
helper T cell (T H) resp onses (6 helper peptides, 6MHP), and  has clinical activity in patients with 
advanced melanoma  (5).  The 6MHP vaccine has also been shown to induce Th1 dominant T 
cell responses (6)  and cross -priming of CD8+ T cells (7). The current protocol is to obtain 
preliminary data on whether the combination of th e 6MHP vaccine with immune checkpoint 
blockade of PD -1 is safe and improve s immunologic and clinical outcomes compared to  prior 
experience with  each single agent alone. This trial will incorporate correlative studies of 
immune responses in blood, lymph nod es, and tumor to obtain a more complete understanding 
of the host: tumor relationship in the context of these combination therapies. These studies hold 
promise:  
 To modulate T cell infiltration into metastases  
 To increase helper T cell responses to vaccine , and  
 To increase clinical response rates and to extend the life of patients with melanoma . 
 
4.2 Study Rationale  
Evidence for the Role of the Immune System in Protecting Against the Development of Solid 
Tumors  
Product:   Pembrolizumab (MK -3475)  9 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 There has long been evidence of immune responses t o cancer, but evidence of impact on 
tumor progression has not been well demonstrated until recently.  The most convincing 
experimental evidence of the importance of immune surveillance in preventing the development 
of solid tumors is provided by work in mu rine models, in which 50 -100% of knockout mice 
lacking STAT1 and/or IFN γ receptor function developed spontaneous solid tumors of various 
histologies within 12 -15 months, whereas normal mice never developed malignancies during 
the same time period (8).  These st udies strongly support the role of cellular immune function in 
the control of cancer progression.   These findings are supported in humans by the fact that 
blockade of immune checkpoints (CTLA -4 and/or PD -1) induces durable clinical responses in 
patients wi th melanoma and other cancers (9-11). 
The Role of CD4+ Helper T Lymphocytes in Anti -tumor Immune Responses.    
 
Initially, the majority of cancer vaccines were designed to activate the CD8+ cytotoxic T cell arm 
of the host immune system. However, more recent approaches target the activation of CD4+ Th 
cells.  This is based in part on results from earlier studies which demonstrated that depletion of 
CD4+ T-cells abrogates all or part of protective immune response to vaccines (12).  
Furthermore, adoptive therapy with CD4+ T-cells has been show n to induce tumor p rotection in 
some model systems (13,14) .   
 
There are several mechanisms by which T h cells mediate anti -tumor responses.  Th cells can 
activate dendritic cells (DC) for heightened antigen pre sentation, causing the DC to secrete IL -2 
and other cytokines and co -stimulatory molecules that support the induction of CD8+ T cell 
immune response s (15-18). In addition , Th responses support  the establishment  of CD8+ T cell 
memory responses  (19-22). Furthermore, strong T h1 help produces a cytokine milieu which is 
critical to the induction of immune -mediated tumor destruction (23,24) .   
 
4.2.1  Pharmaceutical and Therapeutic Background  
The importance of intact immune surveillance in controlling outgrowth of neoplastic 
transformation has been known for decades  (25).  Accumulating evid ence shows a correlation 
between tumor -infiltrating lymphocytes (TILs) in cancer tissue and favorable prognosis in 
various malignancies   (26-30).  In particular, the presence of CD8+ T-cells and the ratio of CD 8+ 
effector T -cells / FoxP3+ regulatory T -cells seems to correlate with improved prognosis and 
long-term survival in many solid tumors.  
The PD -1 receptor -ligand interaction is a major pathway hijacked by tumors to suppress 
immune control.  The normal funct ion of PD -1, expressed on the cell surface of activated T -
cells under healthy conditions, is to down -modulate unwanted or excessive immune responses, 
including autoimmune reactions.  PD -1 (encoded by the gene Pdcd1) is an Ig superfamily 
member related to C D28 and CTLA -4 which has been shown to negatively regulate antigen 
receptor signaling upon engagement of its ligands (PD -L1 and/or PD -L2) (31-34).  The 
structure of  murine PD -1 has been resolved (35).  PD -1 and family members are type I 
transmembrane glycoproteins containing an Ig Variable -type (V -type) domain responsible for 
ligand binding and a cytoplasmic tail which is responsible for the binding of signaling mole cules.  
The cytoplasmic tail of PD -1 contains 2 tyrosine -based signaling motifs, an immunoreceptor 
tyrosine -based inhibition motif (ITIM) and an immunoreceptor tyrosine -based switch motif 
(ITSM).  Following T -cell stimulation, PD -1 recruits the tyrosine ph osphatases SHP -1 and SHP -
2 to the ITSM motif within its cytoplasmic tail, leading to the dephosphorylation  of effector 
molecules such as CD3ζ, PKCθ and ZAP70 which are involved in th e CD3 T -cell signaling 
cascade (31,36) .  The mechanism by which PD -1 down modulates T -cell responses is similar 
to, but distinct from that of CTLA -4, as both molecules regulate an overlap ping set of signaling 
proteins (37,38) .  PD -1 was shown to be expressed on activated lymphocytes including 
Product:   Pembrolizumab (MK -3475)  10 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 peripheral CD4+ and CD8+ T-cells, B -cells, T  regs and Natural Killer cells (39,40) .  Expression 
has also been shown during thymic development on CD4-CD8- (double negative) T -cells as well 
as subsets of m acrophages and dendritic cells (41).  The ligands for PD -1 (PD -L1 and PD -L2) 
are constitutively expressed or can be induced in a variety of cell types, including non -
hematopoietic tissues as well as in various tumors (37,4 2-44).  Both ligands are type I 
transmembrane receptors containing both IgV - and IgC -like domains in the extracellular region 
and contain short cytoplasmic regions with no known signaling motifs.  Binding of either PD -1 
ligand to PD -1 inhibits T -cell acti vation triggered through the T -cell receptor.  PD -L1 is 
expressed at low levels on various non -hematopoietic tissues, most notably on vascular 
endothelium, whereas PD -L2 protein is only detectably expressed on antigen -presenting cells 
found in lymphoid tis sue or chronic inflammatory environments.  PD -L2 is thought to control 
immune T -cell activation in lymphoid organs, whereas PD -L1 serves to dampen unwarranted T -
cell function in peripheral tissues (37).  Althou gh healthy organs express little (if any) PD -L1, a 
variety of cancers were demonstrated to express abundant levels of this T -cell inhibitor.  PD -1 
has been suggested to regulate tumor -specific T -cell expansion i n subjects with melanoma 
(MEL) (45).  This suggests that the PD -1/PD -L1 pathway plays a critical role in tumor immune 
evasion and should be considered as an attractive target for therapeutic intervention.  
Pembrolizumab  (previously known as SCH 900475  and MK-3475 ) is a potent and highly 
selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly 
block the interaction between PD -1 and its ligands, PD -L1 and PD -L2.   
4.2.2  Preclinical and Clinical Trial Data  
Refer to the Investigato r’s Brochure for Preclinical and Clinical data.  
4.3 Rationale  
4.3.1  Rationale for the Trial and Selected Subject Population  
Melanoma is the fifth most common cancer in the United States , and over 70,000 new cases 
will be diagnosed this year  (46).  Worldwide, approximately 50,000 people die each year from 
melanoma.  When diagnosed and treated for localized disease , a patient’s prognosis is often 
favorable; how ever,  approximately 12% of patients with localized disease eventually recur with 
metastatic disease.  Factors associated with an increased risk of recurrence include the 
presence of ulceration, microsatellitosis, intransit disease and lymph node involvemen t.  Prior to 
the current era of checkpoint blockade therapy, t he median survival time for patients with  stage 
IV metastatic melanoma was  only about 6 -10 months  (47).  
 
CD4+ T-helper  cells have been shown to pla y an important role in anti -tumor immunity.   Anti-
tumor responses can occur  via direct interactions between  CD4+ T cells and tumor cells  or 
alternative ly, through indirect mechanisms  including  the licensing and activation of antigen 
presenting cells  (15,16,48) . The 6MHP vaccine incorporates known MHC class II -restricted 
peptides derived from melanoma -associated tumor antigens and administration of the vaccine 
in an emulsion with Montanide ISA -51 induce s Th1-domi nant CD4+ T cell responses  to the 
peptides  (5,7).   T cell responses against the vaccine  have been induced in 40 -80% of patients, 
and RECIST -defined clinical response rates and disease control rates have been o bserved in  
8% and 30%, respectively. In prior melanoma studies , Mel41  and E1602 , durations of SD and 
clinical responses have been durable, ranging from 1 to 7 years (5,49)  (Table 1). Also, there 
has been a strong and significant association between immune response to the 6MHP and 
survival, in patients with advanced melanoma in the ECOG trial E1602 (univariate, p = 0.005, 
multivariate p =0.038, H R 0.50)  (49)(Reed 2015 3)(Figure 2). 
 
Product:   Pembrolizumab (MK -3475)  11 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
  
 
 
 
 
 
 
 
The programmed cell death receptor -1 (PD -1) is found on activated T cells, and binding of this 
receptor with its ligands results in the down -regulation of T cell responses  (50).  Pembrolizumab 
blocks the interaction between PD-1 and  its ligands , prevent ing down -regulation of the T cell 
response . Clinical responses with pembroliz umab in the melanoma setting have been observed 
in approximately 26% of patients who h ave progressed after ipilimumab therapy  
(51).  Combining  pembrolizumab  with the 6MHP vaccine may lead to enhanced targeted T cell 
responses  against defined tumor antigens and result in the induction of improved  clinical 
response  rates in patient s with metastatic disease .  The goals of this phase I study are to 
evaluate the safety of the combination of 6MHP  and pembroliz umab and also to evaluate the T 
cell response against the 6MHP vaccine in the context of pembr olizumab administration.  
Clinical responses will also be measured.  
 
 
Figure 2:  Overall Survival on E1602  
Overall survival by helper T cell response to 6MHP 
in analyzable patients on arms C  and D of E1602 
trial (n = 64) . 
 
To improve the clinical benefit of this and other vaccines, it is critical to support T cell infiltration 
and function in the tumor microenvironment. We have reported that melanoma metastases can 
be categorized into 3 Immunotypes based on immune cell infiltrate s, where Immunotype A 
melanomas (29%) lack infiltrates, Immunotype B (63%) have immune cell infiltrates cuffing 
intratumoral vessels but not infiltrating tumor nests, and only Immunotype C melanomas (8%) 
have diffuse immune infiltrates  (52). Blockade of PD -1/PD -L1 can increase T cell infiltration and  
combination with a vaccine should improve tumor targeting. Also, recent data have revealed Table 1.  Clinical Response Rates to 6MHP Vaccines in Subjects 
with Advanced Melanoma in Mel41 and E1602 Trials (RECIST)  
Study  N CR+PR  CR+PR+SD  RR DCR  
Mel41  17 2 4 12% 24% 
E1602 Arm D  (6MHP)  42 3 15 7.1%  36% 
E1602 Arm C  32 2 8 6.3%  25% 
All studies  91 7 27 7.7%  30% 

Product:   Pembrolizumab (MK -3475)  12 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 increased PD1 expression on exhausted CD4+ T cell s (53); thus, blocking PD1/PDL1 is 
expected to support CD4+ T cell function.  
The current proposal is for a clinical trial combining this active 6MHP vaccine with 
pembrolizumab . Primary endpoints include safety  and immune response. Se condary endpoints 
will include assessment of changes in the tumor microenvironment. Exploratory objectives will 
include assessment of  objective response rate , overall clinical outcome and association 
between immune response and survival .   There is great i nterest in obtaining preliminary data 
on whether the combination of 6MHP vaccine and pembrolizumab may increase objective 
clinical response rates, PFS, or overall survival. However, patterns of care for patients are 
changing rapidly as new immunotherapy ag ents are becoming available.  On one hand, the 
overall response rate for patients pretreated with ipilimumab is about 2 3%, but  for patients 
treated with pembrolizumab as first -line therapy is 33%.  Thus, powering the study for response 
rate would depend on  limiting enrollment to only one of these approaches. In addition, 
combination immunotherapy with PD -1 blockade plus CTLA -4 blockade is being employed, with 
response rates of about 50%, but with much higher toxicity than with pembrolizumab alone.  
Patients  may be selected for one of these 3 regimens (pembrolizumab first, CTLA -4 blockade 
first, or combination therapy) for reasons that may affect the patient populations, including 
patient frailty, age, or biomarker assessment of metastases.  Thus, the present  study is 
designed to obtain pilot data on clinical outcome but to power the study for safety, detection of 
effects on the immune responses (in all patients), and for detection of changes in the tumor 
microenvironment (in a subset of patients).  
4.3.2  Rationale f or Dose Selection/Regimen/Modification   
Pembrolizumab :   
The rationale for further exploration of 2 mg/kg and comparable doses of pembrolizumab in 
solid tumors is based on: 1) similar efficacy and safety of pembrolizumab when dosed at either 
2 mg/kg or 10 mg/kg Q3W in melanoma patients, 2) the flat exposure -response relationships of 
pembrolizumab for both efficacy and safety in the dose ranges of 2 mg/kg Q3W to 10 mg/kg 
Q3W, 3) the lack of effect of tumor burden or indication on distribution behavior of 
pembrolizumab (as assessed by the population PK model) and 4) the assumption that the 
dynamics of pembrolizumab target engagement will not vary meaningfully with tumor type.  
The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is  based 
on simulations performed using the population PK model of pembrolizumab showing that the 
fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent with 
those obtained with the 2 mg/kg dose every 3 weeks, 2) will main tain individual patient 
exposures in the exposure range established in melanoma as associated with maximal efficacy 
response and 3) will maintain individual patients exposure in the exposure range established in 
melanoma that are well tolerated and safe.  
A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and 
to reduce potential for dosing errors.  A fixed dosing scheme will also reduce complexity in the 
logistical chain at treatment facilities and reduce wastage.  
Standard of care in the metastatic/unresectable setting is administration of pembrolizumab for 
up to two years. Regulatory approval does not limit the time on therapy. In this study, we will 
continue pembrolizumab  for 2 years of therapy in the setting of stable disease or response 
without limiting toxicity.  
Product:   Pembrolizumab (MK -3475)  13 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 6MHP vaccine :   
The 6MHP vaccine was tested at 3 dose levels (200, 400, 800 mcg per vaccine) and no 
differences were observed in immunogenicity, Th1 profiles or in toxicity (6).  Thus the lowest 
dose of 200 mcg will be used in this protocol.  
4.3.3  Rationale for Endpoints  
The 6MHP vaccine has been administered to over 200 subjects and overall has been  well-
tolerated.   A summary of toxicities related to 6MHP administrat ion may be found in Table 2.   
Table 2.  Reported Toxicities for 6MHP Vaccines in Humans (n=207)  
Toxicity (based on max grade)  Grade 1  Grade 2  Grade 3  Grade 4  
     
LOCAL, INJECTION SITE      
Injection site reaction  18% 56% 2.4%   
Ulceration   5% 1.4%   
     
CONSTITUTIONAL      
Fatigue  43% 8% 3.4%   
Headache  27% 1.4%  0.5%   
Rigors, Chills  24% 1.4%  --  
Nausea  23% 2% 0.5%   
Sweating  19% 1%   
Myalgias  18% 0.5%    
Arthralgias  17% 0.5%    
Fever  16% 2%   
Dizziness  13%    
Anorexia  13% 3%   
Diarrhea  12% 2%   
Cough  13%    
Allergic rhinitis  11%    
Nasal/paranasal reactions  11%    
Pain larynx/throat  10%    
Flushing  10%    
Pruritis  9% 0.5%    
Rash  6% 3.4%    
Dyspnea  5% 1% 0.5%   
Vomiting  5% 1% 0.5%   
Flu-like syndrome  6%    
Mucositis  6%    
Constipation  5%    
Autoimmune reaction  4% 0.5%    
Wound, non -infectious  4%    
Pain, other  2% 1% 0.5%   
Abdominal pain  1.4%   0.5%   
Tinnitus   0.5%  0.5%   
Tumor pain  0.5%   0.5%   
Hearing (without monitoring program)    0.5%   
     
CLINICAL LABORATORY      
Hyperglycemia (not fasting)  22% 1%   
Hemoglobin, low  17% 1% 0.5%   
Hyperkalemia  13%    
Lymphopenia  9% 2.9%  1%  
Product:   Pembrolizumab (MK -3475)  14 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 Toxicity (based on max grade)  Grade 1  Grade 2  Grade 3  Grade 4  
Leukocytes  8% 1%   
Hyponatremia  7%    
Increased creatinine  6% 0.5%   
Hypoglycemia  6%    
AST, SGOT  5%   0.5%  
ALT, SGPT  4%  1%  
Neutrophils  3% 2%   
Metabolic, Other  3% 0.5%  0.5%   
Alk phos  4% 0.5%    
Bilirubin  3%  0.5%   
 
Pembrolizumab  has been evaluated in multiple studies with doses ranging from 1 mg/kg to 10 
mg/kg Q2W to Q3W.  Safety  data from the prior PN001 phase I clinical trial study  (479 
subjects)  suggest  that pembrolizumab is well -tolerated, with 4.2% of study subjects 
discontinuing study treatment due to a treatment -related AE  (Investigator’s Brochure) .   
The described trial is the first evaluation of  pembrolizumab  combined  with a peptide -based 
vaccine (6MHP)  and the first evaluation of any PD -1/PD -L1 antibody in combination with a 
helper -peptide vaccine .  Thus, safety is included as a primary endpoint for this trial .   Additional 
endpoints include measures of immunogenicity and clinical efficacy.   
4.3.3.1  Efficacy Endpoints  
From prior clinical trials with the 6MHP vaccine, we determined that we can induce T cell 
responses to the peptides following vaccination  (5,49,54) . In addition, vaccination with 6MHP  
led to clinical responses in a modest number of subjects  (5,49) .  Administration of 
pembrolizumab with 6MHP may enhance  CD4+ T cell response s directed against tumor -derived 
peptides within the vaccine and lead to improved disease control by preventing down -regulation 
of the T cell response following vaccination. Accordingly, we have included endpoints to obtain 
preliminary da ta on whether combination of 6MHP with immune chec kpoint blockade improves 
immunologic and clinical outcomes compared with historical data for each single agent alone.    
Biomarker Research  
In order to optimize co mbinatorial immunotherapy approaches for the  treatment of  cancer, we 
must obtain a more complete understanding of the host: tumor relationship in the context of 
these combination therapies . The following analyses are included as part of this study to 
evaluate the biology of host immune responses in the peripheral blood , within a lymph node 
immediately draining a vaccine site (sentinel immunized node (SIN)),  and within  sites of tumor .  
Blood and tumor tissue samples will be taken pre - and post - study drug administration to 
evaluate changes over time.  A SIN biopsy will be taken one we ek following the third vaccine  
for a subset of patients . 
Measuring T cell responses to Melanoma Antigens in the Vaccine :  To estimate whether the 
immunogenicity of 6MHP, and induction of epitope -spreading, will be increase d by co -
administration with pembrolizumab.   
We anticipate that co -administration of pembrolizumab with a helper peptide vaccine may 
increase the CD4+ T cell response to the vaccines.  We have also observed induction of CD8+ 
T cells  following vaccination w ith 6MHP , presumably due to epitope spreading  (7).  Thus, w e 
hypothesize that CD4 and CD8 T cell responses will increase in frequency, magnitude, and 
duration with pembrolizumab.  
Product:   Pembrolizumab (MK -3475)  15 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 Immune responses in PBMC and SI N will be measured by ELIspot  assay, proliferation assay, 
and/or flow cytometry .  Increases in immune response rate, magnitude, and duration will all be 
of interest.  Of greatest interest will be the induction of durable helper T cell responses, defined 
as responses in PBMC at 2 or more of the blood draws after day 85 .  Also, we will test for T cell 
responses to multiple antigens, using overlapping 15 -mers from NY -ESO -1, MelanA, MAGE -
A1, MAGE -A3, tyrosinase, and gp100, as well as for CD8+ T cell responses t o a panel of at 
least 14 defined epitopes from these proteins. This will also include analysis of immune 
responses in the tumor microenvironment, as detailed  below, with the expectation of tumor 
biopsies in at least 14 of the patients enrolled on this tria l. 
Since we have observed induction of epitope spreading to peptide antigens not in the vaccine, 
we hypothesize that vaccination with helper peptides will also induce epitope spreading to 
mutated neoantigens, and that the activity of T cells reactive to th em in the tumor may be 
supported by co -administration with pembrolizumab.  Thus, we propose exploratory studies to 
identify putative neoantigens in these patients and to test whether patients with immune 
responses to the vaccine also have epitope spreading  to recognition of those mutated 
neoantigens, and whether T cells reactive to those antigens may be identified among tumor 
infiltrating lymphocytes.  
Impact of sentinel immunized node biopsy, and presence of tumor, on circulating immune 
response .  The induc tion of immune responses to vaccines are presumed to be mediated by 
interactions of T cells and antigen presenting cells in the vaccine -draining node (sentinel 
immunized node, SIN).  Measurement of circulating T cell responses thus may be affected by 
remov al of the SIN at week 3 in the first set of patients enrolled on this trial.  They may also be 
affected by homing to metastatic tumor.  For those tumors that permit infiltration by vaccine -
reactive T cells , it would be ideal if T cells induced by vaccinati on primarily home to tumor and 
are relatively depleted from circulation.  Thus, we are interested in obtaining preliminary data on 
whether circulating immune responses differ, after the SIN is harvested, for the first patients 
enrolled, who undergo SIN bio psy, compared to those who do not undergo SIN biopsy.  To 
address this, the protocol is revised for the latter group of patients not to have SIN biopsy.   
Tumor microenvironment .  To determine whether Th1 CD4+ T cells induced by vaccination 
infiltrate the tumor microenvironment and whether they are associated with a favorable immune 
signature.      
Induction of T cells reactive to melanoma antigens in the circulation is necessary but not 
sufficient for tumor control.  We will test whether CD4+ T cells induc ed by the 6MHP vaccine 
infiltrate melanoma metastases, for the subset of patients (at least 12 patients)  who have tumor 
accessible for biopsy (typically skin metastases, superficial nodes, and soft tissue masses). 
Tumor tissue can be limiting; so isolation  of viable cells in adequate number from metastatic 
tumor biopsies can be challenging.  An alternate approach is to identify T cell receptors of the T 
cells induced by the vaccines.  We hypothesize that there will be increased infiltration of T cells 
induc ed by 6MHP vaccine when co -administered with pembroliz umab, compared to pre -
treatment biopsies.  We also hypothesize that expansion of Th1 CD4+ cells will support 
expansion of tumor -reactive CD8+ T cells in the tumor microenvironment, which will be 
evaluat ed simultaneously.  
We will determine if there is evidence of a T cell response in PBMC. Immune responses are 
anticipated in more than 50% of patients.  The PBMC samples with responses and 
corresponding pretreatment PBMC samples will be prepared as isolated  CD4+ T cell 
populations by negative selection using Miltenyi beads. Those cells will be submitted for T -cell 
receptor (TCR) sequence profiling by ImmunoSeq (Adaptive Biotechnologies, Seattle, WA), 
which will identify TCRs enriched in the PBMC and SIN as T  cells responding to the vaccines.   
Product:   Pembrolizumab (MK -3475)  16 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 We will also send frozen (or FFPE) tumor tissue for the same analysis, as a measure of 
whether T cells induced by vaccination are then found infiltrating the tumors.   In cases where 
tumor -infiltrating lymphocytes can b e isolated in adequate quantity to perform functional 
analyses, this will be done as well, as validation of the TCR sequencing studies, but we expect 
that to be an uncommon event.  The TCR molecular analysis will be feasible in a larger 
proportion of patie nts. Associations with clinical outcome will be noted as pilot data.  
To understand whether the combination therapy induces Th1 -biased immune signatures in the 
tumor microenvironment, we will perform gene expression analysis on pretreatment tumors day 
1 and treated tumors day 22. Tumor specimens placed in RNA -Later at the patient bedside, 
typically within 5 min of excision and stored at -80oC, provide source material. RNA will be 
isolated by our laboratory staff from those specimens. RNA amplification, arra y application 
using HUMAN GENE 2.0 ST chips from Affymetrix Inc, RNA -seq, or comparable analysis, and 
data analyses will be performed using Partek Genomic Suite & Ingenuity Pathway Analysis 
(IPA) software to provide principal component analysis, identifica tion of genes differentially 
expressed on day 22 (vs. day 1) to mark effects of the combination therapy.  Changes will be 
evaluated in canonical pathways, gene network, and transcription factor expression. Gene 
expression of pretreatment samples will be co rrelated with clinical responses.   
The histology evaluations will be compared to the TCR expression data, to assess whether 
infiltration with vaccine -reactive CD4+ T cells is associated with increased infiltration of CD4+ 
cells or lymphocytes overall, or with Immunotype C infiltration patterns  (55) in particular.  
Immunohistochemical stains to clarify these observations may be performed on tumors.  
5.0 METHODOLOGY  
5.1 Entry Criteria  
5.1.1  Diagnosis/Condition for Entry into th e Trial  
Subject s with unresectable stage IIIB or IIIC melanoma, or stage IV metastatic melanoma  that 
have clinical or radiological evidence of disease. Stage definition may occur at original 
diagnosis or after recurrence.  These subject s may have had cutane ous, uveal, mucosal primary 
melanoma, or an unknown primary melanoma.  Staging must be confirmed by cytological or 
histological examination. Staging of cutaneous melanoma will be based on the AJCC  v7 
staging system (Appendix 12.4) (56). Subjects  must be eligible to be treated with 
pembrolizumab based on clinician judgement.  
5.1.2  Subject Inclusion Criteria  
In order to be eligible  for participation in this trial : 
1. A subject must b e willing and able to provide written informed consent/assent for the trial.  
2. A subject must b e  18 years of age on day of signing informed consent.  
3. A subject  may be naïve for immunotherapy agents or have r eceived interferon -alpha, 
ipilimumab or other CTLA -4 antibody, PD -1 antibody (or anti -PD-L1 antibody), interleukin -2, 
or prior cancer vaccines other than the 6MHP vaccine . Patients who have received a PD -
1/PD -L1 antibody may be enrolled in either of the fo llowing settings:  
a) A patient who has experienced progression of melanoma during that therapy or 
after having completed that therapy ,  
Product:   Pembrolizumab (MK -3475)  17 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 b) A patient who fails to experience an objective clinical response  (partial response or 
complete response by RECIST 1.1 crit eria) after either 12 weeks of continuous 
anti-PD1 antibody or anti -CTLA4/anti -PD1 combination therapy, and is a candidate 
to receive pembrolizumab therapy  
4. A subject must h ave measurable disease based on RECIST 1.1 .   
Subject s will be required to have radi ological studies to define radiologically evident 
disease.  Required studies include:  
 Chest CT scan,  
 Abdominal and pelvic CT scan, and  
 Head CT scan or MRI  
PET/CT fusion scan may replace scans of the chest, abdomen, and pelvis.  
5. Subject s who have metastatic melanoma available for biopsy pretreatment and on day 22 
must consent to having those biopsies.  These me lanoma lesions  may be in nodes, skin, 
soft tissue, liver, or other sites that can be accessed safely by needle biopsy, incisional or 
excisional biopsy,  with or without image guidance.  The lesions to be biopsied must be 
specified at study enrollment and not included as target lesions for RECIST calculations.  In 
instances where disease that is accessible to biopsy is limited, archival tissue specimens 
collected after a subject ’s last systemic therapy may be used for baseline measures.  
Subjects must have  measurable disease in addition to the lesion(s) to be biopsied.  
6. Subject s who have had brain metastases will be eligible if all of the following are true:  
 Each brain metastasis must have been completely removed by surgery or each 
unresected brain metastasis must have been treated with stereotactic radiosurgery.   
 There has been no evident growth of any brain metastasis since the most recent 
treatment  
 No brai n metastasis is > 2 cm in diameter at the time of registration.  
 Neurologic symptoms have returned to baseline,  
 There is  no evidence of new or enlarging brain metastases,  
 Subjects  are not using steroids for at least 7 days prior to registration .   
7. The mos t recent surgical resections or gamma -knife therapy for malignant melanoma must 
have been compl eted ≥ 1 week prior to r egistration.  
8. A subject must h ave a performance status of 0 or 1 on the ECOG Performance Scale.  
9. A subject must d emonstrate adequate organ function as defined in  Table 3, all screening 
labs should be performed within 28 days of treatment initiation.           
Table 3.  Adequate Organ Function Laboratory Values  
System  Laboratory Value  
Hematological   
Absolute neutrophil count (ANC)  ≥1,500 /mcL  
Platelets  ≥100,000 / mcL  
Hemoglobin  ≥9 g/dL or ≥5.6 mmol/L  
Renal   
Serum creatinine OR 
Measured or calculateda creatinine 
clearance  ≤1.5 X upper limit of normal (ULN) OR 
 
≥60 mL/min f or subject with creatinine levels > 1.5 X 
Product:   Pembrolizumab (MK -3475)  18 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 System  Laboratory Value  
(GFR can also be used in place of 
creatinine or creatinine clearance ) institutional ULN  
Hepatic   
Serum total bilirubin  ≤ 1.5 X ULN OR 
 Direct bilirubin ≤ ULN for subjects with total bilirubin levels 
> 1.5 ULN  
AST (SGOT) and ALT (SGPT)  ≤ 2.5 X ULN  OR 
≤ 5 X ULN for subjects with l iver metastases  
Coagulation  
International Normalized Ratio (INR) or 
Prothrombin Time (PT)  
 
Activated Partial Thromboplastin Time 
(aPTT)  ≤1.5 X ULN unless subject is receiving anticoagulant 
therapy  
as long as PT or PTT is within therapeutic range of 
inten ded use of anticoagulants  
≤1.5 X ULN unless subject is receiving anticoagulant 
therapy  
as long as PT or PTT is within therapeutic range of 
intended use of anticoagulants  
aCreatinine clearance should be calculated per institutional standard.  
 
10. Female subje cts of childbearing potential should have a negative urine or serum pregnancy  
test within 72 hours prior to receiving the first dose of study medication.  If the urine test is 
positive or cannot be confirmed as negative, a serum pregnancy test will be requ ired.   
11. Female subjects of childbearing potential (Section 5.7.2) must  be willing to use an 
adequate method of contracept ion as outlined in Section 5.7.2  – Contraception , for the 
course of the study through 120 days after the last dose of study medication.    
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for 
the subject.  
12. Male subjects of childbearing potential (Section 5.7.2) must  agree to use an adequate 
method of contraception as outlined in Section 5.7.2 – Contr aception, starting with the first 
dose of study therapy through 120 days after the last dose of study therapy.  
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for 
the subject.  
13. Blood is to be collected for HLA typin g (Class I and Class II), which will be analyzed as part 
of the immunologic endpoints, but HLA type will not be an inclusion/exclusion criterion.  
14. A subject  must have at least two intact (undissected) axillary and/or inguinal lymph node 
basins.  
5.1.3  Subject Excl usion Criteria  
    The subject must be excluded from participating in the trial if the subject:  
1. Is currently participating in or has participated in a study of an investigational agent or using 
an investigational device within 4 weeks of the first dose of treatment.  
2. Is currently receiving Interferon (e.g. Intron -A®), growth factors (e.g. Procrit®, Aranesp®, 
Neulasta®), or interleukins (e.g. Proleukin®), or has received these agents  within 4 weeks of 
the first dose of treatment.  
3. Is currently receiving nitros ureas or has received this therapy within the preceding 6 weeks  
of first dose of treatment . 
Product:   Pembrolizumab (MK -3475)  19 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 4. Has a diagnosis of immunodeficiency  or is receiving systemic steroid therapy or any other 
form of immunosuppressive therapy within 7 days prior to registration  with the following 
exceptions (which are permitted):  
 replacement steroid doses i n patients with adre nal or pituitary insufficiency  
 Intra-articular steroid injections  
 Inhaled steroids (e.g.: Advair®, Flovent®, Azmacort®) at low doses (less than 500 
mcg flutica sone per day, or equivalent)  
 Topical and nasal corticosteroids  
 Non-steroidal anti -inflammatory drugs  
5. Has had a prior monoclonal antibody within 3 weeks prior to study Day 1 or who has not 
recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to agents administered 
more than 4 weeks earlier .   
6. Has had prior chemotherapy, targeted small molecule therapy, or external beam radiation 
therapy  within 2  weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at 
baseline) from adverse events due to a previously administered agent.   
- Note:  Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and 
may qualify for the  study.  
- Note:  If subject received major surgery, they must have recovered adequately 
from the toxicity and/or complications from the intervention prior to starting therapy.   
7. Has a known additional malignancy that is progressing or requires active treatme nt.  
Exceptions include carcinoma in situ of the breast (DCIS or LCIS) , basal cell carcinoma of 
the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone 
potentially curative therapy.   
8. Has known active central nervous sy stem (CNS) metastases and/or carcinomatous 
meningitis.   
9. Has an active autoimmune disease requiring systemic treatment within the past 3 months 
or a documented history of clinically severe autoimmune disease, or a syndrome that 
requires systemic steroids o r immunosuppressive agents.  Exceptions to this criterion 
include:  
 Subjects with vitiligo or other depigmenting illness.  
 Resolved childhood asthma/atopy  
 Intermittent use of bronchodilators or local steroid injections  
 Hypothyroidism stable on hormone repl acement or Sjog ren’s syndrome  
 The presence of laboratory evidence of autoimmune disease (e.g. positive ANA 
titer) without symptoms  
 Mild arthritis requiring NSAID medications  
10. Has a history of  (non-infectious ) pneumonitis  that required steroids or current e vidence of 
interstitial lung disease or pneumonitis .  
11. Has an active infection requiring systemic therapy.  
12. Has a history or current evidence of any condition, therapy, or laboratory abnormality that 
might confound the results of the trial, interfere with th e subject’s participation for the full 
Product:   Pembrolizumab (MK -3475)  20 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 duration of the trial, or is not in the best interest of the subject to participate, in the opinion 
of the treating investigator.   
13. Has known psychiatric or substance abuse disorders that would interfere with cooperat ion 
with the requirements of the trial.  
14. Is pregnant or breastfeeding, or expecting to conceive or father children within the 
projected duration of the trial, starting with the pre -screening or screening visit through 120 
days after the last dose of trial t reatment.  
15. Is HIV positive or has evidence of active Hepatitis C virus (testing to be done within 6 
months of study entry) or active Hepatitis B virus . 
16. Has rece ived a live vaccine  or allergy desensitization injections  within 30 days prior to the 
first dose of trial treatment .   
17. Has known or suspected allergies to any component of the vaccine.  
18. Has been vaccinated previously with any of the synthetic peptides included in this protocol.  
19. Is classified according to the New York Heart Association classification a s having Class III 
or IV heart disease  (Appendix 12.5 ). 
20. Has uncontrolled diabetes, defined as having a HGBA1C  8.5%. 
21. Has a b ody weight < 110 pounds (without clothes) at enrollment, due to the amount and 
frequency with w hich blood will be drawn.  
5.2 Trial Treatments  
The treatment to be used in this trial is outlined below in Table 4. 
Table 4.  Trial Treatment  
 
Drug  Dose/Potency  Dose 
Frequency  Route of 
Administration  Regimen/Treatment 
Period  Use 
Pembrolizumab1 200 mg  Q3W  
starting at 
Day 1  IV infusion  Up to 2 y ears Experimental  
6MHP  200 mcg each 
peptide  Days 1, 8, 
15, 43, 64, 
85 SQ and ID  
Injection  Through Day 85  Experimental  
1The pembrolizumab  dosing interval may be increased as described in Section 5.2.1. 3. 
Trial treatment should begin within 14 days of registration . 
5.2.1  Dose Selection/Modification  
5.2.1.1  Dose Selection  
The rationale for selection of doses to be used in this trial is provided in Section 4.0 – 
Background and Rationale.   
5.2.1.2  Study Drug Preparation and Administration  
Pembrolizumab  
Details on the preparation and administration of pembrolizumab are provided in the Pharmacy 
Manual  for MK -3475 (pembrolizumab).  
Product:   Pembrolizumab (MK -3475)  21 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 6MHP  
Details on the prepara tion of 6MHP will be provided on vaccine mixing forms .  The prepared 
peptide vaccines  will be stored in a plastic syringe and delivered to the clinicians in a plastic 
bag.  This bag with the syringe will be stored at room temperature until the vaccine is 
administered.  Ideally, the vaccine should be administered  within  1-2 hours after mixing.  If the 
vaccine is not administered within 4 hours after mixing, it should be discarded.  
Designation of Vaccine Sites  
Evidence suggests nodes proximal to a tumor site may be relatively immunosuppressed; 
therefore, the vaccination sites will be selected to be distant from the sites of tumor whenever 
possible.  In general, subject s will be vaccinated in upper arm or thigh sites with intact draining 
nodes.  Vaccines will b e administered at the designated site(s).  Chronic inflammatory reactions 
are expected to occur in patients at their vaccine sites. Induration may persist for months, but is 
not expected to require additional therapy.  Sterile abscesses may occur in some p atients.  
These are not a basis for discontinuation of the vaccines unless they lead to ulceration of 
greater than 2 cm diameter, require antibiotics, or require surgical debridement.    
Administration of 6MHP  
The vaccine regimen will be the same for all su bjects.  Days 1, 8, 15, 43, 64, 85:  200 mcg each 
of the 6 peptides (Table 5), emulsified in Montanide ISA -51 adjuvant  (2 ml total will be 
administered) .  Each of vac cines 1-6 will be admi nistered subcutaneously (50%) and 
intradermally (50%) .  Vaccines 1 -3 will be administered  at one skin site . Vaccines  4-6 will also 
be administered at one skin site, but in a separate location than vaccines 1 -3.  If either vaccine 
site has severe inflammati on or ulceration after 1 -2 vaccines, the next vaccine(s) may be 
placed near the original site.  
 
Table 5.  Class II -Restricted Melanoma Peptides  
Allele  Sequence  Epitope  
HLA-DR4 AQNILLSNAPLGPQFP  Tyrosinase 56-70#  
HLA-DR15  FLLHHAFVD SIFEQWLQRHRP  Tyrosinase 386-406 
HLA-DR4 RNGYRALMDKSLHVGTQCALTRR  Melan -A/MART -151-73 
HLA-DR11  TSYVKVLHHMVKISG  MAGE -3 281-295 
HLA-DR13  LLKYRAREPVTKAE  MAGE -1,2,3,6 121-134 
HLA-DR4 & -DR1 WNRQLYPEWTEAQRLD  gp100 44-59 
# An alanine residue was added to the N-terminus to prevent cyclization.  
 
Pre-medications  
None required.  
Post-Vaccination Observation  
All subject s will be closely observed for adverse events for at least 20 minutes following each 
vaccination.  Any time thereafter, subject s should report any ad verse events to the research 
coordinator or research clinician.  
Product:   Pembrolizumab (MK -3475)  22 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 5.2.1.3  Dose Modification  
6MHP vaccines :  There will be no dose modifications of the vaccine components.   
In circumstances where assessment of an AE is limited, such as by intercurrent illness, or w hen 
laboratory studies are required to assess for other causes of toxicity, the vaccine schedule may 
be interrupted for up to 21 days.  Delay of one vaccine administration by up to 21 days will not 
be considered a protocol violation if due to an AE, regard less of attribution.  If more than one 
vaccine is delayed by 21 days due to an AE, regardless of attribution, vaccine treatment should 
be discontinued, though the other systemic therapy may be continued.  
Pembrolizumab:   Pembrolizumab  will be withheld for d rug-related AEs as detailed  below  and in  
Table  6.  In the event that the dose of pembrolizumab is held, subjects may continue receiving 
the 6MHP vaccine  if the investigators do not believe the toxicities are attrib utable to the 
vaccines.   
Adverse events (both non -serious and serious) associated with pembrolizumab  exposure may 
represent an immunologic etiology.  These adverse events may occur shortly after the first dose 
or several months after the last dose of trea tment. Pembrolizumab must  be withheld  for drug-
related  toxicities  and severe or life -threatening AEs as per Table  6, below. See Section 5.6 and 
Table 8 for supportive care guidelines, including use of corticosteroids.  
Table 6. Dose Modification and Toxicity Management Guidelines for Immune -related AEs Associated 
with Pembrolizumab  
General instructions:  
1. Corticos teroid taper should be initiated upon AE improving to Grade 1 or less and continue to taper over at least 4 
weeks.  
2. For situations where pembrolizumab has been withheld, pembrolizumab can be resumed after AE has been reduced to 
Grade 0 -1 and cor ticosteroid has been tapered. Pembrolizumab should be permanently discontinued if AE does not 
resolve within 12 weeks of last dose or corticosteroids cannot be reduced to ≤10 mg prednisone or equivalent per day 
within 12 weeks.  
3. For severe and life -threatening irAEs, IV corticosteroid should be initiated first followed by oral steroid. Other 
immunosuppressive treatment should be initiated if irAEs cannot be controlled by corticosteroids.  
 
Immune -
related AEs  Toxicity grade or 
conditions 
(CTCAEv4.0)  Action taken to 
pembrolizumab  irAE management with 
corticosteroid and/or other 
therapies  Monitor and follow -up  
Pneumonitis  Grade 2  Withhold   Administer corticosteroids 
(initial dose of 1 -2 mg/kg 
prednisone or equivalent) 
followed by taper  
  Monitor participants for signs and 
symptoms of pneumonitis  
 Evaluate participants with 
suspected pneumo nitis with 
radiographic imaging and initiate 
corticosteroid treatment  
 Add prophylactic antibiotics for 
opportunistic infections  Grade 3 or 4, or 
recurrent Grade 2  Permanently 
discontinue  
Diarrhea / 
Colitis  Grade 2 or 3  Withhold   Administer corticoster oids 
(initial dose of 1 -2 mg/kg 
prednisone or equivalent) 
followed by taper  
  Monitor participants for signs and 
symptoms of enterocolitis (ie, 
diarrhea, abdominal pain, blood or 
mucus in stool with or without 
fever) and of bowel perforation 
(ie, peritoneal  signs and ileus).  
 Participants with ≥ Grade 2 
Product:   Pembrolizumab (MK -3475)  23 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 Grade 4  Permanently 
discontinue  diarrhea suspecting colitis should 
consider GI consultation and 
performing endoscopy to rule out 
colitis.  
 Participants with diarrhea/colitis 
should be advised to drink liberal 
quantities of clear fluids.  If 
sufficient oral fluid intake is not 
feasible, fluid and electrolytes 
should be substituted via IV 
infusion.  
AST / ALT 
elevation or 
Increased 
bilirubin  Grade 2  Withhold   Administer corticosteroids 
(initial dose of 0.5 - 1 mg/kg 
prednisone or equivalent) 
followed by taper   Monitor with liver function tests 
(consider weekly or more 
frequently until liver enzyme value 
returned to baseline or is stable  
Grade 3 or 4  Permanently 
discontinue   Administer corticosteroids 
(initial d ose of 1 -2 mg/kg 
prednisone or equivalent) 
followed by taper  
Type 1 diabetes 
mellitus (T1DM) 
or 
Hyperglycemia  
 Newly onset 
T1DM or  
Grade 3 or 4 
hyperglycemia 
associated with 
evidence of -cell 
failure  Withhold   Initiate insulin replacement 
therapy for pa rticipants with 
T1DM  
 Administer anti -hyperglycemic 
in participants with 
hyperglycemia  
  Monitor participants for 
hyperglycemia or other signs and 
symptoms of diabetes.  
Hypophysitis  Grade 2  Withhold   Administer corticosteroids and 
initiate hormonal replace ments 
as clinically indicated.    Monitor for signs and symptoms of 
hypophysitis (including 
hypopituitarism and adrenal 
insufficiency)   Grade 3 or 4  Withhold or 
permanently 
discontinue1  
Hyper -
thyroidism  Grade 2  Continue   Treat with non -selective bet a-
blockers (eg, propranolol) or 
thionamides as appropriate   Monitor for signs and symptoms of 
thyroid disorders.  
 
Grade 3 or 4  Withhold or  
permanently 
discontinue1 
Hypothyroidism  Grade 2 -4 Continue   Initiate thyroid replacement 
hormones (eg, levoth yroxine or 
liothyroinine) per standard of 
care  Monitor for signs and symptoms of 
thyroid disorders.  
 
Nephritis and 
Renal 
dysfunction  Grade 2  Withhold   Administer corticosteroids 
(prednisone 1 -2 mg/kg or 
equivalent) followed by taper.   Monitor changes of r enal function  
 
Grade 3 or 4  Permanently 
discontinue  
Myocarditis  Grade 1 or 2  Withhold   Based on severity of AE 
administer corticosteroids   Ensure adequate evaluation to 
confirm etiology and/or exclude 
other causes  
 Grade 3 or 4  Permanently 
discontinu e 
All other 
immune -related Intolerable/ 
persistent Grade 2  Withhold   Based on type and severity of 
AE administer corticosteroids   Ensure adequate evaluation to 
confirm etiology and/or exclude 
Product:   Pembrolizumab (MK -3475)  24 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 AEs Grade 3  Withhold or 
discontinue based 
on the type of 
event.  Events 
that require 
discontinuation 
include and not 
limited to:  
Gullain -Barre 
Syndrome, 
encephalitis  other causes  
 
Grade 4 or 
recurrent Grade 3  Permanently 
discontinue  
1. Withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physician.   
NOTE:  
For participants with Grade 3 or 4 immune -related endocrinopathy where withhold of pembrolizumab is required, pembrolizumab may be 
resumed when AE resolves to ≤ Grade 2 and is controlled with hormonal replac ement therapy or achieved metabolic control (in case of 
T1DM).   
 
Dosing interruptions are permitted in the case of medical / surgical events or logistical reasons 
not related to study therapy  (e.g., elective surgery, unrelated medical events, patient vac ation, 
and/or holidays). Subjects should be placed back on study therapy within 3 weeks of the 
scheduled interruption, unless otherwise discussed with the Sponsor -Investigator . The reason 
for interruption should be documented in the patient's study record.  
5.2.1.4  Delayed Visit for Reasons Other Than Toxicity  
A schedule for return visits should be established at the first visit.  If a subject  misses a 
treatment, the missed treatment will be administered as soon as possible, and treatment will be 
continued for an ad ditional time period so that the subsequent vaccinations are given in the 
appropriate intervals.  Subject s who are vaccinated outside of the established schedule should 
return to the original schedule as soon as possible.  
The table below ( Table 7) defines what constitutes a delayed visit, whether the subject  should 
continue to be treated, and whether a protocol violation should be reported and recorded.  The 
range of days is counted from the original scheduled date.    
Table 7.  Delayed Visit for Reasons other than Toxicity  
Treatment Period  Range of Days  Subject  Treatment  Protocol  
Deviation  
Biopsy/ Vaccine 
1*/Pembrolizumab     
Day 1   2 days  Vaccine, Labs, Pembrolizumab  No 
         3 to 7 da ys Vaccine, Labs, Pembrolizumab  Yes 
  8 or more days  Labs  Yes 
Vaccines 2 -3*    
Days 8, 15   2 days  Vaccine/Labs  No 
         3 to 7 days  Vaccine/Labs  Yes 
  8 or more days  Labs  Yes 
Biopsy/Pembrolizumab     
Day 22   2 days  Labs, Biopsies, Pembrolizum ab No 
Product:   Pembrolizumab (MK -3475)  25 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
   3 to 7 days  Labs, Biopsies, Pembrolizumab  Yes 
  8 or more days  Labs  Yes 
Vaccine 4 */Pembrolizumab     
Days 43   2 days  Vaccine, Labs, Pembrolizumab  No 
  3 to 7 days  Vaccine, Labs, Pembrolizumab  Yes 
  8 or more days  Labs  Yes 
Assessment     
Day 57   7 days  Scans**  No 
  8 to 14 days  Scans  No 
  15 or more days  Scans  Yes 
Vaccine 5 */Pembrolizumab     
Day 64   7 days  Vaccine, Labs, Pembrolizumab  No 
  8 to 14 days  Vaccine, Labs, Pembrolizumab  Yes 
  15 or more days  Labs  Yes 
Vaccine 6 */Pemb rolizumab     
Day 85   7 days  Vaccine, Labs, Pembrolizumab  No 
  8 to 14 days  Yes 
  15 or more days  Labs  Yes 
Assessment     
Day 92   7 days  Labs  No 
  8 to 14 days  Labs  Yes 
  15 or more days  Labs  Yes 
Pembrolizumab     
Day 106 +  7 days  Labs/ Pembro lizumab  No 
  8 to 14 days  Labs/ Pembrolizumab  Yes 
  15 or more days  Labs, Pembrolizumab/ Scans ** Yes 
    
Safety Follow -up    
30-days after last dose of 
pembro lizumab    14 days  Labs  No 
  15 or more  days  Labs  Yes 
* A subject  will be taken off protoc ol treatment if more than one vaccination is delayed [  3 to 7 days] 
during the treatment period.  
** CT scans on days 57 and 127 ( weeks 8  and 18) should also be completed within these time limits.  
Subsequent scans should be completed per clinical care.  The scan at week 8 is to measure 
response, with confirmatory scans if needed.  Scans beyond week 1 8 may be performed earlier or 
more frequently than specified in the protocol if indicated as part of clinical care.   
5.2.2  Timing of Dose Administration  
Trial treat ment should be administered after all procedures/assessments have been completed 
as detailed on the Trial Flow Chart (Section 6.0).  All trial treatments will be administered on an 
outpatient basis.  
Pembrolizumab  will be administered as a 30 minute IV infu sion (treatment cycle intervals may 
be increased due to toxicity as described in Section 5. 2.1.3 .  Sites should make every effort to 
target infusion timing to be as close to 30 minutes as possible.  However, given the variability of 
infusion pumps from sit e to site, a window of -5 minutes and +10 minutes is permitted (i.e., 
infusion time is 30 minutes: -5 min/+10 min).  
Product:   Pembrolizumab (MK -3475)  26 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 The Pharmacy  Manual  for MK -3475  contains specific instructions for pembrolizumab dose 
calculation, reconstitution, preparation of the infusi on fluid, and administration.  
6MHP will be administered as a subcutaneous and intradermal  injection.  
On days when both pembrolizumab and vaccine are administered, the vaccine may be 
administered before or after pembrolizumab, but preferably before.   
5.2.3  Trial  Blinding/Masking  
This is an open -label trial; therefore, the Sponsor -Investigator  and subject will know the 
treatment administered.  
5.3 Randomization or Treatment Allocation  
All subjects will receive 6MHP plus pembrolizumab following the same treatment regime n. 
5.4 Stratification  
Patients will be monitored for post entry stratification by whether or not biopsies are obtained at 
baseline and  day 22 . 
5.5 Concomitant Medications/Vaccinations (allowed & prohibited)  
Medications or vaccinations specifically prohibited in th e exclusion criteria are not allowed 
during the ongoing trial.  If there is a clinical indication for one of these or other medications or 
vaccinations specifically prohibited during the trial, discontinuation from trial therapy or 
vaccination may be requi red.  The investigator should discuss any questions regarding this with 
the Sponsor -Investigator .  The final decision on any supportive therapy or vaccination rests with 
the investigator and/or the subject's primary physician.  However, the decision to con tinue the 
subject on trial therapy or vaccination schedule requires the mutual agreement of the 
Investigator, the Sponsor -Investigator , and the subject.  
5.5.1  Acceptable Concomitant Medications  
All treatments that the investigator considers necessary for a subj ect’s welfare may be 
administered at the discretion of the investigator in keeping with the community standards of 
medical care  including the following:  
 Nonsteroidal anti -inflammatory agents  
 Anti-histamines (e.g. Claritin®, Allegra®) 
 Topical and nasal corticosteroids or steroids for the reasons cited in sections 5.5.2 . 
 Short -term therapy for acute conditions not specifically related to melanoma  
 Chronic medications except those listed in section 5.5.2  
 Influenza vaccines (excluding the live version of the vac cine) are permitted, but 
should be administered at least 2 weeks prior to or at least 2 weeks after 
administration of study drug . 
 
All concomitant medication will be recorded on the case report form (CRF) including all 
prescription, over -the-counter (OTC),  herbal supplements, and IV medications and fluids.  If 
Product:   Pembrolizumab (MK -3475)  27 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 changes occur during the trial period, documentation of drug dosage, frequency, route, and 
date may also be included on the CRF.  
All concomitant medications received within 28 days before the first do se of trial treatment and 
30 days after the last dose of trial treatment should be recorded.  Concomitant medications 
administered after 30 days after the last dose of trial treatment should be recorded for SAEs 
and ECIs  as defined in Section 7.2.  
5.5.2  Prohibit ed Concomitant Medications  
Subjects are prohibited from receiving the following therapies during the Screening and 
Treatment Phase of this trial:  
 Anti-cancer  systemic chemotherapy or biological therapy  
 Immunotherapy not specified in this protocol  
 Chemothe rapy not specified in this protocol  
 Investigational agents ; Note: pembrolizumab  and 6MHP  are permitted during the 
treatment phase, per the protocol.  
 Radiation therapy ; Note: Radiation therapy to a symptomatic solitary lesion or to the 
brain may be allowed after consultation with Sponsor -Investigator .   
 Allergy desensitization injections  
 Systemic steroid therapy or any other form of immunosuppressive therapy with the 
following exceptions (which are permitted):  
o replacement steroid doses in patients with adren al or pituitary 
insufficiency  
o Inhaled steroids (e.g.: Advair®, Flovent®, Azmacort®) at low doses (less 
than 500 mcg fluticasone per day, or equivalent)  
 Street drugs  
 Live vaccines within 30 days prior to the first dose of trial treatment , while participati ng 
in the trial  and for at least 2 weeks after the last dose of study drug . Examples of live 
vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken 
pox, yellow fever, rabies, BCG, Flu-Mist ®, and typhoid (oral) vaccine.  
Subjects who, in the assessment by the investigator, require the use of any of the 
aforementioned treatments for clinical management should be removed from the trial.  
Subjects may receive other medications that the investigator deems to be medically 
neces sary.  
The Exclusion Criteria describes other medications which are prohibited in this trial.  
There are no prohibited therapies during the Post -Treatment Follow -up Phase.  
5.6 Rescue Medications & Supportive Care  
Subjects should receive appropriate supportive ca re measures as deemed necessary by the treating 
investigator.  Suggested supportive care measures for the management of adverse events with 
potential immunologic etiology are outlined below. Where appropriate, t hese guidelines include the 
use of oral or in travenous treatment with corticosteroids as well as additional anti -inflammatory 
agents if symptoms do not improve with administration of corticosteroids.   Note that several courses 
of steroid tapering may be necessary as symptoms may worsen when the ster oid dose is decreased. 
For each disorder, attempts should be made to rule out other causes such as metastatic disease  or 
bacterial or viral infection, which might require additional supportive care. The  treatment guidelines 
Product:   Pembrolizumab (MK -3475)  28 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 are intended to be applied when the investigator  determines the events to be related to 
pembrolizumab.  
Note: if after the evaluation the event is determined not to be related, the investigator does not need 
to follow the treatment guidance (as outlined below). Refer to Section 5.2.1 for  dose modification.  
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event.  
 Pneumonitis :  
o For Grade 2 events , treat with systemic corticosteroids. When symptoms improv e to 
Grade 1 or less, steroid taper should be started and continued over no less than 4 
weeks . 
o For Grade 3 -4 events , immediately treat with intravenous steroids.  Administer 
additional anti -inflammatory measures, as needed.  
o Add prophylactic antibiotics for  opportunistic infections in the case of prolonged 
steroid administration.  
 Diarrhea/Colitis :  
Subject s should be carefully monitored for signs and symptoms of enterocolitis (such as 
diarrhea, abdominal pain, blood or mucus in stool, with or without fever) and of bowel 
perforation (such as peritoneal signs and ileus).   
 
o All subject s who experience diarrhea /colitis  should be advised to drink liberal 
quantities of clear fluids.  If sufficient oral fluid intake is not feasible, fluid and 
electrolytes should be  substituted via IV infusion.   For Grade 2 or higher diarrhea, 
consider GI consultation and endoscopy to confirm or rule out colitis.  
o For Grade 2 diarrhea/colitis  that persists greater than 3 days, administer oral 
corticosteroids.  
o For Grade 3 or 4 diarrhe a/colitis  (or Grade 2 diarrhea that persists > 1 week ), treat 
with intravenous steroids followed by high dose oral steroids .   
o When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.  
 
 Type 1 diabet es mellitus (if new onset , including diabetic ketoacidosis [DKA] ) or ≥ 
Grade 3 Hyperglycemia , if associated with ketosis (ketonuria) or metabolic acidosis 
(DKA)  
 
o For T1DM  or Grade 3 -4 Hyperglycemia  
 Insulin replacement therapy is recommended for Type I diabetes mellitus and 
for Grade 3 -4 hyperglycemia associated with me tabolic acidosis or ketonuria.  
 Evaluate patients with serum glucose and a metabolic panel, urine ketones, 
glycosylated hemoglobin, and C -peptide.  
 
 Hypophysitis : 
 
o For Grade 2  events, treat with corticosteroids . When symptoms improve to Grade 1 
or less, st eroid taper should be started and continued over no less than 4 weeks. 
Replacement of appropriate hormones may be required as the steroid dose is 
tapered.  
o For Grade 3 -4 events, treat with an initial dose of IV corticosteroids followed by oral 
corticosteroi ds. When symptoms improve to Grade 1 or less, steroid taper should be 
Product:   Pembrolizumab (MK -3475)  29 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 started and continued over no less than 4 weeks. Replacement of appropriate 
hormones may be required as the steroid dose is tapered.  
 
 
 
 
 Hyperthyroidism or Hypothyroidism :  
Thyroid disor ders can occur at any time during treatment. Monitor patients for changes in 
thyroid function (at the start of treatment, periodically during treatment, and as indicated 
based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders . 
 
o Grade 2  hyperthyroidism events (and Grade 3 -4 hypothyroidism):  
 In hyperthyroidism, non -selective beta -blockers (e.g. propranolol) are 
suggested as initial therapy.  
 In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine 
or liothyronin e, is indicated per standard of care.  
o Grade 3 -4 hyperthyroidism  
 Treat with an initial dose of IV corticosteroid followed by oral corticosteroids. 
When symptoms improve to Grade 1 or less, steroid taper should be started 
and continued over no less than 4 w eeks. Replacement of appropriate 
hormones may be required as the steroid dose is tapered.  
 
 Hepatic : 
o For Grade 2  events, monitor liver function tests more frequently until returned to 
baseline values (consider weekly).  
 Treat with IV or oral corticosteroids  
o For Grade 3 -4 events, treat with intravenous corticosteroids for 24 to 48 hours.  
o When symptoms improve to Grade 1 or less, a steroid taper should be started and 
continued over no less than 4 weeks.  
 
 Renal Failure or Nephritis : 
o For Grade 2  events, treat wi th corticosteroids.  
o For Grade 3 -4 events, treat with systemic corticosteroids.  
o When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.  
 
 Management of Infusion Reactions : Signs and symptoms usually  develop during or shortly 
after drug infusion and generally resolve completely within 24 hours of completion of infusion.  
Table 8 shows treatment guidelines for subjects who experience a n infusion reaction 
associated with administration of pembrolizumab (MK -3475).  
Table 8. Infusion Reaction Treatment Guidelines  
NCI CTCAE Grade  Treatment  Premedication at subsequent 
dosing  
Grade 1  
Mild reaction; infusion interruptio n 
not indicated; intervention not 
indicated  Increase monitoring of vital signs as 
medically indicated until the subject  is 
deemed medically stable in the opinion of the 
investigator.  None  
Grade 2  
Requires infusion interruption but 
responds promptly to sym ptomatic Stop Infusion and monitor symptoms.  
Additional appropriate medical therapy may 
include but is not limited to:  Subject  may be premedicated 
1.5h (± 30 minutes) prior to 
infusion of pembrolizumab ( MK-
Product:   Pembrolizumab (MK -3475)  30 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 NCI CTCAE Grade  Treatment  Premedication at subsequent 
dosing  
treatment (e.g., antihistamines, 
NSAIDS, narcotics, IV fluids); 
prophylactic medications indicated 
for < =24 hrs  IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  
Increase monitoring of vital signs as 
medically indicated until the subject  is 
deemed medically stable in the opinion of the 
investigator.  
If symptoms resolve within one hour of 
stopping drug infusion, the infusion may be 
restarted at 50% of the original infusion rate 
(e.g., from 100 mL/hr to 50 mL/hr).  
Otherwise dosing will be held until symptoms 
resolve and the subject  should be 
premedicated for the next scheduled dose.  
Subject s who develop Grade 2 toxicity 
despite adequat e premedication should 
be permanently discontinued from further 
trial treatme nt administration.  3475 ) with: 
 
Diphenhydramine 50 mg po (or 
equivalent dose of 
antihistamin e). 
 
Acetaminophen 500 -1000 mg 
po (or equivalent dose of 
antipyretic).  
Grades 3 or 4  
Grade 3:  
Prolonged (i.e., not rapidly 
responsive to symptomatic 
medication and/or brief interruption 
of infusion); recurrence of 
symptoms following initial 
improvement; h ospitalization 
indicated for other clinical sequelae 
(e.g., renal impairment, pulmonary 
infiltrates)  
Grade 4:  
Life-threatening; pressor or 
ventilatory support indicated  Stop Infusion.  
Additional appropriate medical therapy may 
include but is not limited to : 
IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  
Oxygen  
Pressors  
Corticosteroids  
Epinephrine  
 
Increase monitoring of vital signs as 
medically indicated until the subject  is 
deemed medically stable in the opinion of the 
investigator.  
Hospitalizatio n may be indicated.  
Subject  is permanently discontinued from 
further trial treatment administration.  No subsequent dosing  
Appropriate resuscitation equipment should be available in the room and a physician readily available during the period 
of drug admin istration.  
 
 
5.7 Diet/Activity/Other Considerations  
5.7.1  Diet 
Subjects should maintain a normal diet unless modifications are required to manage an AE 
such as diarrhea, nausea or vomiting.  
5.7.2  Contraception  
Pembrolizumab may have adverse effects on a fetus in utero.  Furthermore, it is not known if 
pembrolizumab has transient adverse effects on the composition of sperm.   
Product:   Pembrolizumab (MK -3475)  31 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 For this trial, male subjects will be considered to be of non -reproductive potential if they have 
azoospermia (whether due to having had a vasectomy or due to an underlying medical 
condition).   
Female subjects will be considered of non -reproductive potential if they are either:  
(1) postmenopausal (defined as at least 12 months with no menses without an alternative medical 
cause; in women < 45 years o f age a high follicle stimulating hormone (FSH) level in the 
postmenopausal range may be used to confirm a post -menopausal state in women not using 
hormonal contraception or hormonal replacement therapy. In the absence of 12 months of 
amenorrhea, a single FSH measurement is insufficient.);  
OR  
(2) have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral 
tubal ligation/occlusion, at least 6 weeks prior to screening;  
OR  
(3) has a congenital or acquired condition that prev ents childbearing.  
Female and male subjects of reproductive potential must agree to avoid becoming pregnant or 
impregnating a partner, respectively, while receiving study drug and for 120 days after the last 
dose of study drug by complying with one of the following:   
(1) practice abstinence† from heterosexual activity;  
OR  
(2) use (or have their partner use) acceptable contraception during heterosexual activity.   
Acceptable methods of contraception are‡: 
Single method (one of the following is acceptable) : 
 intrauterine device (IUD)  
 vasectomy of a female subject’s male partner  
 contraceptive rod implanted into the skin  
  
Combination method (requires use of two of the following):  
 diaphragm with spermicide (cannot be used in conjunction with cervical cap/sper micide)  
 cervical cap with spermicide (nulliparous women only)   
 contraceptive sponge (nulliparous women only)  
 male condom or female condom (cannot be used together)  
 hormonal contraceptive: oral contraceptive pill (estrogen/progesti n pill or progestin -only 
pill), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous contraceptive 
injection  
  
†Abstinence (relative to heterosexual activity) can be used as the sole method of 
contraception if it is consistently employed as the subject’s preferre d and usual lifestyle and if 
Product:   Pembrolizumab (MK -3475)  32 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 considered acceptable by local regulatory agencies and ERCs/IRBs.  Periodic abstinence 
(e.g., calendar, ovulation, sympto -thermal, post -ovulation methods, etc.) and withdrawal are 
not acceptable methods of contraception.  
 ‡If a contraceptive method listed above is restricted by local regulations/guidelines, then it 
does not qualify as an acceptable method of contraception for subjects participating at sites 
in this country/region.  
Subjects should be informed that taking the stu dy medication may involve unknown risks to the 
fetus (unborn baby) if pregnancy were to occur during the study.  In order to participate in the 
study , subjects of childbearing potential  must adhere  to the contraception requirement 
(described above) from th e day of study medication initiation (or 14 days prior to the initiation of 
study medication for oral contraception)  throughout the study period up to 120 days after the 
last dose of trial therapy.  If there is any question that a subject of childbearing p otential will not 
reliably comply with the requirements for contraception, that subject should not be entered into 
the study.  
5.7.3  Use in Pregnancy  
If a subject inadvertently becomes pregnant while on treatment with pembrolizumab , the 
subject will immediately b e removed from the study.  The site will contact the subject at least 
monthly and document the subject’s status until the pregnancy has been completed or 
terminated.  The outcome of the pregnancy will be reported to the Sponsor -Investigator  and to 
Merck without delay and within 24 hours if the outcome is a serious adverse experience (e.g., 
death, abortion, congenital anomaly, or other disabling or life -threatening complication to the 
mother or newborn).  The study investigator will make every effort to obta in permission to follow 
the outcome of the pregnancy and report the condition of the fetus or newborn to the Sponsor -
Investigator .  If a male subject impregnates his female partner the study personnel at the site 
must be informed immediately and the pregna ncy reported to the Sponsor -Investigator  and to 
Merck and followed as described in Section 7.2.8. 
5.7.4  Use in Nursing Women  
It is unknown whether pembrolizumab is excreted in human milk.  Since many drugs are 
excreted in human milk, and because of the potential  for serious adverse reactions in the 
nursing infant, subjects who are breast -feeding are not eligible for enrollment.  
5.8 Subject Withdrawal/Discontinuation Criteria  
Subjects may withdraw consent at any time for any reason or be dropped from the trial at the 
discretion of the investigator should any untoward effect occur.  In addition, a subject may be 
withdrawn by the investigator or the Sponsor -Investigator  if enrollment into the trial is 
inappropriate, the trial plan is violated, or for administrative and/o r other safety reasons.  
Specific details regarding discontinuation or withdrawal are provided in Section 7.1.4 – Other 
Procedures.  
Protocol treatment includes both the 6MHP vaccine and pembrolizumab.  Either or both may be 
discontinued for any of the foll owing reasons.   
 The subject or legal representative (such as a parent or legal guardian) withdraws 
consent.  
 Confirmed radiographic disease progression  
Product:   Pembrolizumab (MK -3475)  33 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 Note : A subject may be granted an exception to continue on treatment with confirmed 
radiographic progres sion if clinically stable or clinically improved .  Patients with 
progressive disease  should undergo a second scan at least 4 weeks later to confirm 
progression and exclude the possibility of a tumor flare reaction, according to immune -
related response crit eria ( irRC) guidelines . 
 Any dose -limiting toxicity (DLT), as defined in  Section 7.2.7 , warrants discontinuation of 
the agent to which the DLT is attributed. If a DLT attributed to one intervention is not 
believed to be related to the other treatment, only the one to which the DLT is attributed 
must be discontinued , and other protocol interventions may be continued as close to the 
original schedule as possible . However, management of toxicities attributed to PD -1 
antibody should follow current standard pract ice guidelines, including use of steroids 
when indicated.   Also, if a patient is discontinued from PD -1 antibody but not from 
vaccine, the visits every 3 weeks for PD -1 antibody, and the associated safety studies 
(e.g.: CBC, chemistries) do not need to be  performed.  
 Disease progression requiring other therapy (e.g. surgery under general anesthesia, 
radiation, chemotherapy, or steroid therapy).  The appearance of small metastases or 
recurrent tumor deposits will not be a basis for discontinuing the vaccinat ions.  Biopsy to 
determine the nature of new lesions, or minor surgical procedures to excise a new lesion, 
will not be a basis for discontinuing vaccinations.  Also, surgery to perform a biopsy of 
tumor at day 22, in accord with the protocol, will not be a  basis for discontinuing therapy, 
whether done under local anesthesia or general anesthesia.   
 Intercurrent illness that prevents further administration of treatment  
 Initiation of cytotoxic chemotherapy, radiation therapy, or targeted therapy for melanoma 
or other cancer.  
 Initiation of systemic steroid therapy, or other  systemic  immunosuppressive therapy , 
except  that steroid or immunosuppressive therapy for management of toxicities of 
pembrolizumab is allowed without discontinuation of vaccines.    
 Any other  potential adverse reaction deemed sufficiently serious to warrant 
discontinuation of therapy by the Principal Investigator or one of the Associate 
Investigators.  
 Investigator’s decision to withdraw the subject  
 The subject has a confirmed positive serum pr egnancy test  
 Noncompliance with trial treatment or procedure requirements  
 The subject is lost to follow -up 
 Completed 24 months of uninterrupted treatment with pembrolizumab or 35 
administrations of study medication, whichever is later.  
Note: 24 months of s tudy medication is calculated from the date of first dose. Subjects 
who stop pembrolizumab after 24 months may be eligible for additional pembrolizumab 
treatment as part of their clinical care  if they progress after stopping study treatment .  
 Administrativ e reasons  
 
The End of Treatment and Follow -up visit procedures are listed in Section 6  (Protocol Flow 
Chart) and Section 7.1.5  (Visit Requirements).  After the end of treatment, each subject will be 
followed for 30 days for adverse event monitoring (seriou s adverse events will be collected for 
90 days after the end of treatmen t as described in section 7.1.5.3.1  and 7.2.7.8 ).  Subjects who 
discontinue for reasons other than progressive disease will have post -treatment follow -up for 
disease status until disea se progression, initiating a non -study cancer treatment, withdrawing 
Product:   Pembrolizumab (MK -3475)  34 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 
 consent or becoming lost to follow -up (every 8 weeks post discontinuation up to 2 years  or until 
the toxicity resolves ).  After documented disease progression each subject will be followe d by 
telephone annually  for overall survival until death, withdrawal of consent, or until study  closure , 
whichever occurs first.  
5.9 Subject Replacement Strategy  
A subject  who is enrolled but does not receive  any pembrolizumab or 6MHP,  or any of the 
study -related procedures may  be replaced.  Every attempt will be made to evaluate data for 
endpoint assessment from subjects who withdrawal from the study .    
5.10 Clinical Criteria for Early Trial Termination  
Early trial termination will be the result of the criteria sp ecified below:  
1. Quality or quantity of data recording is inaccurate or incomplete  as determined by the 
Sponsor -Investigator.  
2. Poor adherence to protocol and regulatory requirements  
3. Incidence or severity of adverse drug reaction in this or other studies indic ates a potential 
health hazard to subjects  
4. Plans to modify or discontinue the development of the study drug  
In the event of Merck decision to no longer supply study drug, ample notification will be 
provided so that appropriate adjustments to subject treatm ent can be made.  
Product:   Pembrolizumab (MK -3475)  35 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 6.0 TRIAL FLOW CHART  
 
6.1 Study Flow Chart  
Trial Period:  Active Treatment  
Day Main Study 
Screening  1 8 15 22 43 57 64 85 92 106 127 148 169 190 365 730 
Week   0 1 2 3 6 8 9 12 13 15 18 21 24 27 52 104 
Scheduling Window  (Days):    ± 2 ± 2 ± 2 ± 2 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 
Administrative Procedures                   
Informed Consent  Xa                 
Pathology Review at UVA  Xa                 
Inclusion/Exclusion Criteria  Xb                 
Laboratory Procedures                   
CBC with Differential m Xb Xf   X X  X X  X X X X X X X 
Comprehensive Serum Chemistry Panel m,v Xb,e Xf   X X  X X  X X X X X X X 
HGBA1C  Xb                 
Urinalysis  Xb                 
Pregnancy Test: Serum  or urine  -HCG  in 
women  Xc Xu                
T3, FT4 and TSH   X    X   X   X  X  X X 
PT/INR and aPTT  X                 
HIV/HCV/HBV  Xd                 
ANA/R F  X    X   X       X X 
Clinical Assessments                   
Demographics and Medical History  Xb                 
Physical Exam  Xb Xf X X X X  X X X  X  X X X X 
Product:   Pembrolizumab (MK -3475)  36 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 Trial Period:  Active Treatment  
Day Main Study 
Screening  1 8 15 22 43 57 64 85 92 106 127 148 169 190 365 730 
Week   0 1 2 3 6 8 9 12 13 15 18 21 24 27 52 104 
Scheduling Window  (Days):    ± 2 ± 2 ± 2 ± 2 ± 14 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 
Prior and Concomitant Medication Review  Xb X X X X X  X X X X X X X X X X 
Record Baseline Symptoms   X                
Review Adverse Events    X X X X  X X X X X X X X X X 
Designation of potential vacc ination sites  Xb                 
Assessment of skin and nodal basins for 
evidence of disease  Xb                 
Assessment of skin for vitiligo   X   X    X     X X X X 
Assessment of hair and eye color   X   X    X     X X X X 
Visual acuity exam/color vi sion  X                
Patient diary reviewed and/or distributed   X X X X X  X X X X X      
Efficacy Measures /Tumor Imaging                   
CT chest/abdomen/pelvis or PET -CTr X      Xh     Xh   Xj Xj Xj 
Head MRI/CTr X      Xi     Xi   Xi Xi Xi 
Digita l images of cutaneous lesionsr X      Xh     Xh   Xj Xj Xj 
Research Specimen Collection  and 
Procedures                   
120 cc blood - green top tube   Xk                
80 cc blood - green top tube    X X X X  X X X  X  X X X X 
20 cc blood - red top tube   X X X X X  X X X  X  X X X X 
Tumor Biopsy   X   X             
SIN biopsy  (thru protocol v04 -04-17 only)     X             
Study Drug Administration                   
6MHP   X X X  X  X X         
Pembrolizumab every 3 weeks   X   X X  X X  X X X X X X Xt 
Product:   Pembrolizumab (MK -3475)  37 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
  
 
 End of Treatment Post -Treatment  
 
Discon tinuation  of 
pembrolizumab or of 
both drugsl Safety Follow -up 
Discon tinuation of 
pembrolizumab or of 
both drugsl  Follow Up Visits o 
After discontinuation 
for reasons other than 
disease progression  Survival Follow -Upq  
After discontinuation of 
therapy for disease 
progression and/or 
initiation of new 
antineoplastic therapy  
Scheduling Window (days)   ± 14 Days  ± 15 Days  ± 28 Days  
 
At time of 
discon tinuation  of 
pembrolizumab   30 days post 
discon tinuation  of 
pembroliz umab   Every 8 weeks post 
discon tinuation  up to 2 
years  or until resolution 
of toxicitys Annually  
Laboratory Procedures      
CBC with Differential  X X   
Comprehensive Serum Chemistry Panelv X X   
Urinalysis  X    
T3, FT4 and TSH  X X   
Clinical Assessmen ts     
Physical Exam  X X X  
Prior and Concomitant Medication Review  X X   
Review Adverse Events  X X X  
Efficacy Measures /Tumor Imaging      
CT chest/abdomen/pelvis or PET -CT Xj  Xj  
Head MRI/CT  Xi    
Digital images of cutaneous lesions  Xj  Xj  
Resea rch Specimen Collection and 
Procedures      
80 cc blood - green top tube  X X Xs  
20 cc blood - red top tube  X X Xs  
Product:   Pembrolizumab (MK -3475)  38 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
  End of Treatment Post -Treatment  
 
Discon tinuation  of 
pembrolizumab or of 
both drugsl Safety Follow -up 
Discon tinuation of 
pembrolizumab or of 
both drugsl  Follow Up Visits o 
After discontinuation 
for reasons other than 
disease progression  Survival Follow -Upq  
After discontinuation of 
therapy for disease 
progression and/or 
initiation of new 
antineoplastic therapy  
Scheduling Window (days)   ± 14 Days  ± 15 Days  ± 28 Days  
 
At time of 
discon tinuation  of 
pembrolizumab   30 days post 
discon tinuation  of 
pembroliz umab   Every 8 weeks post 
discon tinuation  up to 2 
years  or until resolution 
of toxicitys Annually  
Tumor Biopsy  Xn   Xn 
Survival Status      
Survival Status   X X X X 
Start of Antineoplastic therapy     X 
     
a  Any point prior to regis tration   
 b Pre-study within 6 weeks of registration  
 c  Within 2 weeks of registration (for childbearing women)  
 d  Within 6 months of registration   
 e To include fasting glucose  
f History & physical, comprehensive chemistry, and CBC with differential , for Day 1 are not required if  the pre-study assessment was completed within 10 
calendar days of day 1 . 
g For patients who have tumor accessible to biopsy, biopsies will be completed 1) at screening or up until day 1, and 2) at day  22.  Additional biopsies 
may be performed during the study or during follow -up if subjects are removed from the study or experience progression.  
h Tumor imaging (window of ± 14 Days ) should be performed when clinically needed to verify objective clinical responses  (per RECIST v1.1)  and every  8-
12 weeks as indicated per standard care . 
 i  Head imaging  should  be completed when clinically indicated . 
 j Tumor imaging should be completed as indicated per standard care . 
 k Blood for HLA typing is included in the research bloods  
l If a subj ect is discontinued and the assessments have been completed as part of a regularly scheduled visit, the assessments do not ne ed to be 
repeated.   If a subject is discontinued from 6MHP but continues with pembrolizumab, the safety follow -up visit for 6 MHP w ill occur at the time of their 
next infusion of pembrolizumab.  
m Repeat CBC and chemistries every 3 weeks, just prior to the next dose of pembrolizumab. If there is a delay in pembrolizumab treatment for toxicity or 
other reasons, the CBC and chemistries s hould be delayed comparably, to enable those blood studies on the same day (before) each dose of 
pembrolizumab.  
Product:   Pembrolizumab (MK -3475)  39 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 n If subjects develop superficial metastatic deposits accessible to biopsy/excision with minimal morbidity , an optional  biopsy may be collected  for research 
purposes.  If surgical resection or biopsies are completed for clinical care , the tumor tissue may be collected for study related analyses . 
o Follow -up visits every 8 weeks will not be required beyond 2 years from study entry.  If a subject is managed locally and is not able to return to UVA 
every 8 weeks after discontinuation  for reasons other than disease progression, because of toxicity or intercurrent health problems, every effort will be 
made to obtain records that supply data comparable to  what is specified in the table . 
p Head MRI/CT may be performed every 6 months or as clinically indicated.  
q At the time of disease progression or if a subject begins receiving a new antineoplastic therapy, the subject will move into survival follow -up.  S ubjects 
may be contacted by telephone for survival follow -up status. The expectation is that there will be additional follow -up as part of standard of care, either by 
the study physician or by a local referring physician. Every effort will be made to obtai n data on disease status and survival at all such visits, in addition to 
the mandated study visits.  
r Patients with progressive disease should undergo a second scan at least 4 weeks later to confirm progression and exclude the possibility of a tumor 
flare reaction, according to irRC guidelines.  
S If a subject discontinues pembrolizumab for toxicity, that patient should be followed every 8 weeks until resolution of the to xicity or until 2 years from 
study entry, whichever is longer. If the toxicity resolves before 2 years, then the patient should continue with visits requiring research blood draws and 
tumor biopsies.  
t Week 52 is last planned clinical trial intervention other than continued dosing of pembrolizumab every 3 weeks; pembrolizumab is to be continu ed every 
3 weeks between week 26 and week 52 , and beyond that to 2 years , along with safety labs as needed in routine clinical care.   
u Must be completed within 72 hours prior to receiving the first dose of study drug.  If the screening test is completed within 72 hours prior to Day 1, this 
test does not need to be repeated.  
v Refer to Table 9 for a complete list of analyses to be completed as part of the comprehensive chemistry panel.  
 
 
 
Product:   Pembrolizumab (MK -3475)  40 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
  
7.0 TRIAL PROCEDURES  
7.1 Trial P rocedures  
The Trial Flow Chart - Section 6.0 summarizes the trial procedures to be performed at each 
visit.  Individual trial procedures are described in detail below.  It may be necessary to perform 
these procedures at unscheduled time points if deemed cl inically necessary by the investigator.  
Furthermore, additional evaluations/testing may be deemed necessary by the Sponsor -
Investigator  and/or Merck for reasons related to subject safety. In some cases, such 
evaluation/testing may be potentially sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus 
local regulations may require that additional informed consent be obtained from the subject.  In 
these cases, such evaluations/testing will be performed in accordance with those regulations.  
7.1.1  Administrative  Procedures  
7.1.1.1  Informed Consent  
The Investigator must obtain documented consent from each potential subject prior to 
participating in a clinical trial . 
7.1.1.1.1  General Informed Consent  
Consent must be documented by the subject’s dated signature or by the s ubject’s legally 
acceptable representative’s dated signature on a consent form along with the dated signature 
of the person conducting the consent discussion.  
A copy of the signed and dated consent form should be given to the subject before participation 
in the trial.  
The initial informed consent form, any subsequent revised written informed consent form and 
any written information provided to the subject must receive the IRB/ERC’s approval/favorable 
opinion in advance of use.  The subject or his/her legal ly acceptable representative will be 
informed in a timely manner if new information becomes available that may be relevant to the 
subject’s willingness to continue participation in the trial.  The communication of this information 
will be provided and docu mented via a revised consent form or addendum to the original 
consent form that captures the subject’s dated signature or by the subject’s legally acceptable 
representative’s dated signature.  
Specifics about a trial and the trial population will be added t o the consent form template at the 
protocol level.   
The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations 
and Sponsor -Investigator  requirements.  
7.1.1.2  Inclusion/Exclusion Criteria  
All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee to 
ensure that the subject qualifies for the trial.  
Product:   Pembrolizumab (MK -3475)  41 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
 7.1.1.3  Registration  
All subject s must sign the consent form prior to determination of eligibility for this study.  
Registration will occur following verificati on of eligibility by the treating physician.  Subject s will 
be registered in the OnCore database and should receive their first study treatment within 2 
weeks of registration.  
7.1.1.4  Medical History  
A medical history will be obtained by the investigator or quali fied designee.  Medical history will 
include all active conditions, and any condition diagnosed within the prior 10 years that are 
considered to be clinically significant by the Investigator.  Details regarding the disease for 
which the subject has enrolle d in this study will be recorded separately and not listed as 
medical history.   
7.1.1.5  Prior and Concomitant Medications Review  
7.1.1.5.1  Prior Medications  
The investigator or qualified designee will review prior medication use, including any protocol -
specified washout re quirement, and record prior medication taken by the subject within 42 days 
before starting the trial.  Treatment for the disease for which the subject has enrolled in this 
study will be recorded separately and not listed as a prior medication.  
7.1.1.5.2  Concomitant  Medications  
The investigator or qualified designee will record medication, if any, taken by the subject during 
the trial.  All medications related to reportable SAEs and ECIs should be recorded as defined in 
Section 7.2. 
7.1.1.6  Disease Details and Treatments  
7.1.1.6.1  Disease Details  
The investigator or qualified designee will obtain prior and current details regarding disease 
status.   
7.1.1.6.2  Prior Treatment Details  
The investigator or qualified designee will review all prior cancer treatments including systemic 
treatments, radia tion and surgeries.  
7.1.1.6.3  Subsequent Anti -Cancer  Therapy Status  
The investigator or qualified designee will review all new anti -neoplastic therapy initiated after 
the last dose of trial treatment.  If a subject  initiates a new anti -cancer  therapy within 30 days 
after the last dose of trial treatment, the 30 day Safety Follow -up visit must occur before the first 
dose of the new therapy.  Once new  anti-cancer  therapy has been initiated the subject will 
move into survival follow -up.  
Product:   Pembrolizumab (MK -3475)  42 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
 7.1.1.7  Trial Compliance (Medication/Die t/Activity/Other)  
Treatment compliance may be evaluated through drug accountability assessments and through 
the evaluation of subject medical records and CRF documents.  
7.1.2  Clinical Procedures/Assessments  
The following evaluations will be performed on an outpa tient basis.   
7.1.2.1  Adverse Event (AE) Monitoring  
The investigator or qualified designee will assess each subject to evaluate for potential new or 
worsening AEs as specified in the Trial Flow Chart and more frequently if clinically indicated.  
Toxicity diaries will also be distributed to subject s and reviewed by study personnel.  Adverse 
experiences will be graded and recorded throughout the study and during the follow -up period 
according to NCI CTCAE Version 4.0 (see Section 12.2).  Toxicities will be character ized in 
terms regarding seriousness, causality, toxicity grading, and action taken with regard to trial 
treatment.  
All AEs of unknown etiology associated with pembrolizumab exposure should be evaluated to 
determine if it is possibly an event of clinical i nterest (ECI) of a potentially immunologic etiology 
(irAE).  See Section 5.6.1  regarding the identification, evaluation and management of AEs of a 
potential immunological etiology.   
Please refer to section 7.2  for detailed information regarding the assess ment and recording of 
AEs.   
7.1.2.2  Physical Exam s 
The investigator or qualified designee will perform a complete physical exam during the 
screening period.  Clinically significant abnormal findings should be recorded as medical 
history.   
Physical exams will inc lude the following:  
 vital signs  (temperature, pulse, respiratory rate, blood pressure)  
 weight,  
 ECOG performance status,  
 medication review,  
 neurologic function -general  
 
 Height will be measured at screening only  
7.1.2.3  Vital Signs  
The investigator or qualified designee will take vital signs at screening, prior to the 
administration of each dose of trial treatment and at treatment discontinuation as specified in 
the Trial Flow Chart (Section 6.0).  Vital signs should include temperature, pulse, respiratory 
rate, weight and blood pressure.  Height will be measured at screening only.  
 
Product:   Pembrolizumab (MK -3475)  43 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
 7.1.2.4  Eastern Cooperative Oncology Group (ECOG) Performance Scale  
The investigator or qualified designee will assess ECOG status (see Section 12.1 ) as specified 
in the Trial Flow Chart.  
7.1.2.5  Designation of Vaccine Sites  
Evidence suggests nodes proximal to a tumor site may be relatively immunosuppressed; 
therefore, the vaccination sites will be selected to be distant from the sites of tumor whenever 
possible.  In general, subject s will be vaccinat ed in upper arm or thigh sites with intact draining 
nodes.  Vaccines will be administered at the designated site(s).   
7.1.2.6  Visual Assessments  
Visual acuity will be assessed using the Snellen chart.  
Color vision will be assessed using an Ishihara eye chart.  
 
7.1.2.7  Tumor Imaging and Assessment of Disease  
Tumor Imaging  
Tumor imaging may include CT/PET -CT scans and/or MRI.  These will complement physical 
exam and other imaging as required, but the primary measures of clinical response will be 
based on CT/PET -CT and/or MR I and will use RECIST v1.1 criteria . For each subject , the 
same method of assessment will be used to evaluate tumor burden at baseline and throughout 
the course of the study.  
Tumor Measur ements  
RECIST 1.1 Criteria will be used to evaluate tumor burden  (Section 12.3).  
7.1.2.8  Tumor Tissue Collection and Correlative Studies Blood Sampling  
7.1.2.8.1   Tumor Biopsies  
Tumor biopsies will be completed in subject s who have adequate and accessible metastatic 
tumor in addition to  at least one site of  measurable disease.   Biopsy sites  may be in nodes, 
skin, soft tissue, liver, or other sites that can be accessed by needle biopsy, incisional or 
excisional biopsy.  Biopsies may be completed  with or without image guidance.   
Size Requirements  
A critical component of this protocol is the h istologic and cytologic evaluation of changes in 
immune effectors and the tumor microenvironment after vaccination and systemic therapy.  A 
minimum of 0.1 6 cm3 but ideally 0.3 cm3 or more of tumor tissue will be needed for each biopsy 
time point as describ ed in the inclusion criteria. Biopsies may be taken from a single lesion or 
multiple lesions at each of the time points depending on the size of each lesion.  If taken from 
multiple lesions, those lesions should be similar.  For example, three non -ulcerate d skin 
metastases would be considered similar; one bleeding small bowel metastasis would not be 
considered similar to a subcutaneous nodule).  
Sampling  
Product:   Pembrolizumab (MK -3475)  44 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
 The biopsies will vary based on the clinical scenario and may include six core biopsies, an 
incisional bi opsy or an excisional biopsy as outlined in the inclusion criteria . 
Procedure  
When appropriate (and we anticipate the majority of cases) the biopsies will be performed 
under local anesthesia (typically  lidocaine HCl 1% and epinephrine 1:100,000 injection +  or - 
8.4% sodium bicarbonate ), in the outpatient clinic or comparable procedure room, using sterile 
technique.  In cases when clinical standard of care requires a larger procedure the biopsies 
may be performed in the operating room under standard techniqu e. 
To minimize errors in analysis due to sampling error and specimen heterogeneity, each study 
biopsy specimen will be divided into several components and randomly allocated into various 
preservation conditions . Ideally, tissue will be divided into the fol lowing preservation conditions, 
using core needle biopsies (19 mm long and 2 mm diameter; about 80 mm3), or incisional or 
excisional biopsies with at least the same minimum tissue volume:  
It is most critical to obtain the following:  
 Formalin : 1 core biopsy  or similar tissue volume (about 80 mm3 or greater)  will be fixed 
in formalin, then paraffin -embedded (for histology/immunohistology)  
 
 Quick -frozen : 2 core biopsies or similar tissue volume (each about 80 mm3 or greater)  
quick -frozen processed for protein studies , histology, or nucleic acid studies. If only one 
core can be obtained, t his portion should be provided as two specimens (eg cut the 
core biopsy specimen in half).  
 
When sufficient tissue is available, the following should also be obtained:  
 RNA -later: 1 core biopsy  or similar tissue volume (about 80 mm3 or greater)  will be 
placed in RNA -later (for RNA/RT PCR)  
 Viable cell suspension :  2 core biopsies or similar tissue volume (total about 160 mm3 
or greater)  will be processed for single -cell suspension  by mechanical disaggregation, 
then enzymatic digestion (collagenase, hyaluronidase, DNAase).  The resulting 
suspensions will be cryopreserved in FBS serum and DMSO (for cellular immune 
function and flow cytometry).  
 If there is additional tissue, it may be  processed for additional immunologic studies.  
 
The incisions will be sutured closed.   Toxicities related to the biopsies will be recorded.    
Based on our experience in prior clinical trials ( Mel48 ([STUDY_ID_REMOVED]), Mel51 ([STUDY_ID_REMOVED] ) , 
and Mel53 (NCT0126473 1)), it is adequate, for each specimen, to have at least the equivalent 
of a core biopsy specimen that is 19  mm long and 2 mm in diameter (about 80 mm3), or a cubic 
specimen 5 mm in width. Thus, for 1 FFPE and 1-2 QF specimens, we need about 160-240 
mm3 (2-3 cores, or 1 lesion about 7-10 mm in diameter).  For those with larger specimens (>1 
cm diameter), some will also be saved as viably cryopreserved single cell suspensions.  
A 5 micron section of each tumor specimen will be stained by H&E and reviewed to assess the 
extent and quality of viable tumor. For FFPE specimens, only those with at least 4 mm2 viable 
tumor (on cross -section) will be considered evaluable for histologic and immunohistologic 
studies. FFPE tissue will be evaluated for immunotype and for  immune cell infiltrates. For QF 
specimens, those with at least 70% tumor will be considered evaluable.   
Evaluations  
Product:   Pembrolizumab (MK -3475)  45 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
 Tissue samples may be screened for antigen expression or protein profiles using tests such as 
Western blots, immunohistochemistry, PCR, flo w cytometry or gene chip analysis.   
Tumor escape mechanisms may also be evaluated.   
Specimens will be used in immunological assays to assess T cell function or antibody 
response.  Assays generally used for this type of testing include, but are not limite d to, ELIspot 
assays, ELISAs, chromium -release assays, proliferation assays, intracellular cytokine staining, 
and T cell receptor sequencing.   
Specimens may be used to study the immunologic aspects of the tumor microenvironment or 
as targets or controls i n laboratory assays.  
Specimens may be used to establish cell lines for long -term studies . 
This tissue may also be compared to lesions resected prior to enrollment, which will be 
requested from the pathology department of each institution as paraffin -embed ded tissue 
samples, and these tissues may be banked for use in future studies.   
HLA typing (Class I and Class II) will be analyzed as part of the immunologic endpoints. (8 ml)  
7.1.2.8.2  Optional Tumor Biopsies (at the time of progression , after study completion 
and withdrawal ) 
If during the study, participants develop superficial metasta tic deposits accessible to 
biopsy/excision with minimal morbidity, a n optional biopsy may be collected for research 
purposes.  
If tumor samples are collected when a Mel 64 participant  is no longer participating in the Mel 64 
study and the participant consents  to allow their tissue to be collected  under the IRB #10598  
tissue banking study  to be analyzed for Mel 64 , the tissue may be  analyzed as part of th e Mel 
64 analysis . 
Optional biop sy samples may be evaluated as described in section 7.1.2.8.1.  
7.1.2.8.3  Tumor Collected for Clinical Care  
If during the study, participants develop metastases or recurrences, or progress, these may be 
removed  as part of their clinical care , and following receipt by  pathology, may be evaluated by 
the study research team.   
7.1.2.8.4  Blood Collection for Research Analyses  
Blood should be obtained prior to the vaccine injection if a vaccine is scheduled to be 
administered.  Results of research blood  tests are not required prior to administering the 
vaccine on that date.    
The following blood samples for research will be  collected  and processed by the UVA 
Biorepository and Tissue Research Facility (BTRF).  
 80 cc -120 cc  blood collected in heparinized green top tubes for  lymphocytes .  
 20 cc blood collected in red top tubes for serum  
 
Product:   Pembrolizumab (MK -3475)  46 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
 Samples will be analyzed for  analyses that may include the following ( and leftover sample will 
be banked and stored for future biomedical research ): 
 Functional assays for T cell responses to melanoma ant igens (the 6 melanoma helper 
peptides of the vaccine, and other melanoma antigens, and control antigens), including 
ELIspot assays, and multiparameter flow cytometry for cytokine release.  
 Multimer assays for T cell receptor specificity  
 High throughput T c ell receptor sequencing.  
 Genetic polymorphisms of immune -related genes  
 Gene expression profiling of blood cells  
 Production of chemokines, cytokines from circulating lymphocytes and other immune 
cells.  
 Multiparam eter flow cytometry for cellular markers, in cluding markers of regulatory T 
cells, myeloid cells, and T cell maturation.  
 Serum antibodies  
 Serum cytokines, chemokines or other serum proteins  
 
7.1.3  Laboratory Procedures/Assessments  
Laboratory tests for hematology, chemistry, urinalysis, and others are spec ified in  Table 9.   
 
Table 9.  Laboratory Tests  
Hematology  Chemistry  Urinalysis  Other  
Hematocrit  Albumin  Blood  Urine pregnancy or s erum 
β-human chorionic 
gonadotropin  (β-hCG)† 
Hemoglobin  Alkaline phosphatase  Glucose  HgB-A1C  
Platelet count  Alanine aminotransferase (ALT)  Protein  PT (INR)  
WBC (total and 
differential)  Aspartate aminotransferase 
(AST)  Specific gravity  aPTT  
Red Blood Cell Count  Lactate dehydrogenase (LDH)  
(every 6 weeks)  Microscopic exam (If abnormal)   Total triiodothyronine (T3)  
Absolute Neutrophil 
Count  Carbon Dioxide  
    (CO 2 or bicarbonate)  results are noted  Free t hyroxine (T4)  
 Creatinine   Thyroid stimulating 
hormone (TSH)  
 Uric Acid   HIV testing  
 Calcium   HCV testing  
 Chloride   HBV testing  
 Glucose    ANA/RF   
 Phosphorus     
 Potassium      
 Sodium     
 Magnesium     
 Total Bilirubin     
 Direct Bilirubin (If total bilirubin is 
elevated above the upper lim it of 
normal)    
Product:   Pembrolizumab (MK -3475)  47 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
 Hematology  Chemistry  Urinalysis  Other  
 Total protein    
 Blood Urea Nitrogen    
† Perform on women of childbearing potential only. If urine pregnancy results cannot be confirmed as negative, a serum 
pregnancy test will be required.   
 
7.1.4  Other Procedures  
7.1.4.1  Sentinel Immunized Node (SIN) Biopsy  
The SIN biopsy  will be perform ed until the approval of the protocol modification  where the 
requirement for SIN biopsy was removed  (through protocol v04 -04-17).  Thereafter, SIN 
biopsies will not be performed.  
Procedure  
The node (sentinel immu nized node, SIN) will be identified by radiocolloid (usually technetium 
99 sulfur colloid) injection, with or without lymphoscintigraphy imaging, and with use of a 
handheld gamma probe during the procedure. This will be performed under local anesthesia in 
the clinic, in conjunction with the vaccine site biopsy, by a qualified surgeon.   
Lymphatic mapping will be initiated, usually in the nuclear medicine suite, after intradermal 
injection with radiocolloid (typically technetium 99 -sulfur colloid).   The node  excision will be 
performed under local anesthesia (usually  lidocaine HCl 1 -2%, with or without epinephrine 
1:100,000 injection, with or without 8.4% sodium bicarbonate ), in the outpatient clinic or 
comparable procedure room, using sterile technique.  A ha ndheld gamma probe will be used.  
When possible, the node will be sectioned into 5 sections:  a central  section (10 -20% of the  
node), leaving  two adjacent sections of about 40% each.  These latter two sections will be 
bisected.  They will be allocated into various preservation conditions:  
 1 central section  will be fixed in formalin, then paraffin -embedded  
 (for histology/immunohistology)  
 1 section will be placed in RNA -later. (for RNA/RT PCR)  
 1 section will be quick -frozen (for immunohistology/protein studie s) 
 2 sections (40%) will be processed for single cell suspension by  mechanical 
disaggregation, then enzymatic digestion (collagenase, hyaluronidase, DNAase).  The 
resulting suspensions will be cryopreserved in FBS and DMSO (for cellular immune 
function and  flow cytometry).   
If there is additional tissue, it may be processed for additional immunologic or angiogenic 
studies.  
The incisions will be sutured closed.  
Toxicities related to the biopsies will be recorded.  
7.1.4.2  Withdrawal/Discontinuation  
When a subject di scontinues/withdraws prior to trial completion, all applicable activities 
scheduled for the final trial visit should be performed at the time of discontinuation.  Any 
adverse events which are present at the time of discontinuation/withdrawal should be foll owed 
in accordance with the safety requirements outlined in Section 7.2 - Assessing and Recording 
Product:   Pembrolizumab (MK -3475)  48 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
 Adverse Events.  Subjects who a) attain a  CR or b) complete 24 months of treatment with 
pembrolizumab may discontinue treatment with the option of restarting treatment upon 
progression.  Restarting treatment will be completed as part of a subject’s standard clinical 
care, at the discretion of their treating physician.   After discontinuing treatment following 
assessment of CR, these subjects should return to the  site for a Safety Follow -up Visit 
(described in Section 7.1.5.3.1) and then proceed to the Follow -Up Period of the study 
(described in Section 7.1.5.4).  
7.1.5  Visit Requirements  
Visit requirements are outlined in Section 6.0 - Trial Flow Chart.   Specific proce dure-related 
details are provided above in Section 7.1 - Trial Procedures.  
7.1.5.1  Screening  
A member of the study team will explain the purpose of the study and the study -related 
procedures to potential subjects.  Subjects will be asked to provide written informe d consent 
prior to the initiation of any study -related procedures.  The results from a ssessments performed 
as part of a subject ’s clinical care prior to receipt of informed consent may be utilized to fulfill a 
screening requirement, if the assessments were  completed within the required window for 
screening.  
7.1.5.2  Treatment Period  
The treatment period will begin on Day 1 and will continue until the subject completes  the 
treatment regimen or discontinues treatment.  
7.1.5.2.1  End of Treatment Visit  
This visit will o ccur at t he time that a subject is discontinued from the study . 
7.1.5.2.2  Second Course (Retreatment Period for Post -Complete Remission Relapse 
Only)  
Subjects who stop pembrolizumab  with SD or better and who experience disease progression 
may receive additional doses of pemb rolizumab as part of their clinical care following evaluation 
by their treating physician.  
 
7.1.5.3  Post -Treatment Visits  
7.1.5.3.1  Safety Follow -Up Visit  
The mandatory Safety Follow -Up Visit should be conducted approximately 30 days after the 
last dose of trial treatment (pembrolizumab or 6MHP) or before the ini tiation of a new anti -
cancer  treatment, whichever comes first.  All AEs that occur prior to the Safety Follow -Up Visit 
should be recorded.  Subjects with an AE of Grade > 1 will be followed until the resolution of 
the AE to Grade 0 -1 or until the beginning of a new anti -neoplastic therapy, whichever occurs 
first.  SAEs that occur within 90 days of the end of treatment or before initiation of a new anti -
cancer  treatment should also be followed and recorded.   
Product:   Pembrolizumab (MK -3475)  49 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
 7.1.5.4  Follow -up Visits  
Subjects who discontinue treatment pembrolizumab or both drugs for a reason other than 
disease progression will move into the Follow -Up Phase and should be assessed every 8 
weeks (56 ± 7 days) by radiologic imaging to monitor disease status.  Every  effort should be 
made to collect information regarding disease status until the start of new anti -neoplastic 
therapy, disease progression, death, end of the study or if the subject begins retreatment with 
pembrolizumab as detailed in Section 7.1.5.2. 2. Information regarding post -study anti -
neoplastic treatment will be collected if new treatment is initiated.  
Follow -up visits every 8 weeks will not be required beyond 2 years from study entry.  If a subject 
is managed locally and is not able to return to UVA every 8 weeks after discontinuation  for 
reasons other than disease progression, because of toxicity or intercurrent health problems, 
every effort will be made to obtain records that supply data comparable to what is specified in 
the study calendar.  
 
If a s ubject discontinues pembrolizumab for toxicity, that subject  should be followed every 8 
weeks until resolution of the toxicity or until 2 years from study entry, whichever is longer. If the 
toxicity resolves before 2 years, then the subject  should continue  with visits requiring research 
blood draws and tumor biopsies.  
 
Subjects  with progressive disease should undergo a second scan at least 4 weeks later to 
confirm progression and exclude the possibility of a tumor flare reaction, according to irRC 
guideline s. 
 
7.1.5.4.1  Survival Follow -up 
Once a subject experiences confirmed disease progression or starts a new anti -cancer 
therapy, the subject moves into the survival follow -up phase and should be contacted by 
telephone annually  for survival status until death, withdraw al of consent, or the end of the 
study, whichever occurs first.   
 
7.2 Assessing , Recording,  and Reporting Adverse Events  
7.2.1  Definitions  
Adverse Event  (AE): An adverse event is defined as any untoward medical occurrence in a 
patient or clinical investigation subje ct administered a pharmaceutical product and which does 
not necessarily have to have a causal relationship with this treatment. An adverse event can 
therefore be any unfavorable  and unintended sign (including an abnormal laboratory finding, for 
example), s ymptom, or disease temporally associated with the use of a medicinal product or 
protocol -specified procedure, whether or not considered related to the medicinal product or 
protocol -specified procedure.  Any worsening (i.e., any clinically significant adver se change in 
frequency and/or intensity) of a preexisting condition that is temporally associ ated with the use 
of the study drugs or protocol -specified procedure  is also an adverse event.  
Changes resulting from normal growth and development that do not var y significantly in 
frequency or severity from expected levels are not to be considered adverse events.   
Merck  product includes any pharmaceutical product, biological product, device, diagnostic 
agent or protocol -specified procedure, whether investigationa l (including placebo or active 
Product:   Pembrolizumab (MK -3475)  50 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
 comparator medication) or marketed, manufactured by, licensed by, provided by or distributed 
by Merck  for human use.  
6MHP includes the 6 melanoma helper peptide vaccine.  
Adverse events may occur during the course of the use o f Merck  product and 6MHP in clinical 
trials or as prescribed in clinical practice, from overdose (whether accidental or intentional), 
from abuse and from withdrawal.  
Progression of the cancer under study is not considered an adverse event.  
Unexpected AE  – Any adverse event not described in section 7.2.5 . 
Serious AE:   A serious adverse event is any adverse event occurring at any dose during the 
study that : 
 Results in death;  
 Is life threatening;  
 Results in persistent or significant disability/incapacity;  
 Resu lts in or prolongs an existing inpatient hospitalization;  
 Is a congenital anomaly/birth defect;  
 Is a new cancer (that is not a condition of the study);  
 Is associated with an overdose;  
 Is an other important medical event  
Refer to Table 10 for additional details regarding each of the above criteria.  Note:  In addition to 
the above criteria, adverse events meeting either of the below criteria, although not  serious per 
ICH definition, are repor table to the Merck in the same timeframe as SAEs to meet certain local 
requirements. Therefore, these events are considered serious by Merck for collection purposes : 
 Is a new cancer (that is not a condition of the study);  
 Is associated with an overdose.  
 
Unanticipated problem  - An unanticipated problem is any event/experience that meets ALL 3 
criteria below:  
 Is unexpected in terms of nature, severity or frequency given the research 
procedures that are described in the protocol -related documents AND in the 
characteristics of t he subject  population being studied.  
 Is related or possibly related to participation in research.  This means that there is a 
reasonable possibility that the incident may have been caused by the procedures 
involved in the research study.   
 The incident suggests that the research placed the subject  or others at greater risk of 
harm than was previously known or recognized OR results in actual harm to the 
subject  or others.  
 
Protocol Violation -  A protocol violation is defined as any change, deviation, or departure from 
the study design or procedures of a research project that is NOT approved by the institution’s 
IRB prior to its initiation or implementation, OR deviation from  standard operating procedures, 
Good Clinical Practices (GCPs), fed eral, state or local regulations. Protocol violations may or 
may not be under the control of the study team or UVa staff. These protocol violations may be 
major or minor violations.  
Product:   Pembrolizumab (MK -3475)  51 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
 Suspected Adverse Reaction  (as defined in 21 CFR 312.32 (a)) - Any adverse event for which 
there is a reasonable possibility that the drug caused the adverse event.  
7.2.2  Attribution Assessment  
Attribution – The determination of whether an adverse event is related to a medical treatment 
or procedure.  The attribution groups are:  
Defini te – Applies to those adverse events which, the investigator feels are incontrovertibly 
related to study drug .  An adverse event may be assigned an attribution of definitely related if or 
when (must have all of the following):  
 It follows a reasonable tempo ral sequence from administration of the test drug.  
 It could not be reasonably explained by the known characteristics of the subject ’s 
clinical state, environmental or toxic factors, or other modes of therapy administered 
to the subject . 
 It disappears or de creases on cessation or reduction in dose with re -exposure to 
drug.  (Note: This is not to be constructed as requiring re -exposure of the subject ; 
however, the group of definitely related can only be used when a recurrence is 
observed.)  
 It follows a known pattern of response to the test drug.  
 
Probable  – Applies to those adverse events for which, after careful consideration at the time 
they are evaluated, are felt with a high degree of certainty to be related to the test drug.  An 
adverse event may be consi dered probably related if or when (must have three of the 
following):  
 It follows a reasonable temporal sequence from administration of the test drug.  
 It could not be reasonably explained by the known characteristics of the subject ’s 
clinical state, environ mental or toxic factors, or other modes of therapy administered 
to the subject . 
 It disappears or decreases on cessation or reduction in dose.  There are important 
exceptions when an adverse event does not disappear upon discontinuation of the 
drug, yet dru g-relatedness clearly exists (e.g. bone marrow depression, fixed drug 
eruptions, tardive dyskinesia).  
 It follows a known pattern of response to the test drug.  
 
Possible  – Applies to those adverse events for which, after careful consideration at the time 
they are evaluated, a connection with the test drug administration appears unlikely but cannot 
be ruled out with certainty.  An adverse event may be considered possibly related if or when 
(must have two of the following):  
 It follows a reasonable temporal seq uence from administration of the test drug.  
 It could not readily have been produced by the subject ’s clinical state, environmental 
or toxic factors, or other modes of therapy administered to the subject . 
 It follows a known p attern of response to the test drug. 
 
Unlikely  – Applies to those adverse events for which, after careful consideration at the time 
they are evaluated, are judged to be unrelated to the test drug.  An adverse event may be 
considered unlikely if or when (must have two of the following):  
 It does not follow a reasonable temporal sequence from administration of the test 
drug.  
Product:   Pembrolizumab (MK -3475)  52 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
  It could readily have been produced by the subject ’s clinical state, environmental or 
toxic factors, or other modes of therapy administered to the subject . 
 It does not f ollow a known pattern of response to the test drug.  
 It does not reappear or worsen when the drug is re -administered.  
 
Unrelated  – Applies to those adverse events, which after careful consideration, are clearly and 
incontrovertibly due to extraneous causes (disease, environment, etc.).  
7.2.3  Evaluating Adverse Events  
An investigator who is a qualified clinician will evaluate all adverse events according to the NCI 
Common Terminology for Adverse Events (CTCAE), version 4.0. Any adverse event which changes 
CTCAE gra de over the course of a given episode will have each change of grade recorded on the 
adverse event case report forms/worksheets.  
All adverse events regardless of CTCAE grade must also be evaluated for seriousness.  
Product:   Pembrolizumab (MK -3475)  53 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
 Table 10.  Evaluating Adverse Events  
An investigator who is a qualified clinician, will evaluate all adverse events as to:  
V4.0 CTCAE 
Grading  Grade 1  Mild; asymptomatic or mid symptoms; clinical or diagnostic observations only; intervention not indicated.  
 Grade 2  Moderate; minimal, local or non invasive intervention indicated; limiting age -appropriate instrumental ADL.  
 Grade 3  Severe or medically significant but not immediately life -threatening; hospitalization or prolongation or hospitalization indicated; disabling; 
limiting self -care ADL.  
 Grade 4  Life threatening consequences; urgent intervention indicated.  
 Grade 5  Death related to AE  
Seriousness  A serious adverse event is any adverse event occurring at any dose or during any use of Merck product  or 6MHP  vaccine that: 
 †Results in death ; or 
 †Is life threatening; or  places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred (Note: This doe s not include an 
adverse event that, had it occurred in a more severe form, might have caused death. ); or 
 †Results in a persistent or significant disability/incapacity  (substantial disruption of one’s ability to conduct normal life functions); or  
 †Results in or prolongs an existing inpatient hospitalization  (hospitalization is defined as an inpatient  admission, regardless of length of stay, even if the 
hospitalization is a precautionary measure for continued observation. (Note: Hospitalization for an elective procedure  to treat  a preexisting condition  that has not 
worsened is not constitute a serious adverse event. .  A pre -existing condition is a clinical condition that is diagnosed prior to the use of investigational  product and is 
documented in the patient’s medical history.) ; or 
 †Is a congenital anomaly/birth defect  (in offspring of subject taking  the product regardless of time to diagnosis);or  
 Is a new cancer;  (that is not a condition of the study) ; (although not serious per ICH definition, is reportable to the Sponsor -Investigator  within 24 hours and to Merck 
within 2 working days to meet certa in local requirements); or 
 Is an overdose  (whether accidental or intentional).  Any adverse event associated with an overdose is considered a serious adverse event  for collection purposes . An 
overdose that is not associated with an adverse event is consi dered a non -serious event of clinical interest and must be reported within 24 hours  to the Sponsor and to 
Merck within 2 working days . 
 Other important medical events  that may not result in death, not be life threatening, or not require hospitalization ma y be considered a serious adverse event when, 
based upon appropriate medical judgment, the event may jeopardize the subject and may require medical or surgical interventio n to prevent one of the outcomes listed 
previously (designated above by a †).  
Durati on Record the start and stop dates of the adverse event. If less than 1 day, indicate the appropriate length of time and units  
Action taken  Did the adverse event cause the Merck product  or 6MHP  to be discontinued?  
Relationship 
to 
investigational  
drug  Did the Merck product or 6MHP cause the adverse event? The determination of the likelihood that the Merck product or 6MHP caused the adverse event will be 
provided by an investigator who is a qualified physician. The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted 
on the AE form, ensures that a medically qualified assessment of causality was done. This initialed document must be retained  for the required regulatory time frame. 
The criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test dr ug and the adverse 
event based upon the available information.  
The following components are to be used to assess the relationship between the Merck product and 6MHP and the AE ; the greater the correlation with the 
components and their respective elements (in number and/or intensity), the more likely the Merck product or 6MHP caused the adverse event (AE):  
 Exposure  Is there evidence  that the subject was actually exposed to the Merck product or 6MHP such as: reliable history, acceptable compliance assessment 
(pill count, diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?  
 Time Course  Did the AE follow in a reasonable temporal sequence from administration of the Merck product  or 6MHP ?  
Is the time of onset of the AE compatible with a drug -induced effect (applies to trials with investigational medicinal product)?  
 Likely Cause  Is the AE n ot reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host or environmen tal factors  
 
Product:   Pembrolizumab (MK -3475)  54 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
  
University of Virginia Human Immune Therapy Center --Confidential  
 
  
 
 
Relationship  The following components are to be used to assess the relationship between the test drug and the AE: (continued)  
to Merck 
product  or 
6MHP  
(continued)  Dechallenge  Was the Merck product  or 6MHP  discontinued or dose/exposure/frequency reduced?  
If yes, did the AE resolve or improve?  
If yes, this is a positive dechallenge. If no, this is a negative dechallen ge. 
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent disability; (2) the AE resolved/improve d despite 
continuation of the Merck product  or 6MHP ; or (3) the trial is a single -dose drug trial); or (4) Merck product(s) or 6MHP is/are only used 
one time.)  
 Rechallenge  Was the subject re -exposed to the Merck product or 6MHP in this study?  
If yes, did the AE recur or worsen?  
If yes, this is a positive rechallenge. If no, this is a negative rechallenge.  
(Note: This criterion i s not applicable if: (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single -dose drug 
trial); or (3) Merck product(s)  or 6MHP  is/are used only one time).  
NOTE: IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS S ERIOUS AND WHICH MAY HAVE BEEN 
CAUSED BY THE MERCK PRODUCT  or 6MHP , OR IF REEXPOSURE TO THE MERCK PRODUCT  OR 6MHP POSES ADDITIONAL 
POTENTIAL SIGNIFICANT RISK TO THE SUBJECT, THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE U.S. 
CLINICAL MONITOR AS P ER DOSE MODIFICATION GUIDELINES IN THE PROTOCOL.  
 Consistency 
with Trial 
Treatment 
Profile  Is the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Merck product or 6MHP drug class 
pharmacology or toxicology?  
The assessment of relationship will be reported on the case report forms /worksheets by an investigator who is a qualified phy sician according to his/her best clinical 
judgment, including consideration of the above elements.  
Record one of the following  Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Merck product or 6MHP 
relationship).  
Yes, there is a reasonable 
possibility of Merck product  or 
6MHP  relationship.  There is evidence of exposure to the Me rck product  or 6MHP .  The temporal sequence of the AE onset relative to the administration of 
the Merck product or 6MHP is reasonable.  The AE is more likely explained by the Merck product or 6MHP than by another cause.  
No, there is not a reasonable 
possi bility of Merck product or 
6MHP relationship  Subject did not receive the Merck product  or 6MHP OR temporal sequence of the AE onset relative to administration of the Merck 
product or 6MHP is not reasonable OR  the AE is more likely explained by  another obvi ous cause than the Merck product or 6MHP .  
(Also entered for a subject with overdose without an associated AE.)  
Product:   Pembrolizumab (MK -3475)  55 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
  
7.2.4  Adverse Event Classifications  
Adverse events (AEs) are classified into sections, specified in the CTCAE v4.03.  For specific 
classifications pertaining to the protocol, we specify the following:  
Hematologic/Metabolic - Any AE coded under one of the following CTCAE v4.03 categories 
should be reported under the Hematologic/Metabolic adverse event classification:   
Table 11.  Hematologic/Metabolic C lassifications  
Section  AE 
Blood and lymphatic  Anemia  
Leukocytosis  
Investigations  ALL EXCEPT:  
Carbon monoxide diffusing capacity decreased  
Ejection fraction decreased  
Forced expiratory volume decreased  
Vital capacity abnormal  
Weight gain  
Weight loss  
Metabolism and nutrition 
disorders  ALL EXCEPT:  
Alcohol intolerance  
Anorexia  
Dehydration  
Glucose intolerance  
Iron overload  
Obesity  
Tumor lysis syndrome  
 
Non-hematologic/Non -Metabolic - Any AE not reported under hematologic/metabolic, ocular, 
or allergic/autoim mune, should be reported under the non -hematologic/non -metabolic 
adverse event classification.  
Ocular  – Any AE coded under one of the following CTCAE v4.03 Adverse Event Terms 
should be reported under the Ocular adverse event classification:  
 Eye Disorders:  Night blindness (nyctalopia)  
 Eye Disorders: Papilledema  
 Eye Disorders: Retinopathy  
 Eye Disorders: Blurred vision  
 Eye Disorders: Flashing lights  
 Eye Disorders: Floaters  
 
Allergic/Autoimmune  – Only AEs coded as Immune System Disorder: Allergic reaction, 
autoimmune disorder, or anaphylaxis should be reported under the Allergic/Autoimmune 
adverse event classification. Other AEs coded under Immune System Disorder should be 
reported under Non-hematologic/Non -metabolic  
Product:   Pembrolizumab (MK -3475)  56 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 7.2.5  Agent -Specific Expected Adverse Events List  
7.2.5.1  6MHP  
The following toxicities are those greater than grade 1 that are to be considered expected :   
Table 102.  Expected Toxicities for 6MHP vaccines  
 Grade 2  Grade 3  
Injection site reaction  + +a 
Ulceration  +  
Fatigue  +  
a Note:  Injection site reaction with ulceration ≤2 cm is expected. This is consistent 
with the CTCAE v4.0 coding for ulceration (Grade 2).   Other grade 3 injection site 
reactions are not expected.  
7.2.5.2  Pembrolizumab  
Treatment -related adverse reactions are described in Section 7 of the Investigator’s 
Brochure . 
 
7.2.5.3  Tumor Biopsies, Vaccine Site Biopsies, and Sentinel Immunized Node Biopsies  
The following are toxicities that are greater than grade 1 and that are to be considered 
expected (up to grade 2) :  
 Bleeding  
 Bruising  
 Pain 
 Infection  
 Lymphedema  
 Delayed wound hea ling 
 Scarring  
 Numbness  
 
7.2.6  Dose -Limiting Tox icities  
6MHP  
A DLT of 6MHP vaccine is defined as any Grade 3 or greater hematologic or non -
hematologic toxicity that is definitely, probably, or possibly related to the administration of the 
vaccine.  Small ulcerati ons of the skin at vaccine sites are expected in a subset of subjects 
and are not considered DLTs.  Ulcerations will be considered DLTs only if the ulcers are > 2 
cm in diameter, require antibiotics or surgical debridement.  
Pembrolizumab  
A DLT of pembroliz umab is defined as any toxicity requiring permanent 
discontinuation per Table 6:  Dose Modification Guidelines for Drug -Related Adverse 
Events . 
 
Pembrolizumab and/or 6MHP  
≥ Grade 2 ocular adverse events as defined below, regardless of the agent to which the 
event may be attributed:  
Product:   Pembrolizumab (MK -3475)  57 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 1) A single ≥ Grade 2 treatment -related experience of the following adverse events will be 
classified as a DLT:  
 Eye Disorders: Night blindness (ny ctalopia)  
 Eye Disorders: Papilledema  
 Eye Disorders: Retinopathy  
Subjects  will be referred for an ophthalmologic exam if any of these ocular adverse events 
occur.  
2) For ≥ Grade 2 of the following, treatment will be held and subject s will be referred for 
an ophthalmologic  exam .  Evidence of eye inflammation will be a basis for 
discontinuation of pembrolizumab and 6MHP.   If no inflammation is noted and subject s 
improve to ≤ Grade 1 by the next scheduled visit, subject s can resume treatment with 
both agents.  
 Eye Disorders: Blurred vision  
 Eye Disorders: Flashing lights  
 Eye Disorders: Floaters  
 
7.2.7  Recording and Reporting Adverse Events  
7.2.7.1  Time Span for Reporting Adverse Events  
Reporting of AEs will begin when the subject  is administered the  study drug or has a study 
related biopsy.  Reporting will continue through 30 days following cessation of treatment and at 
each examination on the Adverse Event case report forms/worksheets. The reporting timeframe 
for adverse events meeting any serious criter ia is described below . The i nvestigator will make 
every attempt to follow all subjects with non -serious adverse events for outcome.  
 All adverse events that occur after the consent form is signed, but before tr eatment allocation  
must be reported by the investigator if they cause the subject to be excluded from the trial, or 
are the result of a protocol -specified intervention, including but not limited to washout or 
discontinuation of usual therapy, diet, placebo treatment or a procedure.  
Adverse events will not be collected for subjec ts during the pre -screening period (for 
determination of archival tissue status) as long as that subject has not undergone any protocol -
specified procedure or intervention.  If the subject requires a blood draw, fresh tumor biopsy 
etc., the subject is firs t required to provide consent to the main study and AEs will be captured 
according to guidelines for standard AE reporting.  
7.2.7.2  Process for Recording Adverse Events  
Dose -limiting toxicities  
DLTs will be entered into OnC ore within 5 calendar days of the study t eam learning of the 
event. DLT’s that are deemed serious and unexpected will be submitted to the IRB per 
institutional guidelines (see below).  
Other AEs     
AEs must be recorded into the University of Virginia Cancer Center OnCore database per the 
guideline s in Table 113. 
 
 
Product:   Pembrolizumab (MK -3475)  58 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
  
 
 
 
 
Table 113.  AE reporting  
 High Risk Studies  
Reporting requirements for AEs that occur within 30 days of the last dose of protocol specified treatment  
 Grade 1  Grade  2 Grade 3  Grade 4 & 5  
Expected  
and 
unexpected   
Expected   
Unexpected  Expected  Unexpected  Expected  
and 
Unexpected  Without  
hospitalization  With 
hospitalization  Without  
hospitalization  With 
hospitalization  
Unrelated  
Unlikely  OnCore  
30 daysa OnCore  
30 days  OnCore  
30 days  OnCore  
30 days  OnCore  
15 days  OnCore  
30 days  OnCore  
15 days  OnCore  
7 days  
Possible  
Probable  
Definite  OnCore  
30 daysa OnCore  
30 days  OnCore  
15 days  OnCore  
30 days  OnCore  
15 days  OnCore  
7 days  OnCore  
7 days  OnCore  
(24-hrs)*  
7 days  
*Enter into OnCore database within 24 hours if unexpected and definitely related to protocol specified treatment  
Hospitalization defined as an inpatient hospital stay or prolongation of a hospital stay equal to or greater than 24 hours  
a Grade 1 unexpected or expected hematologic/metabolic events will be recorded in the Cancer Center Database; however, regardless of 
attribution, these events do not have to be reported.  
 
7.2.7.3  Recording Laboratory Values  
The following laboratory values will be recorded in the UVA Can cer Center database, 
graded using the CTCAE v4.03 (if a grading category exists), and reported as described in  
Section 7.2. 8.3. 
1. Alk Phosphatase  
2. ALT (SGPT)  
3. ANA 
4. AST (SGOT)  
5. Bilirubin, total  
6. Creatinine  
7. Eosinophil #  
8. Hepatitis B virus  
9. Hepatitis C virus  
10. beta-HCG 
11. Hgb 
12. HgbA1C  
13. HIV 
14. HLA type  
15. LDH 
16. Potassium  
17. RF 
18. Urinalysis  
19. WBC  
20. T3 
21. TSH 
22. Free T4  
23. PT/INR and aPTT  
 
Product:   Pembrolizumab (MK -3475)  59 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 Any abnormal laboratory values captured which are not included in the above list, but are 
considered to be pertinent positive clinical signs/symptoms, and laboratory  results obtained 
as part of routine care of patients will be recorded in the UVA Cancer Center database and 
reported .  If there is any doubt on the part of study personnel concerning what constitutes a 
pertinent positive finding, sponsor -investigator  will be consulted.  
7.2.7.4  UVA IRB Reporting Requirements  
The University of Virginia is responsible for reporting to the UVA IRB -HSR per the following 
guidelines:  
Table 124.  UVA IRB -HSR Reporting Guidelines  
Type of Event  To whom will it be 
reported:  Time Frame for Reporting  How reported?  
Any internal event resulting 
in death that is deemed 
DEFINITELY related to 
(caused by) study 
participation  
(Note:  An internal event is 
one that occurs in a subject 
enrolled in a UVa protocol.)  IRB-HSR  Within 24 hours  IRB Online and phone call  
 
www.irb.virginia.edu/  
 
Internal, Serious, 
Unexpected adverse event.  
 IRB-HSR  Within 7 calendar days from the 
time the study team received 
knowledge of the event.  
 
Timeline in cludes submission of 
signed hardcopy of AE form.  IRB Online  
 
www.irb.virginia.edu/  
 
Unanticipated Problems 
that are not adverse events 
or protocol violations  
This would include a Data 
Breach.   IRB-HSR  
 
 Withi n 7 calendar days from the 
time the study team received 
knowledge of the event.  Unanticipated Problem 
report form.  
http://www.virginia.edu/v pr
gs/irb/HSR_docs/Forms/R
eporting_Requirements -
Unanticipated_Problems.d
oc ) 
 
  
Protocol Violations ( The 
IRB-HSR only requires that 
MAJOR violation be 
reported, unless otherwise 
required by your sponsor, if 
applicable.)  
 
Or Enrollment Exceptions  IRB-HSR  
 
 Within 7 calendar days from the 
time the study team received 
knowledge of the event.  
 Protocol Violation and 
Enrollment Exception 
Reporting Form  
 
http://www.virginia.edu/vpr
gs/irb/hsr_forms. html 
Data Breach  
 
 The UVa Corporate 
Compliance and 
Privacy Office and  
 
ITC:  if breach 
involves  electronic 
data-  
 
UVa Police if breach 
includes such things 
as stolen computers.  As soon as possible and no 
later than 24 hours from the 
time the inciden t is identified.  
 
As soon as possible and no 
later than 24 hours from the 
time the incident is identified.  
 
IMMEDIATELY.  UVa Corporate 
Compliance and Privacy 
Office - Phone 924 -9741  
 
ITC:  Information Security 
Incident Reporting 
procedure ,  
http://www.itc.virginia.edu/
security/reporting.html  
 
Ph(434) 924 -7166  
Product:   Pembrolizumab (MK -3475)  60 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
  
7.2.7.5  Reporting to the FDA  
The Sponsor -Investigator  for th e study (the UVA PI or designee) is responsible for providing 
safety updates to the FDA per the following guidelines.  The reporting times refer to the time 
the study team received knowledge of the AE.  
 
Table 135.  FDA Reporting Req uirements  
UVa PI HELD IND  
Type of Event  To whom will it 
be reported:  Time Frame for 
Reporting  How reported?  
Life-threatening and/or 
fatal unexpected events 
related or possibly related 
to the use of the 
investigational agent.  FDA Within 7 calendar 
days of  the study 
team learning of the 
event  Form FDA 3500A (MedWatch) or 
narrative  
Serious, unexpected and 
related or possibly related 
adverse events  FDA Within 15 calendar 
days after the study 
team receives 
knowledge of the 
event  Form FDA 3500A (MedWatch) or 
narrative  
All adverse events  FDA Annually  IND annual report  
 
 
7.2.7.6  Reporting of Pregnancy and Lactation to the Sponsor -Investigator  and to Merck  
Although pregnancy and lactation are not considered adverse events, it is the responsibility of 
investigators or th eir designees to report any pregnancy or lactation in a subject (spontaneously 
reported to them), including the pregnancy of a male subject's female partner that occurs during 
the trial . 
Pregnancies and lactations that occur after the consent form is signe d but before treatment 
allocation/randomization must be reported by the investigator if they cause the subject to be 
excluded from the trial, or are the result of a protocol -specified intervention, including but not 
limited to washout or discontinuation of  usual therapy, diet, placebo treatment or a procedure.  
 
Pregnancies and lactations that occur from the time of treatment allocation/randomization 
through  120 days following cessation of Sponsor’s product, or 30 days following cessation of 
treatment if th e subject initiates new anticancer therapy, whichever is earlier, must be reported 
by the investigator.   All reported pregnancies must be followed to the completion/termination of 
the pregnancy.  Pregnancy outcomes of spontaneous abortion, missed abortion,  benign 
hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth must 
be reported as serious events (Important Medical Events).  If the pregnancy continues to term, 
the outcome (health of infant) must also be reported.  
Such events must be reported within 24 hours to the Sponsor -Investigator  and within 2 working 
days to Merck Global Safety.  (Attn: Worldwide Product Safety; FAX 215-661-6229 ) 
Product:   Pembrolizumab (MK -3475)  61 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 7.2.7.7  Definition of an Overdose for This Protocol and Reporting of Overdose to the Spons or-
Investigator and to Merck  
For purposes of this trial, an overdose will be defined as any dose exceeding the prescribed 
dose for pembrolizumab by 20% over the prescribed dose. No specific information is available 
on the treatment of overdose of pembroliz umab . In the event of overdose, pembrolizumab 
should be discontinued and the subject should be observed closely for signs of toxicity.  
Appropriate supportive treatment should be provided if clinically indicated.  
If an adverse event(s)  is associated with ( “results from”) the overdose of a Merck product , the 
adverse event(s) is reported as a serious adverse event, even if no other seriousness criteria 
are met.  
If a dose of Merck’s product  meeting the protocol definition of overdose is taken without any 
assoc iated clinical symptoms or abnormal laboratory results, the overdose is reported as a non -
serious Event of Clinical Interest (ECI), using the terminology “accidental or intentional 
overdose without adverse effect.”  
All reports of overdose with and without an adverse event must be reported within 24 hours to 
the Sponsor -Investigator and within 2 working days hours to Merck Global Safety. (Attn: 
Worldwide Product Safety; FAX 215-661-6229 ) 
7.2.7.8  Immediate Reporting of Adverse Events to the Sponsor -Investigator  and t o Merck  
Serious Adverse Events  
For the time period beginning when the consent form is signed until treatment 
allocation/randomization,  any serious adverse event, or follow up to a serious adverse event, 
including death due to any cause other than progressi on of the cancer under study (see section 
7.2.8.8) that occurs to any subject  must be reported within 24 hours to the Sponsor -Investigator  
and within 2 working days to Merck Global Safety if it causes the subject to be excluded from 
the trial, or is the re sult of a protocol -specified intervention, including but not limited to washout 
or discontinuation of usual therapy, diet, placebo treatment or a procedure.  
 
For the time period beginning at treatment allocation/randomization through  90 days following 
cessation of treatment, or 30 days following cessation of treatment if the subject initiates new 
anticancer therapy, whichever is earlier, any serious adverse event, or follow up to a serious 
adverse event, including death due to any cause other than progress ion of the cancer under 
study  whether or not related to the Merck product, must be reported within 24 hours to the 
Sponsor and within 2 working days to Merck Global Safety.  
Non-serious Events of Clinical Interest related to the Merck product will be forwa rded to Merck 
Global Safety and will be handled in the same manner as SAEs.  
Additionally, any serious adverse event, considered by an investigator who is a qualified 
clinician to be related to Merck product that is brought to the attention of the investig ator at any 
time following consent through the end of the specified safety follow -up period specified in the 
paragraph above, or at any time  outside of the time period specified in the previous paragraph 
also must be reported immediately to the Sponsor -Investigator  and to Merck  Global Safety . 
All subjects with serious adverse events must be followed up for outcome.  
Product:   Pembrolizumab (MK -3475)  62 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 SAE reports and any other relevant safety information are to be forwarded to the Merck 
Global Safety facsimile number:  +1 -215-661-6229  
A copy o f all 15 Day Reports and Annual Progress Reports is submitted as required by FDA, 
European Union (EU), Pharmaceutical and Medical Devices agency (PMDA) or other local 
regulators. Investigators will cross reference this submission according to local regulat ions to 
the Merck Investigational Compound Number (IND, CSA, etc.) at the time of submission.  
Additionally investigators will submit a copy of these reports to Merck & Co., Inc. (Attn: 
Worldwide Product Safety; FAX 215-661-6229 ) at the time of submission to FDA.  
All subjects with serious adverse events must be followed up for outcome.  
7.2.7.9  Protocol -Specific Exceptions to Serious Adverse Event Reporting  
Efficacy endpoints as outlined in this section will not be reported to Merck as described in 
Section 7.2. 7.8.- Immediate Reporting of Adverse Events to the Sponsor and to Merck, unless 
there is evidence suggesting a causal relationship between the drug and the event. Any such 
event will be submitted to the Sponsor within 24 hours and to Merck Global Safety within  2 
working days either by electronic or paper media.  
Specifically, the suspected/actual events covered in this exception include any event that is 
disease progression of the cancer under study.  
The Sponsor will monitor unblinded aggregated efficacy endpoin t events and safety data to 
ensure the safety of the subjects in the trial. Any suspected endpoint which upon review is not 
progression of the cancer under study will be forwarded to Merck Global Safety as a SAE within 
2 working days of determination that the event is not progression of the cancer under study  
Hospitalization related to convenience (e.g.transportation issues etc.) will not be considered a n 
SAE.  
7.2.7.10  Events of Clinical Interest  
Selected non -serious and serious adverse events are also known as Even ts of Clinical Interest 
(ECI) and must be recorded as such on the Adverse Event case report forms/worksheets and 
reported within 24 hours to  the Sponsor -Investigator  and within 2 working days to Merck Global 
Safety.  (Attn: Worldwide Product Safety; FAX 215-661-6229 ) 
For the time period beginning when the consent form is signed until treatment 
allocation/randomization, any ECI, or follow up to an ECI, that occurs to any subject must be 
reported within 24 hours to the Sponsor and within 2 working days to Merc k Global Safety if it 
causes the subject to be excluded from the trial, or is the result of a protocol -specified 
intervention, including but not limited to washout or discontinuation of usual therapy, diet, 
placebo treatment or a procedure.  
For the time pe riod beginning at treatment allocation/randomization through 90 days following 
cessation of treatment, or 30 days following cessation of treatment if the subject initiates new 
anticancer therapy, whichever is earlier, any ECI, or follow up to an ECI, wheth er or not related 
to Merck product, must be reported within 24 hours to the Sponsor and within 24 hours to 
Merck Global Safety.  
Events of clinical interest for this trial include:  
Product:   Pembrolizumab (MK -3475)  63 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 1. An overdose of Merck  product, as defined in Section 7.2. 7.7 - Definition of an 
Overdose for This Protocol and Reporting of Overdose to the Sponsor -Investigator , 
that is not associated with clinical symptoms or abnormal laboratory results.  
2. An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit 
of norm al and an elevated total bilirubin lab value that is greater than or equal to 2X 
the upper limit of normal and, at the same time, an alkaline phosphatase lab value 
that is less than 2X the upper limit of normal, as determined by way of protocol -
specified l aboratory testing or unscheduled laboratory testing.*  
*Note:   These criteria are based upon available regulatory guidance documents. 
The purpose of the criteria is to specify a threshold of abnormal hepatic tests that 
may require an additional evaluation f or an underlying etiology.  
7.2.8  Sponsor Responsibility for Reporting Adverse Events  
All Adverse Events will be reported to regulatory authorities, IRB/IECs and investigators in 
accordance with all applicable global laws and regulations.  
8.0 STATISTICAL  CONSIDERATI ONS  
8.1 Design  
This is an early phase trial to assess the safety  and immunogenicity of the combination therapy 
of a helper peptide vaccine (6MHP) plus PD -1 blockade (pembrolizumab) in patients with 
advanced melanoma.  In addition, exploratory analysis of clini cal benefit will be described.   
8.2 Evaluation of Sample Populations and Criteria  
8.2.1  Safety  
All participant s receiving any protocol treatment will be evaluated for safety. The 6MHP vaccine 
has been safe, with lower toxicities than with class I peptides, in part icular with lower 
autoimmune or hyperimmune toxicities. Based upon reported results in th e patient population 
treated with pembrolizumab  (51), drug -related serious adverse  events occurred in 7/89 (7.9%, 
95% CI( 3.2, 15.5%))  of participant s treated at the 2mg/kg dose every 3 weeks . These results 
are assumed to be reflective of the safety profile for the 200 mg study dose , as described  in 
section 4.3.2.  Thus, this trial will be designed with stopping rules for observed toxicities beyond 
those expected with pembrolizumab  alone. Specifically, f ormal safety bounds based upon 
monitoring dose -limiting toxicities (DLT) attributed to 6MHP or pembrolizumab  will guide 
decision s about early stopping due to potential safety c oncerns.  
DLTs will be defined based on the agent to which they are attributed, as specified in section 
7.2.6.  If a stopping bound is crossed then accrual to the study will be suspended until the study 
PI, co -investigators and the DSMC can review the data , and determine if the study should  
continue, be amended or be closed to further accrual.   
8.2.2  Immunogenicity  
All eligible participant s receiving any protocol treatment will be evaluated for the following 
immune response parameters.  
Primary:  
Product:   Pembrolizumab (MK -3475)  64 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 CD4+ T cell respo nse to 6MHP peptides  
CD4+ T cell responses to the 6MHP peptides will be evaluated in the blood using the direct 
ELIspot assay .  In order to be classified as achieving a high durable immune response in the 
blood, at least two 5 -fold increases  over baseline  must be observed  in the blood .   
 
Secondary:  
Tumor Microenvironment  (in the subset of participant s for which tumor biopsies are obtained)  
Infiltration of CD4+ and CD8+ T cells in the tumor microenvironment and Th1 -dominant immune 
signatures will be evalua ted by immunohistochemistry/immunofluorescence and/or by flow 
cytometry . 
 
Evaluated in the blood and in the SIN  (in the  subset of participant s for which SINs are 
obtained ): 
CD4+ T cell response s to the 6MHP peptides in the SIN . 
Epitope -spreading for CD8+ T cells reactive to a panel of defined melanoma antigens  will be 
evaluated by ELIspot assay.  
IgG antibody responses to 6MHP  will be evaluated by ELISA.  
 
8.2.3  Clinical efficacy  
All participant s receiving any protocol treatment will be evaluated for clinical benef it to treatment 
as defined by the following measures.  
 Clinical  response  by RECIST 1.1  
 Clinical response  by irRC  
 Progression -free survival  (PFS), defined as the time from the date of start of treatment 
to the date of progression or death from any cause, whichever occurs first. A participant  
who dies without a reported progression will be considered an event on the date of 
death. Participant s who have neither progressed nor died will be censored on the date 
of last evaluable tumor assessment . 
 Overall survi val (OS),  defined as the time from the date of start of treatment to the date 
of death from any cause. Participant s who do not experience an event (death) will be 
censored at date of last follow -up/contact . 
 
8.3 Sample Size and Accrual  
Conditional on safety bo unds not being crossed , maximum  target sample size is based upon 
having sufficient information to obtain preliminary information on whether  combined treatment 
with 6MHP vaccine plus pembrolizumab  increases the immunogenicity of 6MHP alone  in the 
entire stu dy population . Data from Mel44 on immune response as measured by direct ELIspot 
in blood  through month 12 for arms C and D (which included vaccination with  6MHP ) resulted in 
a high durable response rate  in the blood  (at least two 5 -fold increases) of 20% with an upper 
bound 90% CI of 26.7% . Lower responses (at least two 2 -fold increases) occurred in 32% of 
subjects ( upper bound 90% CI of 39.1% ). Based upon these prior results, for this study we 
would be interested in detecting an improvement in the percent of high durable responders in 
the blood from a null rate of 20% to 45% (above the low responder upper limit ) using a using a 
fixed sample design with approximate  type I and type II error rates of 10% (α=β=0.10). Note, 
Mel44 did not include assessments in the SIN thus sample size determination is based upon 
prior results for the blood only.  
Accrual of a total of 2 2 eligible participants provides 90% power to test f or a null high immune 
response rate of 20% vs an alternative high immune response rate of 45% with a one -side 10% 
level binomial test. At study conclusion the null hypothesis will be rejected and the treatment 
Product:   Pembrolizumab (MK -3475)  65 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 regimen considered worthy of further study if at least 8/2 2 (36%) eligible participants 
experience a  high durable im mune response.  
Maximum target sample size is estimated to be 25 participant s, which assumes a 10% 
dropout/ineligibility/lost to follow -up adjustment. Accrual is estimated at approximatel y 12 
participant s per year .  Considering enrollment as of May 2018 , accrual to the study should be 
completed in June 2019 .  
8.4 Stratification  
Participant s will be monitored for post entry stratification by whether or not biopsies are 
obtained at baseline and  day 22 ; (yes/no).   Target sample size for participant s for whom 
biopsies are obtained is set at a minimum of 12 eligible participant s. If increased infiltration of 
CD4+ response on day 22 compared to day 1 is observed in  the tumor in  9/12 participant s then  
the lower limit of a one -sided 90% confidence interval exceeds 50% and this would be 
considered a promising result and support ive of  further study of the treatment regimen.  
Similarly, i f increased infiltration of CD8+ response on day 22 compared to day 1 is observed in  
the tumor in  9/12 participant s then this would be considered a promising result and support ive 
of further study of the treatment regimen.  
 
8.5 Safety Monitoring  
Toxicities will be monitored using CTCAE 4.03 criteria. Stopping rules will be base d on the 
serious adverse  events rate of 7.9% (95% CI(3.2, 15.5%)) reported by Roberts, 2014 .  
Significant increases over these rates are not expected but would be a reason for early 
discontinuation.  Thus, f ormal safety bounds based upon the observed number  of participant s 
who experience a DLT related to 6MHP or pembrolizumab  as defined in  Section 7.2.6  will guide 
decisions about early stopping due to potential safety concerns.  The rate of DLTs for early 
stopping will include assessment up to the day 43 trea tment.   DLTs will be monitored up to 30 
days after the last study treatment and late observed rates that cross the bound would be 
reason to suspend accrual for a safety review by the Sponsor -Investigator and the  DSMC.   A 
sequential probability ratio test ( SPRT) based upon a binomial test of proportions for DLTs will 
be used.  Only the upper boundary will be used for monitoring to protect against excessive 
failure rates.  The stopping boundary are for a SPRT contrasting a 15% versus 30% DLT rate, 
with nomina l type I and II errors of 10% and 10%, respectively.  The slope of the parallel lines 
for monitoring is 0.219 and the intercept for the upper bound is 2.476.  
 
Table 146.  Stopping guideline for DLTs  
Number of participant s Boundary  
4-6 ≥ 4 
7-11 ≥ 5 
12-15 ≥ 6 
16-20 ≥ 7 
21-25 ≥ 8 
 
8.6 Analyses  
Study populations and evaluation criteria are noted in Section  8.2.  Adverse events will be 
summarized by frequency and magnitude of event. Incidence of DLTs will be monitored against 
the safety bou nds above. The bounds are non -binding, and provide a guideline that may result 
in study modification or closure  
Product:   Pembrolizumab (MK -3475)  66 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 Previous methods used to measur e responses to 6MHP include ELIspot assay s, proliferation 
assay s, and flow cytometry (Mel41, Mel44, E1602 trials) .  In the proposed trial, the study 
hypothesis will be tested using the direct ELIspot assay  results from the blood .  The criteria for 
defining immune responses have been reported for ELIspot assays  (54).  The circulating CD4+ 
T cell response rate to 6MHP peptides in participant s treated with 6MHP vaccine plus PD -1 will 
be assessed at each time noted in the study calendar. Hypothesis testing will be based upon 
the number of participant s that satisfy the criteria  of high durable immune response  in the 
blood . The proportion of participant s with high immune response overall as measured in the 
SIN or blood will be calculated along with 90% confidence intervals.      
Secondary measures will also be used to evaluate 6M HP specific CD4+ T cell responses.  Flow 
cytometry has value in defining the responding cell population and the function of responding  
cells using  multi -parameter staining.  CyTOF mass cytometry also is evolving as a valuable 
method. Additional  methods may  be incorporated over time as new technologies are developed 
and validated; however, for the purposes of testing the study hypothesis, the direct ELIspot 
assay will used as the primary measure.  A secondary endpoint will also be to assess the CD4+ 
T cell re sponse to 6MHP in the sentinel immunized node, using methods used for assessment 
of circulating responses.  
Our prior measures of immune response in the blood to the 6MHP resulted in high durable 
immune response rates of 20%. An observed high immune respons e rate of 36% overall would 
support further study of the treatment regimen.   Other measures assessed over time in the 
blood include a) epitope -spreading for circulating CD8+ T cells reactive to a panel of defined 
melanoma antigens  by ELispot assay , and  b) production of serum IgG reactive to 6MHP , by 
ELISA assay .   
Assessments in the tumor microenvironment include assessment of CD4+ and CD8+ T cells 
into melanoma  by immunohistochemistry/immunofluorescence and/or by flow cytometry . Each 
participant  will be as sessed for the endpoints of interest and the proportion of participant s 
experiencing an event (immune response, IgG antibody response to 6MHP, presence of CD8+ 
T cell infiltrates into the tumor (a subset), etc) will be estimated along with 95% confidence 
intervals. Repeated measure models will be used to estimate changes over time in interval  
measurements in the blood and tissue.  
Participant s will be assessed for clinical response and will be classified by best overall 
response by week 52  and at final asses sment. ORR will be estimated along with a 95% 
confidence interval around the point estimate.  
TTR, PFS, DFS and OS distributions will be estimated by the product limit method of Kaplan 
and Meier. Other summary measures for time to event distributions  will include estimates and 
95% CIs for median and 1 -year estimates to assess relative to published data. Exploratory 
proportional hazard models will be used to obtain preliminary estimates of potential 
associations with T cell  and antibody responses to melanoma antigens and survival.  
 
9.0 LABELING, PACKAGING,  STORAGE AND RETURN O F CLINICAL SUPPLIES  
9.1 Investigational Product  
The investigator  shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, ha ndling, distribution and usage of 
investigational product in accordance with the protocol and any applicable laws and 
regulations.  
Product:   Pembrolizumab (MK -3475)  67 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 Clinical Supplies will be provided by Merck  and UVA -HITC as summarized in  Table 15.  The 
peptide vaccine will undergo stability testing as described in Appendix 12.6 . 
Table 158.  Product Descriptions  
Product Name & Potency  Dosage Form  Supplier  
pembrolizumab 100 mg/ 4mL  Solution for Injection  Merck  
6MHP  Lyophilized Powder for Injection  UVA 
Montanide ISA -51 Solution for Injection  Seppic, Inc. (purchased by UVA)  
 
9.2 Packaging and Labeling Information  
Clinical supplies will be affixed with a clinical label in acc ordance with regulatory requirements.  
9.3 Clinical Supplies Disclosure  
This trial is open -label; therefore, the subject, the trial site personnel, the Sponsor -Investigator  
and/or designee are not blinded to treatment. Drug identity (name, strength) is included  in the 
label text; random code/disclosure envelopes or lists are not provided.  
9.4 Storage and Handling Requirements  
Clinical supplies must be stored in a secure, limited -access location under the storage 
conditions specified on the label.   
Receipt and dispe nsing of trial medication must be recorded by an authorized person at the trial 
site. 
Clinical supplies may not be used for any purpose other than that stated in the protocol.  
9.5 Returns and Reconciliation  
The investigator is responsible for keeping accurate records of the clinical supplies received 
from Merck  or designee, the amount dispensed to and returned by the subjects and the amount 
remaining at the conclusion of the trial.  
Upon  completion  or termination  of the study,  all unused  and/or  partially used i nvestigational 
product will be destroyed at the site per institutional policy.  It is the Investigat or’s respon sibility  
to arrange f or disposal of all empty containers, provided that procedures for proper disposal 
have been established according to applicab le federal, state, local and institutional guidelines 
and procedures, and provided that appropriate records of disposal are kept.  
10.0 ADMINISTRATIVE AND R EGULATORY DETAILS  
10.1 Study Conduct and Ethical Considerations  
This study will be conducted in accordance with  the standards of Good Clinical Practice, all 
applicable federal, state, and local laws, and in accord with the ethical principles that originated 
in the Declaration of Helsinki.  The PI will ensure that staff are trained and carry out the study in 
accord with the protocol specifications.   The PI will ensure that all study site personnel are 
aware that the study protocol and all data generated are confidential and should not be 
Product:   Pembrolizumab (MK -3475)  68 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 disclosed to third parties (with the exception of local and national regulatory bodies which 
require access for oversight purposes).  
10.2 UVA Institutional Review Board for Health Sciences Research  
The UVA Institutional Review Board for Health Sciences Research (UVA IRB -HSR) will 
approve all aspects of this study, including the clinical trial protocol, informed consent 
documents, and patient materials.  Modifications to the protocol or consent form will be 
reviewed and approved by the UVA IRB -HSR prior to implementation, except when necessary 
to eliminate apparent immediate hazards to the  study subject s. The study will undergo 
continuing IRB review based on the level of risk as assessed by the IRB.  This review will take 
place no less than annually. Reporting to the UVA IRB -HSR will occur as specified in Section 
7.2. 
10.3 Consent Forms and the Consenting Process  
Consent forms will be written in accord with 21 CFR 50 and will be reviewed and approved by 
the UVA IRB -HSR prior to use. Subjects will be given an approved consent form to review .  A 
member of the study team will  explain the study and s tudy procedures to each subject and will  
be available to answer questions .   Informed consent will be obtained from each subject prior to 
conducting any study -specific procedures or administering study drug.  
10.4 Compliance with Trial Registration and Results P osting Requirements  
Under the terms of the Food and Drug Administration Modernization Act (FDAMA) and the 
Food and Drug Administration Amendments Act (FDAAA), the Sponsor of the trial is solely 
responsible for determining whether the trial and its results are subject to the requirements for 
submission to the Clinical Trials Data Bank, http://www.clinicaltrials.gov.  Information posted will 
allow subjects to identify potentially appropriate trials for their disease conditions and pursue 
participation by call ing a central contact number for further information on appropriate trial 
locations and trial site contact information.     
10.5 Maintenance of Study Documents  
Signed consent forms and other research records will be retained in a confidential manner. 
Study reco rds will be kept for at least 6 years after completion of the study.  
10.6 Data Collection  
Data will be collected using a centralized electronic case report form called ON-line Clinical 
Oncology Research Environment = Oncore . 
10.6.1  Endpoint Data  
 Endpoint data will be  collected using HITC IML data forms, subject -specific binders, and 
the HITC laboratory database.  
 The HITC laboratory database, which has password -restricted access, is stored on the 
UVA Health System Computing Services secured server.  
Product:   Pembrolizumab (MK -3475)  69 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 10.7 Monitoring Plan  
The University of Virginia Cancer Center Data and Safety Monitoring Committee (CC DSMC) 
will provide oversight of the conduct of this study.  The CC DSMC will report to the UVA 
Protocol Review Committee (PRC).  
The UVA CC DSMC will review the following:  
 All adv erse events  
 Audit results  
 Application of study designed stopping/decision rules  
 Whether the study accrual pattern warrants continuation/action  
 Protocol violations  
 
10.7.1  Monitoring Schedule  
The UVA CC DSMC will meet every month for aggregate review of data.  Tra cking reports of 
the meetings are available to the PI for review.  Issues of immediate concern by the DSMC are 
brought to the attention of the Sponsor -Investigator  (and if appropriate to the PRC and IRB) 
and a formal response from the Sponsor -Investigator  is requested.  Per the UVA Cancer Center 
NIH approved institutional plan, this study will be audited approximately every 6 months.  The 
audit may include direct access to source data/documents.  
  
Product:   Pembrolizumab (MK -3475)  70 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
  
11.0 LIST OF REFERENCES  
 1.  Topalian, S . L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. 
Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, 
L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Ander s, J. M. Taube, T. L. 
McMiller, H. Xu, A. J. Korman, M. Jure -Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. 
Gupta, J. M. Wigginton, and M. Sznol. 2012. Safety, activity, and immune correlates of anti -PD-
1 antibody in cancer. N. Engl. J. Med.  366: 2443 -2454. 
 2.  Rosenberg, S. A., J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes, G. Q. Phan, D. E. 
Citrin, N. P. Restifo, P. F. Robbins, J. R. Wunderlich, K. E. Morton, C. M. Laurencot, S. M. 
Steinberg, D. E. White, and M. E. Dudley. 2011. Durable comple te responses in heavily 
pretreated patients with metastatic melanoma using T -cell transfer immunotherapy. Clin. 
Cancer Res.  17: 4550 -4557.  
 3.  Higano, C. S., P. F. Schellhammmer, E. J. Small, P. A. Burch, Nemunaitis J, L. Yuh, N. 
Provost, and M. W. Frohli ch. 2009. Integrated data from 2 randomized, double -blind, placebo -
controlled, phase 3 trials of active cellular immunotherapy with sipuleucel -T in advanced 
prostate cancer. Cancer  115: 3670 -3679.  
 4.  Schwartzentruber, D. J., D. H. Lawson, J. M. Richards,  R. M. Conry, D. M. Miller, J. Treisman, 
F. Gailani, L. Riley, K. Conlon, B. Pockaj, K. L. Kendra, R. L. White, R. Gonzalez, T. M. Kuzel, 
B. Curti, P. D. Leming, E. D. Whitman, J. Balkissoon, D. S. Reintgen, H. Kaufman, F. M. 
Marincola, M. J. Merino, S. A.  Rosenberg, P. Choyke, D. Vena, and P. Hwu. 2011. gp100 
peptide vaccine and interleukin -2 in patients with advanced melanoma. N. Engl. J Med.  364: 
2119 -2127.  
 5.  Slingluff, C. L., Jr., G. R. Petroni, W. Olson, A. R. Czarkowski, W. W. Grosh, M. Smolkin, K.  A. 
Chianese -Bullock, Neese P.Y., D. H. Deacon, C. J. Nail, P. Merrill, R. Fink, and P. K. Rehm. 
2008. Helper T cell responses and clinical activity of a melanoma vaccine with multiple peptides 
from MAGE and melanocytic differentiation antigens. J. Clin. O ncol.  26: 4973 -4980.  
 6.  Dillon, P. M., W. C. Olson, A. Czarkowski, G. R. Petroni, M. Smolkin, W. W. Grosh, K. A. 
Chianese -Bullock, D. H. Deacon, and C. L. Slingluff, Jr. 2014. A melanoma helper peptide 
vaccine increases Th1 cytokine production by leukocy tes in peripheral blood and immunized 
lymph nodes. J. Immunother. Cancer  2: 23.  
 7.  Hu, Y., G. R. Petroni, W. C. Olson, A. Czarkowski, M. E. Smolkin, W. W. Grosh, K. A. 
Chianese -Bullock, and C. L. Slingluff, Jr. 2014. Immunologic hierarchy, class II MHC 
promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol. 
Immunother.  63: 779 -786. 
 8.  Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. 
Schreiber. 2001. IFNgamma and lymphocytes prevent p rimary tumour development and shape 
tumour immunogenicity. Nature  410: 1107 -1111.  
 9.  Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. 
Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. van den Eertw egh, J. 
Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbe, C. 
Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. 
Hoos, and W. J. Urba. 2010. Improved Survival with Ipilimu mab in Patients with Metastatic 
Melanoma. N. Engl. J Med.  363: 711 -723. 
Product:   Pembrolizumab (MK -3475)  71 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
  10.  Wolchok, J. D., H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. 
Segal, C. E. Ariyan, R. A. Gordon, K. Reed, M. M. Burke, A. Caldwell, S. A. Kronenberg , B. U. 
Agunwamba, X. Zhang, I. Lowy, H. D. Inzunza, W. Feely, C. E. Horak, Q. Hong, A. J. Korman, 
J. M. Wigginton, A. Gupta, and M. Sznol. 2013. Nivolumab plus ipilimumab in advanced 
melanoma. N. Engl. J Med.  369: 122 -133. 
 11.  Topalian, S. l., F. S. Hod i, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. 
Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, 
L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube,  T. L. 
McMiller, H. Xu, A. J. Korman, M. Jure -Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. 
Gupta, J. M. Wigginton, and M. Sznol. 2012. Safety, activity, and immune correlates of anti -PD-
1 antibody in cancer. N. Engl. J. Med.  366: 2443 -2454.  
 12.  Kaya ga, J., B. E. Souberbielle, N. Sheikh, W. J. Morrow, T. Scott -Taylor, R. Vile, H. Chong, and 
A. G. Dalgleish. 1999. Anti -tumour activity against B16 -F10 melanoma with a GM -CSF 
secreting allogeneic tumour cell vaccine. [erratum appears in Gene Ther 1999 Nov ;6(11):1905]. 
Gene Therapy  6: 1475 -1481.  
 13.  Hunder, N. N., H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly, R. Rodmyre, A. Jungbluth, S. 
Gnjatic, J. A. Thompson, and C. Yee. 2008. Treatment of metastatic melanoma with autologous 
CD4+ T cells against NY -ESO -1. N. Engl. J. Med.  358: 2698 -2703.  
 14.  Kahn, M., H. Sugawara, P. McGowan, K. Okuno, S. Nagoya, K. E. Hellstrom, I. Hellstrom, and 
P. Greenberg. 1991. CD4+ T cell clones specific for the human p97 melanoma -associated 
antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. 
J. Immunol.  146: 3235 -3241.  
 15.  Schoenberger, S. P., R. E. M. Toes, E. I. H. van der Voort, R. Offringa, and C. J. M. Melief. 
1998. T -cell help for cytotoxic T lymphcytes is mediated by CD40 -CD40 L interactions. Nature  
393: 480 -483. 
 16.  Ridge, J. P., F. Di Rosa, and P. Matzinger. 1998. A conditioned dendritic cell can be a temporal 
bridge between a CD4+ T-helper and a T -killer cell. Nature  393: 474 -478. 
 17.  Taraban, V. Y., T. F. Rowley, and A. Al-Shamkhani. 2004. Cutting edge: a critical role for CD70 
in CD8 T cell priming by CD40 -licensed APCs. J. Immunol.  173: 6542 -6546.  
 18.  Bullock, T. N., and H. Yagita. 2005. Induction of CD70 on dendritic cells through CD40 or TLR 
stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T 
cells. J. Immunol.  174: 710 -717. 
 19.  Sun, J. C., and M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection 
without CD4 T cell help. Science  300: 339 -342. 
 20.  Jansse n, E. M., E. E. Lemmens, T. Wolfe, U. Christen, M. G. von Herrath, and S. P. 
Schoenberger. 2003. CD4+ T cells are required for secondary expansion and memory in CD8+ 
T lymphocytes. Nature  421: 852 -856. 
 21.  Bourgeois, C., B. Rocha, and C. Tanchot. 2002. A  role for CD40 expression on CD8+ T cells in 
the generation of CD8+ T cell memory. Science  297: 2060 -2063.  
Product:   Pembrolizumab (MK -3475)  72 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
  22.  Kennedy, R., A. H. Undale, W. C. Kieper, M. S. Block, L. R. Pease, and E. Celis. 2005. Direct 
cross -priming by th lymphocytes generates memory cytotoxic T cell responses. J. Immunol.  
174: 3967 -3977.  
 23.  Hung, K., R. Hayashi, A. Lafond -Walker, C. Lowenstein, D. Pardoll, and H. Levitsky. 1998. The 
central role of CD4+ T cells in the antitumor immune response., 188 ed. 2357 -2368.  
 24.  Matsui, S.,  J. D. Ahlers, A. O. Vortmeyer, M. Terabe, T. Tsukui, D. P. Carbone, L. A. Liotta, and 
J. A. Berzofsky. 1999. A model for CD8+ CTL tumor immunosurveillance and regulation of 
tumor escape by CD4 T cells through an effect on quality of CTL. J. Immunol.  163: 184-193. 
 25.  Disis, M. l. 2010. Immune regulation of cancer. J. Clin. Oncol.  28: 4531 -4538.  
 26.  Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, 
G. Zhu, K. Tamada, V. A. Lennon, E. Celis, and L. Chen. 2002. Tumor -associated B7 -H1 
promotes T -cell apoptosis: a potential mechanism of immune evasion. Nat. Med.  8: 793 -800. 
 27.  Sharpe, A. H., and G. J. Freeman. 2002. The B7 -CD28 superfamily. Nat. Rev. Immunol.  2: 116 -
126. 
 28.  Brown, J. A., D. M. Dorfman, F. R. Ma, E. L. Sullivan, O. Munoz, C. R. Wood, E. A. Greenfield, 
and G. J. Freeman. 2003. Blockade of programmed death -1 ligands on dendritic cells 
enhances T cell activation and cytokine production. J. Immunol.  170: 1257 -1266.  
 29.  Francisco, L. M., P. T. Sag e, and A. H. Sharpe. 2010. The PD -1 pathway in tolerance and 
autoimmunity. Immunol. Rev.  236: 219 -242. 
 30.  Thompson, R. H., H. Dong, C. M. Lohse, B. C. Leibovich, M. L. Blute, J. C. Cheville, and E. D. 
Kwon. 2007. PD -1 is expressed by tumor -infiltrating immune cells and is associated with poor 
outcome for patients with renal cell carcinoma. Clin. Cancer Res.  13: 1757 -1761.  
 31.  Talmadge, J. E., M. Donkor, and E. Scholar. 2007. Inflammatory cell infiltration of tumors: Jekyll 
or Hyde. Cancer Metastasis Re v. 26: 373 -400. 
 32.  Usubutun, A., A. Ayhan, M. C. Uygur, H. Ozen, C. Toklu, and S. Ruacan. 1998. Prognostic 
factors in renal cell carcinoma. J. Exp. Clin. Cancer Res.  17: 77 -81. 
 33.  Diez, M., M. Pollan, J. M. Enriquez, P. Dominguez, A. Santana, E. Toba ruela, J. M. Muguerza, 
F. Arrieta, A. Rodriguez, and A. Ruiz. 1998. Histopathologic prognostic score in colorectal 
adenocarcinomas. Anticancer Res.  18: 689 -694. 
 34.  Galon, J., A. Costes, F. Sanchez -Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce -Pages, M. 
Tosolini, M. Camus, A. Berger, P. Wind, F. Zinzindohoue, P. Bruneval, P. H. Cugnenc, Z. 
Trajanoski, W. H. Fridman, and F. Pages. 2006. Type, density, and location of immune cells 
within human colorectal tumors predict clinical outcome. Science  313: 1960 -1964 . 
 35.  Al-Shibli, K. I., T. Donnem, S. Al -Saad, M. Persson, R. M. Bremnes, and L. T. Busund. 2008. 
Prognostic effect of epithelial and stromal lymphocyte infiltration in non -small cell lung cancer. 
Clin. Cancer Res.  14: 5220 -5227.  
 36.  Deschoolmeester, V ., M. Baay, M. E. Van, J. Weyler, P. Vermeulen, F. Lardon, and J. B. 
Vermorken. 2010. Tumor infiltrating lymphocytes: an intriguing player in the survival of 
colorectal cancer patients. BMC. Immunol.  11: 19.  
Product:   Pembrolizumab (MK -3475)  73 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
  37.  Hiraoka, N. 2010. Tumor -infiltrating lymph ocytes and hepatocellular carcinoma: molecular 
biology. Int. J. Clin. Oncol.  15: 544 -551. 
 38.  Nobili, C., L. Degrate, R. Caprotti, C. Franciosi, B. E. Leone, R. Trezzi, F. Romano, F. Uggeri, 
and F. Uggeri. 2008. Prolonged survival of a patient affected b y pancreatic adenocarcinoma 
with massive lymphocyte and dendritic cell infiltration after interleukin -2 immunotherapy. Report 
of a case. Tumori  94: 426 -430. 
 39.  Hodi, F. S., and G. Dranoff. 2010. The biologic importance of tumor -infiltrating lymphocytes.  J. 
Cutan. Pathol.  37 Suppl 1: 48 -53. 
 40.  Kloor, M. 2009. Lymphocyte infiltration and prognosis in colorectal cancer. Lancet Oncol.  10: 
840-841. 
 41.  Hillen, F., C. I. Baeten, A. van de Winkel, D. Creytens, D. W. van der Schaft, V. 
Winnepenninckx, and A . W. Griffioen. 2008. Leukocyte infiltration and tumor cell plasticity are 
parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol. Immunother.  
57: 97 -106. 
 42.  Lee, H. E., S. W. Chae, Y. J. Lee, M. A. Kim, H. S. Lee, B. L. Lee, and W. H. Kim. 2008. 
Prognostic implications of type and density of tumour -infiltrating lymphocytes in gastric cancer. 
Br. J. Cancer  99: 1704 -1711.  
 43.  Leffers, N., M. J. Gooden, R. A. de Jong, B. N. Hoogeboom, K. A. ten Hoor, H. Hollema, H. M. 
Boezen, A. G. va n der Zee, T. Daemen, and H. W. Nijman. 2009. Prognostic significance of 
tumor -infiltrating T -lymphocytes in primary and metastatic lesions of advanced stage ovarian 
cancer. Cancer Immunol. Immunother.  58: 449 -459. 
 44.  Nishimura, H., T. Honjo, and N. Min ato. 2000. Facilitation of beta selection and modification of 
positive selection in the thymus of PD -1-deficient mice. J. Exp. Med.  191: 891 -898. 
 45.  Liotta, F., M. Gacci, F. Frosali, V. Querci, G. Vittori, A. Lapini, V. Santarlasci, S. Serni, L. 
Cosmi, L. Maggi, R. Angeli, B. Mazzinghi, P. Romagnani, E. Maggi, M. Carini, S. Romagnani, 
and F. Annunziato. 2011. Frequency of regulatory T cells in peripheral blood and in tumour -
infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU. Int.  107: 
1500 -1506.  
 46.  American Cancer Society. 2014. Cancer Facts and Figures 2014.  
http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc -
042151.pdf  
 47.  Korn, E. L., P. Y. Liu, S. J. Lee, J. A. Chapman, D. Niedzwiecki, V . J. Suman, J. Moon, V. K. 
Sondak, M. B. Atkins, E. A. Eisenhauer, W. Parulekar, S. N. Markovic, S. Saxman, and J. M. 
Kirkwood. 2009. Meta -analysis of phase II cooperative group trials in metastatic stage IV 
melanoma to determine progression -free and overa ll survival benchmarks for future phase II 
trials.  J Clin Oncol  26: 527 -534. 
 48.  Bennett, S. R. M., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. A. P. Miller, and W. R. 
Heath. 1998. Help for cytotoxic -T-cell responses is mediated by CD40 signalling.  Nature  393: 
478-480. 
 49.  Slingluff, C. L., Jr., S. Lee, F. Zhao, K. A. Chianese -Bullock, W. C. Olson, L. H. Butterfield, T. L. 
Whiteside, P. D. Leming, and J. M. Kirkwood. 2013. A randomized phase II trial of multi -epitope 
Product:   Pembrolizumab (MK -3475)  74 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 vaccination with melanoma pept ides for cytotoxic T -cells and helper T -cells for patients with 
metastatic melanoma (E1602). Clin. Cancer Res.  19: 4228 -4238.  
 50.  Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. 
Cancer  12: 252 -264. 
 51.  Robert,  C., A. Ribas, J. D. Wolchok, F. S. Hodi, O. Hamid, R. Kefford, J. S. Weber, A. M. 
Joshua, W. J. Hwu, T. C. Gangadhar, A. Patnaik, R. Dronca, H. Zarour, R. W. Joseph, P. 
Boasberg, B. Chmielowski, C. Mateus, M. A. Postow, K. Gergich, J. Elassaiss -Schaap, X.  N. Li, 
R. Iannone, S. W. Ebbinghaus, S. P. Kang, and A. Daud. 2014. Anti -programmed -death -
receptor -1 treatment with pembrolizumab in ipilimumab -refractory advanced melanoma: a 
randomised dose -comparison cohort of a phase 1 trial. Lancet  384: 1109 -1117.  
 52.  Erdag, G., J. T. Schaefer, M. E. Smolkin, D. H. Deacon, S. M. Shea, L. T. Dengel, J. W. 
Patterson, and C. L. Slingluff, Jr. 2012. Immunotype and immunohistologic characteristics of 
tumor -infiltrating immune cells are associated with clinical outcome in  metastatic melanoma. 
Cancer Res.  72: 1070 -1080.  
 53.  Crawford, A., J. M. Angelosanto, C. Kao, T. A. Doering, P. M. Odorizzi, B. E. Barnett, and E. J. 
Wherry. 2014. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic 
infection.  Immunity.  40: 289 -302. 
 54.  Slingluff, C. L., Jr., G. R. Petroni, K. A. Chianese -Bullock, M. E. Smolkin, M. I. Ross, N. B. 
Haas, M. von Mehren, and W. W. Grosh. 2011. A randomized multicenter trial of the effects of 
melanoma -associated helper peptides an d cyclophosphamide on the immunogenicity of a 
multipeptide melanoma vaccine.   J. Clin. Oncol.  29: 2924 -2932.  
 55.  Erdag, G., J. T. Schaefer, M. E. Smolkin, D. H. Deacon, S. Shea, L. T. Dengel, J. W. Patterson, 
and C. L. Slingluff, Jr. 2012. Immunotype and  immunohistologic characteristics of tumor 
infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer 
Res. 72: 1070 -1080.  
 56.  Balch, C. M., A. C. Buzaid, S. J. Soong, M. B. Atkins, N. Cascinelli, D. G. Coit, I. D. Flemi ng, J. 
E. Gershenwald, A. J. Houghton, J. M. Kirkwood, K. M. McMasters, M. F. Mihm, D. l. Morton, D. 
S. Reintgen, M. I. Ross, A. Sober, J. A. Thompson, and J. F. Thompson. 2001. Final version of 
the American Joint Committee on Cancer staging system for cut aneous melanoma. [Review] 
[83 refs]. J. Clin. Oncol.  19: 3635 -3648.  
 
 
 
Product:   Pembrolizumab (MK -3475)  75 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 12.0 APPENDICES  
12.1 ECOG Performance Status  
Grade  Description  
0 Normal activity. Fully active, able to carry on all pre -disease performance 
without restriction.  
1 Symptoms, but ambulatory. Re stricted in physically strenuous activity, but 
ambulatory and able to carry out work of a light or sedentary nature (e.g., 
light housework, office work).  
2 In bed <50% of the time. Ambulatory and capable of all self -care, but 
unable to carry out any work activities. Up and about more than 50% of 
waking hours.  
3 In bed >50% of the time. Capable of only limited self -care, confined to bed 
or chair more than 50% of waking hours.  
4 100% bedridden. Completely disabled. Cannot carry on any self -care. 
Totally co nfined to bed or chair.  
5 Dead.  
* As published in Am. J. Clin. Oncol.:  Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., 
Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern 
Cooperative Oncology Group. Am J Clin On col 5:649 -655, 1982. The Eastern Cooperative 
Oncology Group, Robert Comis M.D., Group Chair.  
 
  
Product:   Pembrolizumab (MK -3475)  76 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
  
12.2 Common Terminology Criteria for Adverse Events V4.0 (CTCAE)  
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for 
Adver se Events (CTCAE) version 4.0 will be utilized for adverse event reporting. 
(http://ctep.cancer.gov/reporting/ctc.html)  
  
Product:   Pembrolizumab (MK -3475)  77 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
  
12.3 Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria for Evaluating 
Response in Solid Tumors  
RECIST version 1.1* will b e used in this study for assessment of tumor response. While either CT or 
MRI may be utilized, as per RECIST 1.1, CT is the preferred imaging technique in this study.  
* As published in the European Journal of Cancer:  
E.A. Eisenhauer, P. Therasse, J. Bogaer ts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, 
S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij. New 
response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Canc er. 
2009 Jan;45(2):228 -47. 4 
 
  
Product:   Pembrolizumab (MK -3475)  78 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 12.4 AJCC Staging System  
Melanoma TNM Classification  
T Classification  Thickness  Ulceration Status  
T1 ≤ 1.0 mm  a:  without ulceration or mitoses  
b:  with ulceration or mitoses  1 
T2 1.01 – 2.0 mm  a:  without ulceration  
b:  with ulceration  
T3 2.01 – 4.0 mm  a:  without ulceration  
b:  with ulceration  
T4 > 4.0 mm  a:  without ulceration  
b:  with ulceration  
   
N Classification  # of Metastatic Nodes  Nodal Metastatic Mass  
N1 1 node  a:  micrometastasis*  
b:  macrometastasis † 
N2 2 – 3  nodes  a:  micrometastasis*  
b:  macrometastasis † 
c: in transit met(s)/satellite(s) 
without metastatic nodes  
N3 4 or more metastatic nodes, 
or matted nodes, or  
in transit met(s)/satellites( s) 
with metastatic node(s)   
   
M Classification  Site Serum Lactate Dehydrogenase  
M1a Distant skin, subcutaneous  
or nodal mets  Normal  
M1b Lung metastases  Normal  
M1c All other visceral metastases  Normal  
Any distant metastasis  Elevated  
* Micrometastas es are diagnosed after sentinel or elective lymphadenectomy.  
† Macrometastases are defined as clinically detectable nodal metastases confirmed by therapeutic 
lymphadenectomy or when nodal metastasis exhibits gross extracapsular extension.  
 
 
  
Product:   Pembrolizumab (MK -3475)  79 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 Stage Groupin gs for Cutaneous Melanoma  
 Clinical Staging  Pathologic Staging  
 T N M T N M 
0 Tis N0 M0 Tis N0 M0 
IA T1a N0 M0 T1a N0 M0 
IB T1b 
T2a N0 
N0 M0 
M0 T1b 
T2a N0 
N0 M0 
M0 
IIA T2b 
T3a N0 
N0 M0 
M0 T2b 
T3a N0 
N0 M0 
M0 
IIB T3b 
T4a N0 
N0 M0 
M0 T3b 
T4a N0 
N0 M0 
M0 
IIC T4b N0 M0 T4b N0 M0 
III‡ Any T  N1-3 M0  
IIIA  T1-4a 
T1-4a N1a 
N2a M0 
M0 
IIIB  T1-4b 
T1-4b 
T1-4a 
T1-4a 
T1-4a/b N1a 
N2a 
N1b 
N2b 
N2c M0 
M0 
M0 
M0 
M0 
IIIC  T1-4b 
T1-4b 
Any T  N1b 
N2b 
N3 M0 
M0 
M0 
IV Any T  Any N  Any M1  Any T  Any N  Any M1  
* Clinical s taging includes microstaging of the primary melanoma and clinical/radiologic evaluation 
for metastases.  By convention, it should be used after complete excision of the primary 
melanoma with clinical assessment for regional and distant metastases.  
† Pathol ogic staging includes microstaging of the primary melanoma and pathologic information 
about the regional lymph nodes after partial or complete lymphadenectomy.  Pathology stage 0 or 
stage 1A patients are the exception; they do not require pathologic evalua tion of their lymph 
nodes.  
‡ There are no stage III subgroups for clinical staging.  
 
 
Staging for Mucosal Melanomas  
This system is based on the staging of cutaneous melanomas.  
 
Stage IIB:  Clinically localized primary melanoma > 4mm thick  
Stage III:  Lymph n ode metastases  
Stage IV:  Distant metastases  
  
Product:   Pembrolizumab (MK -3475)  80 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 12.5 New York Heart Association Disease Classification  
Functional Capacity  Objective Assessment  
Class I.  Patients with cardiac disease but 
without resulting limitation of physical activity. 
Ordinary physical activ ity does not cause undue 
fatigue, palpitation, dyspnea, or anginal pain.  No objective evidence of cardiovascular 
disease.  
Class II.  Patients with cardiac disease resulting 
in slight limitation of physical activity. They are 
comfortable at rest. Ordinary physical activity 
results in fatigue, palpitation, dyspnea, or 
anginal pain.  Objective evidence of minimal cardiovascular 
disease  
Class III.  Patients with cardiac disease 
resulting in marked limitation of physical activity. 
They are comfortable at rest. Less than ordinary 
activity causes fatigue, palpitation, dyspnea, or 
anginal pain.  Objective evidence of moderately severe 
cardiovascular disease.  
Class IV.  Patients with cardiac disease 
resulting in inability to carry on any physical 
activity without di scomfort. Symptoms of heart 
failure or the anginal syndrome may be present 
even at rest. If any physical activity is 
undertaken, discomfort is increased.  Objective evidence of severe cardiovascular 
disease.  
* The Criteria Committee of the New York Heart A ssociation. Nomenclature and Criteria for Diagnosis of 
Diseases of the Heart and Great Vessels . 9th ed. Boston, Mass: Little, Brown & Co; 1994:253 -256 
  
Product:   Pembrolizumab (MK -3475)  81 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 12.6 Vaccine Lot Release and Stability Testing  
A. Preparation of the synthetic melanoma and tetanus peptides  
All peptides were synthesized under GMP conditions by Multiple Peptide Systems (San Diego, 
CA).   
Peptide preparation and vialing were performed under GMP conditions by Clinalfa (Merck 
Biosciences AG, Laufelfingen, Switzerland).  Documentation relating to th e procedures used to 
prepare and vial the peptides were included in the Chemistry and Manufacturing Section of prior 
IND application applications (10825 and 12191).   
B. Quality Assurance Testing  
Prepared peptides were subjected to the following tests:  
1. Identity .  Identity was confirmed by structural studies.  The individual peptides were tested for 
identity by mass spectrometry (to define molecular mass and amino acid sequence) and 
HPLC (to confirm purity) in a GMP laboratory (Polypeptide Group).  
2. Purity.  Purity was assessed before and after vialing the peptide mixtures.  Before vialing the 
peptide mixtures, each synthetic peptide was evaluated for the presence of a single dominant 
species by high pressure liquid chromatography (HPLC) in a GMP laborat ory (Polypeptide 
Group).  Purity of each peptide component exceeded 90%. Variants of the original peptide 
may have included incomplete products of synthesis, minor degradation products due to 
oxidation of methionine residues, and dimerization of cysteine -containing peptides.  After 
vialing the peptide mixture, purity was reconfirmed by HPLC in a GMP laboratory (Clinalfa).  
3. Trifluoroacetic acid (TFA) .  The amount of total fluorine in each peptide preparation was less 
than 0.5% or 5000 ppm as determined by Multiple Peptide Systems.  
4. Potency .  Peptides are synthesized under GMP conditions and the net peptide content 
calculated for each.  The amounts of each peptide (mcg quantities) added to the vaccine vials 
are calculated based on the net peptide content o f the original stock of lyophilized peptides.  
5. Pyrogenicity .  Pyrogenicity testing was conducted by Clinalfa in accordance with USP 
guidelines.  
6. General Safety .  General safety testing was conducted by Clinalfa in accordance with USP 
guidelines.  
7. Sterility.  Sterility testing was conducted by Clinalfa in accordance with USP guidelines.  
8. Stability .  The peptide preparations were assayed for stability at months 3, 6, 12, 24, and 36 
and were shown to be stable. The peptides will continue to be assessed  yearly for stability 
while subjects are on active treatment.  The following analyses will be performed to confirm 
stability.  
a. HPLC :  HPLC will be performed to confirm purity.  An optical comparison to previous 
HPLC data will be performed.  Ideally, the purity of each peptide  component will exceed 
90% (94% -98%).  Variants of the original peptide may include incomplete products of 
synthesis, minor degradation products due to oxidation of methionine residues, and 
dimerization of cysteine -containing peptides .  Such minor variants will be tolerated as 
long as the peptide represents at least 75% of the intended peptide species.  Because 
measures of peptide quantity are subject to variability, a peptide lot will be rejected only if 
two sequential measures fail t o meet the criterion stated above  
Product:   Pembrolizumab (MK -3475)  82 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 b. Sterility .  One vial of peptide will be submitted to the Clinical Microbiology Laboratory at 
the University of Virginia or Microbiology Research Associates, Inc. (Acton, MA) for 
sterility testing.   
  
Product:   Pembrolizumab (MK -3475)  83 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
  
12.7 Summary of Change s 
Version Date  Description of Changes  
7-13-18 1. Section 5.2.1.3: r emoved text “or baseline”  from the general instructions  in 
Table 6 . Dose Modification and Toxicity Management Guidelines for 
Immune -related AEs Associated with Pembrolizumab . 
6-14-18 1. Updated Merck safety fax number through the protocol document.  
2. Removed references for draft text not used in version 6 -01-18. 
6-01-18 1. Study team updated to  reflect personnel changes . 
2. Signature page edited to reflect Sponsor -Investigator role . 
3. Updated table of contents pages numbers .  
4. Updated hyperlinks  and corrected minor typographical errors throughout 
protocol document.  
5. Sections 1, 2.1, 8: target enrollmen t reduced from 47 to 25 (22 eligible).  
6. Section s 2, 3.1 , 4.3.3.1 , 6.1 , 7.1.4.1 , 7, 8.2.2 : requirement for sentinel 
immunized node removed.  
7. Sections 2.1, 5.2.1.4, 6: tumor imaging schedule was revised  to match 
standard clinical care : 
-require d scans at basel ine, days 57 and 127 ( with a window of ± 14 Days ) 
and per standard care thereafter ,  
-head scans at baseline and as clinically indicated  thereafter .  
8. Section s 3, 4.3.3.1 : study endpoints modified to focus more on immune 
response and effects of therapy on t he tumor microenvironment.  
9. Section 4.3.1: added statement regarding factors associated with 
increased risk of recurrence.  
10. Section 4.3.2: added statement regarding 2 year treatment duration.  
11. Section 4.3.3.1: added text regarding measurement of T cell respon se, 
epitope spreading and  the identification of neo antigens.  
12. Section 5.1.1: clarified staging timing, use of AJCC v7, and that subjects 
should be eligible to receive pembrolizumab per clinician judgement.  
13. Section 5.1.3: exclusion criteria 20 revised to i ndicate HGBA1C >8.5% as 
exclusionary.  
14. Section 5.2.1.3: replaced Table 6 with revised Merck provided table “ Dose 
Modification and Toxicity Management Guidelines for Immune -related AEs 
Associated with Pembrolizumab ” 
15. Section 5.2.1.4: edited table 7 to include  biopsy and to indicate that scans 
 8 to 14 days  from day 57 would not be considered a protocol violation . 
Section 5.4  
16. Section 7.1.3 : removed bulleted list of labs and updated table 9 for 
consistency. R emoved redundant Table 10 and renumbered later tables .  
17. Section 8: reduced number of subjects required to have biopsiable disease 
from 14 to 12 . 
04-04-17 1. Section 5.1.3: corrected exclusion criteria 4 regarding immunosuppressive 
therapy to within 7 days of registration to match inclusion criteria 6.  
2. Section 5.8.: referenced section 7.1.5.3.1 and 7.2.7.8 regarding adverse 
event monitoring after study treatment discontinuation.  
3. Section 6.1: removed comprehensive chemistry and CBC on days 8 & 15 , 
and medication review at follow up visits after the safety follow up. Clarified 
biopsies may be collected at progression for research purposes or as part 
of clinical  care in footnote “n”.  
4. Section 7.1.2.8.2: added section describing optional biopsies.  
Product:   Pembrolizumab (MK -3475)  84 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 5. Section 7.1.2.8.3: added section to address tissue removed as part of 
clinicanl care.  
6. Section 7.2.5.1: clarified that an ulceration of 2 cm or less is considered an 
expected toxicity for the 6MHP.  
10-24-16 1. Updated study personnel  
2. Updated Table of Contents  
3. Section 5.1.2  #3a:  revised to clarify the entry criteria for patients  who had 
previously received a PD -1/PD -L1 antibody and p rogressed during or after 
that therapy.  
Section 5.1.2 #3b: revised  to broaden the patient population to include 
patients who have not experienced an objective clinical response after 
anti-PD1 antibody  or anti -CTLA4/anti -PD1 combination therapy, and who 
are candidates to receive pembrolizumab therapy.  
4. Section 5.1.3  #5: revised treatment window for prior monoclonal antibody 
treatment from 4 weeks to 3 weeks.   
5. Section 7.1.3.1: clarified that LDH would be  tested every 6 weeks.  
09-07-16 1. Section 5.1.3: updat ed exclusion criteria of pneumonitis per Merck 
investigator  letter  dated 7/25/16 . 
2. Section 5.2.1.2: under 6MHP added “within” to clarify that the vaccine 
should  be administered  within 1 -2 hours after mixi ng. 
3. Section 5.2.1.4: removed extra “2 years” in table 7 next to last row.  
4. Section 5.8: removed “up to one year of” , “study”  and incorrect section 
reference, clarifying possible extended pembrolizumab treatment as part of 
clinical care.  
5. Section 6.1: added s afety labs on days 8 & 15 , indicated concomitant 
medication review at all clinic visits , and r emoved LDH from end of 
treatment/post -treatment table as it is included in the comprehensive 
chemistry panel.  
6. Section 7.1.5.2.2: removed “Phase” from heading as t he second course 
treatment is not considered part of the study.  
03-21-16 1. Editorial changes and typographical and formatting corrections were made 
throughout the study document.  
2. Updated investigator list.  
3. Section 1.0:  added estimated average length of tre atment per patient to 
the trial summary table in accordance with Merck updates to the protocol 
template.  
4. Section 3.0:  revised the objectives based on the expansion of the patient 
population to include both patients who are naïve for or received 
ipilimumab  or other anti -CTLA -4 antibody in the adjuvant setting or in the 
therapeutic setting for advanced melanoma .  The primary objectives have 
been changed to include  safety and immunogenicity.  Exploratory 
objectives have been revised to include estimates of cl inical response.  
5. Section 4.1:  revised background to include text to address the 
immunologic objectives and removed text related to the clinical objectives  
that were previous ly listed as primary objectives.  
6. Section 4.3 .1:  revised rationale to include text  to address the new primary 
objective of immunogenicity.  
7. Section 4.3.3.1:  added the ELIspot assay, proliferation assay, and/or flow 
cytometry as techniques that will be used to measure immune response.  
8. Section 4.3.3:  added a phrase clarifying that this s tudy is the first 
evaluation of and PD -1/PD -L1 antibody in combination with a helper 
peptide vaccine.  
9. Section 5.1.2:  revised (#3) to broaden the patient population.  Subjects 
may be naïve for immunotherapy agents or have received interferon -alpha, 
Product:   Pembrolizumab (MK -3475)  85 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 ipilimu mab or other CTLA -4 antibody, PD -1 antibody (or anti -PD-L1 
antibody), interleukin -2, or prior cancer vaccines other than the 6MHP 
vaccine; however, patients who have received a PD -1/PD -L1 antibody 
must have experienced progression of melanoma after that th erapy.   
10. Section 5.1.2:  revised (#5) to clarify that biopsies will be completed on 
sites that can be accessed safely.  
11. Section 5.1.2:  revised (#6).  Combined exclusion criterion #8 with 
inclusion criterion #6.  Added the following 3 bullet points to inclu sion 
criterion  #6:  
 Neurologic symptoms have returned to baseline,  
 There is no evidence of new or enlarging brain metastases,  
 Subjects are not using steroids for at least 7 days prior to 
registration  
 Removed the following bullet point from entry criteri a (#6)  
  The total number of brain metastases ever ≤ 3. 
12. Section 5.1.2:  revised (#11) to specify that female subjects of childbearing 
potential must use an adequate method of contraception.  This change 
was based on updates to the Merck protocol template.  
13. Section 5.1.2:  revised (#12) to specify that male subjects of childbearing 
potential must use adequate method of contraception. A note clarifying that 
abstinence is acceptable has been added.  This change was based on 
updates to the Merck protocol template . 
14. Section 5.1.3:  deleted exclusion criteria for anti -PD-1, anti -PD-L1, anti -PD-
L2, or anti -CD137 (or any other antibody or drug specifically targeting T -
cell co -stimulation or checkpoint pathway, w ith the exception of 
ipilimumab).  
15. Section 5.2.13:  added t he revised dose modification guidelines for drug -
related adverse events.  This change was based on updates to the Merck 
protocol template.  
16. Section 5.2.1.4:  corrected T able 7  
a. to specify “safety” follow -up and to remove scans at the safety 
follow -up visit.  
b. Correct description of the timing of the follow -up visits  
17. Section 5.2.1.4:  corrected  
18. Section 5.5.2:  clarified that investigational agents (with the exception of 
pembrolizumab and 6MHP during active treatment) are not permitted.  
19. Section 5.6:  added a sta tement to clarify utilization of the treatment 
guidance (section 5.2.1).  
20. Section 5.7.2:  updated the contraception section of the protocol to clarify 
the criteria for non -reproductive potential, the conditions for using 
contraception and the acceptable met hods of contraception.  These 
changes were based on updates to the Merck protocol template.  
21. Section 5.8:  deleted the note referring to section 5.2.2 for unconfirmed 
disease progression.  
22. Section 5.8:  Clarified the length of time of treatment with pembroli zumab 
for the purposes of discontinuing from the study protocol.  
23. Section 6.1:  Deleted footnote “f” PT/INR and aPTT and removed PT/INR 
and aPTT from footnote “f” as these labs are not completed as part of the 
day 1 assessment.  
24. Revised footnote “l” to speci fy that the safety follow -up visit for subjects 
who discontinue 6MHP will occur at the time of their next infusion of 
pembrolizumab.  
25. Section 7.1.2.1:  removed reference to the separate ECI guidance 
Product:   Pembrolizumab (MK -3475)  86 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 document.  This document is no longer required (per Merck) as the criteria 
for capturing events of clinical interest have been modified (see section 
7.2.7.10).  This change was based on updat es to the Merck protocol 
template.  
26. Section 7.1.3.1:  added LDH to the clinical lab list to be consistent with 
Table 9.  
27. Section 7.2:  revised the ordering of this section to improve readability.  
28. Section 7.2.1:  added a statement to clarify that progression of the cancer 
is not considered to be an adverse event.  
29. Section 7.2.1:  Revised description of collection of adverse events during 
pre-allocation baseline period and moved this paragraph to section 7.2.7.1.  
30. Section 7.2.1:  Added adverse events that are rep ortable to Merck within 
the same timeframe as SAEs, according to the Merck protocol template.  
31. Section 7.2.3,Table 11 : 
a. Added a statement to define pre -existing condition.  
b. Clarified reporting guidelines for the development of new cancers.  
c. Clarified reporting  guidelines for an overdose.  
d. Added the term “investigational” when describing the relationship 
to the drug.  
e. Clarified the description of how to determine whether there is a 
reasonable possibility of Merck product or 6MHP relationship to an 
adverse event.  
32. Section 7.2.6:  Reordered this section to improve readability  
a. Revised the DLT definition for pembrolizumab to be consistent 
with guidelines for discontinuing treatment as outlined in table 6.  
b. Revised definition for ocular DLTs.  
c. Removed Grade 1 ocular toxici ties as DLTs  
33. Section 7.2.7.1:  Added the second paragraph to describe the 
requirements for adverse event reporting after the consent form is signed, 
but before treatemt allocation/randomization occurs. This change was 
based on the language provided in the  Merck template.  
34. Section 7.2.7.6: Revised to describe the requirements for repor ting 
pregnancies and lactation. Changes were based on the updated language 
provided in the Merck template.  
35. Section 7.2.7.8:  Revised the description for reporting SAEs to the 
Sponsor -Investigator and to Merck.  These changes were based on the 
updated language provided in the Merck template.  
36. Section 7.2.7.9:  This section has been added.  These changes were 
based on the updated language provided in the Merck template.  
37. Section 8:  The statistical section was revised based on the changes made 
to the study objectives.  
38. Summary of changes:  reordered list beginning with the most recent 
changes.  
39. Summary of changes:  corrected version date from 07 -29-15 to 07 -30-15. 
07-30-15 1. Updated stu dy personnel.  
2. Updated Table of Contents  
3. Updated Table Numbers.  
4. Editorial changes throughout the document.  
5. Added IND # to the protocol document.  
6. Section 3.3:  removed durable clinical response and durable disease 
control as exploratory objectives as these o bjectives were not meant to be 
included as part of the study design.  
7. Section 5.1.2 (#7):  deleted “and ≤ 6 months” as this time frame was 
incorrect for the intended population.  
Product:   Pembrolizumab (MK -3475)  87 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 8. Section 5.1.3 (#3):  Added wording to clarify the window for receiving 
nitrosureas.  
9. Section 5.1.6 (#6):  Deleted reference to gamma knife administration as the 
timing of gamma knife administration is covered in the inclusion criteria.  
10. Section 5.2.1.2:  Revised to specify that vaccines 4 -6 will be administered 
at the same site.  
11. Section 6.1:  Added footnotes “u” and “v” to the study flow chart to clarify 
reference to timing of the pregn ancy test and to refer the reader to Table 9 
for details on the comprehensive chemistry panel.  
12. Section 6.1:  Revised footnote “f” to include clarification for timing of 
PT/INR and aPTT  
13. Section 6.1:  Removed LDH as a separate line item as LDH is included as  
part of the chemistry panel (see Table 9).  
14. Section 7.1.2.8.1:  Added a statement to clarify that image guidance may 
be used during the biopsy procedures.  This is consistent with section 
5.1.2(#5).  
15. Section 7.1.2.8.1:  Revised the number of core biopsies f rom five to six.  
The intent was to include six core biopsies as described under the 
“Procedure” section of this portion of the protocol.  
16. Section 7.2.5:  Revised this section to move the language describing ocular 
dose -limiting toxicities to section 8.2.1. 1 of the protocol.  
17. Section 7.2.7.2:  Changed the cross -reference for reporting from protocol 
section 9.6 to section 7.2.7.3.  
18. Section 8.2.1.1:  Revised the DLT section to :  
a) Clarify that small ulcerations are expected in a subset of subjects and 
are not cons idered DLTs.  
b) Reformat DLT list and the “Exceptions to DLT” list for pembrolizumab 
to include information in a table, per the suggestion from the IRB.  
c) Added a category of “Other drug -related toxicities not specified in 
8.2.1.1” to the DLT Table 17.  
d)  Moved the definition of ocular DLTs from section 7.2.5 to this section 
of the protocol.  
19. Section 8.5: Added a statement to the Safety Monitoring section to clarify 
the timing of DLT monitoring.  
05-20-15 1. Revised Table of Contents  
2. Section 7.2.5:  Added definitions  for adverse event classifications for 
clarification.  
3. Section 7.2.6.2:  Revised this section to refer the reader to the tables in the 
investigator brochure for a description of treatment -related adverse events.  
4. Section 7.2.6.3:  Added delayed wound healing , scarring, and numbness 
to the list of expected toxicities for the biopsies.  
5. Section 8.2.1.1:  Revised the definitions of dose -limiting toxicities for 6MHP 
and pembrolizumab.  The pembrolizumab definition has been based on 
unacceptable toxicity requiring discontinuation, per table 6.  
6. Editorial changes have been made throughout the study.  
05-18-2015  7. Updated header  
8. Updated study personnel  
9. Added the Investigator Statement page  
10. Updated Table of Contents  
11. Section 5.1.1:  entry criteria revised for clarification  of disease stage in 
response to PRC review.  
12. Section 5.1.2 (#3):  revised for clarification f or subjects who fail ipilimumab  
in response to PRC review.  
13. Section 5.1.3 (bullet point 8):  revised for clarification of brain metastase s 
Product:   Pembrolizumab (MK -3475)  88 
Protocol: UVA-Mel-64  
Version Date:    07/13/18  
  
 
   
University of Virginia Human Immune Therapy Center --Confidential  
 
 in response to PRC review  
14. Section 5.5.1:  revised to include nasal corticosteroids  and to be consistent 
with entry criteria.  
15. Section 5.5.2:  1) revised to specify 6MHP and 2) revised to allow inhaled 
steroids at low doses and to be consistent with entry criteria.  
16. Section 6.1:  rem oved ECGs as part of the required testing as ECGs are 
not required with pembrolizumab treatment.  
17. Section 7.2.2:  1) added “study drugs or protocol -specified procedures” for 
clarification of the definition of adverse event, 2) clarified the definition of 
serious AE to include events that occur during the study.  
18. Section 7.2.6.2:  added this section to specify the lab values that are 
required to be recorded in the UVA Cancer Center database.  
19. Editorial comments were made throughout the study protocol.  
 
 